**Request for a new Urology Department**

**at the Michigan State University College of Human Medicine**

**Submitted October 7, 2022**

**Updated October 20, 2022**

**Updated November 22, 2022**

**Note: Process for requesting establishment of a new department at MSU:**

* Dean first seeks endorsement of the request from the CAC, then Dean takes proposal to the EVP/Provost.
* EVP/Provost will send the request to the Steering Committee to route through academic governance for consideration and a recommendation (e.g., University

Committee on Faculty Affairs; University Committee on Graduate Studies).

* EVP/Provost makes decision to support the request or not and confers with President.
* EVP/Provost takes request and recommendation for approval to Board of Trustees.
* Board of Trustees is required to approve the creation of any new department.

Rationale for a new Urology Department

**The College of Human Medicine seeks to create a state-wide MSU Department of Urology**. Urologists provide medical and surgical management for genitourinary disorders involving the male and female urinary tract and the male reproductive organs, including the kidneys, adrenal glands, ureters, bladder, urethra, testes, epididymis, vas deferens, seminal vesicles, prostate, and penis. Urology manages conditions including urinary-tract infections, benign prostatic hyperplasia, prostate cancer, kidney cancer, bladder cancer, kidney stones, adrenal masses, congenital abnormalities, traumatic injury, and incontinence. Urological procedures include cystoscopies, prostate biopsies, vasectomies, prostatectomy, nephrectomy, adrenalectomy, transurethral resection of prostate (TURP). Areas of sub specialization within urology include urologic oncology, pediatric urology, stone disease (endourology), infertility/andrology, female pelvic medicine, reconstructive surgery, neurology, and laparoscopy/robotic surgery. Urologists often collaborate with other specialties, including medical oncology, radiation oncology, gynecology, pediatric surgery, plastic surgery, colorectal surgery, gastroenterology, and endocrinology.

The college seeks to found this department based on faculty mostly at Henry Ford Health (HFH), which has 21 urologists. They are fellowship trained in prostate cancer, bladder cancer, kidney cancer, penile cancer, testicular cancer, kidney stones, reproductive health, male urinary Issues, men’s health, enlarged prostate, women’s health, FPMRS/Neuro-Urology/ Voiding Dysfunction, reconstructive urology, pediatric, and transgender health. Members of the department are active in clinical practice, research, and teaching. Several members also hold significant administrative leadership roles within the Henry Ford Health.

Please see Attachment 1 for in-depth overview of clinical and research faculty.

Strengths of the current faculty including areas of excellence; overall contribution towards the reputation, financial status, and quality of care provided at HFH and how it will contribute similarly to same for MSU; and elements that respond to MSU’s strategic plan particularly [Sustainable Health,](https://strategicplan.msu.edu/strategic-plan/sustainable-health) [DEI,](https://strategicplan.msu.edu/strategic-plan/dei) and [Discovery](https://strategicplan.msu.edu/strategic-plan/innovation-for-global-impact) pillars. (Please see Attachment 1 for faculty overview)

Attachment 2 – Publications of department faculty for the last three years.

Attachment 3 – Faculty Awards and Honorifics -including state, regional, national, and international awards, major offices, and role in national organizations.

Attachment 4 – Grants (separated into federal and non-federal grants).

The faculty based at Henry Ford Health have a long history of innovation and acclaim in the discipline. These faculty have led or been instrumental in the development of many practice changing innovations including robotic surgery. (Attachment 5 – Practice Changing Contributions)

There are current MSU urological faculty in other departments of the university, most notably in the Department of Osteopathic Surgical Subspecialties, which has several specialties amongst its faculty. The new department would not change the courses, training programs, research, or clinical activity of these faculty. As with any of our statewide departments, the new Department of Urology would welcome faculty for secondary appointments if that is of interest to those faculty members. Given the size, scope, national prominence, and research opportunities the new department will bring to MSU, we believe the new department will expand opportunities for existing urological faculty in the university.

Alignment with MSU DEI Strategic Plan

Increasing diversity in the field of urology is a priority of our faculty who are involved in diversity activities both at a program and national levels. They are one of the leading institutions of the Diversity Initiative of the American Urological Association, Northcentral Section. There are existing faculty who participate in national diversity committees.

Faculty and leadership in the department of Urology have had a long-standing commitment to

DEI. Faculty embrace a culture of diversity and the department has diverse faculty and support staff representation to reflect the diverse patient population in Detroit. Additionally, mentorship is provided to the underrepresented in medicine residents and students. They also have multicultural urology clinics. Faculty perform research on topics related to disparities in urological care in minority populations.

Faculty in the department are so committed to diversity that they raised their own funds to support a scholarship for URiM students to assist with the cost of a one -month rotation in the department. The diversity committee includes those founding members of DEI scholarship but is open to all staff and trainees to meet and provide input to improve recruitment, selection, and retention, and to do activities related to implicit bias testing during interview season and help organize Grand Rounds focusing on diversity for all department members. URiM residency candidates are considered by key members of the Diversity Committee. To achieve/ensure diversity in trainee recruitment, selection and retention, their program participates in recruitment fairs and outreach programs. In accordance with the AAMC

statement about virtual interviews, this year they will be continuing virtual interviewing. This promotes equity in the application process.

The urology program is committed to providing a work environment and culture that maximizes the professional growth of employees and meets the health care needs of diverse communities.

Goals of the Urology Department

(a) Research Mission

The urology faculty has a strong history of clinical research, focusing on improving patient outcomes, with a particular emphasis on urologic oncology. (See Attachment 5 – Practice Changing Contributions) Leveraging the integrated health care delivery system of Henry Ford Health, the faculty have focused mainly on clinical outcomes, care path delivery, health equity, population health, quality, and epidemiological research. Research efforts of the faculty are supported by a full-time biostatistician, with a full access and collaboration with Vattikuti Center for Outcomes Research, analytics, and Evaluation (VCORE) that focus on clinical outcome, and the statewide initiative Michigan Urological Surgery Improvement Collaborative (MUSIC). Faculty have published numerous papers on robotic surgery outcomes with robotic surgery for prostate, kidney, and bladder cancers. Moreover, they have focused on health care equality in the American health system, and specifically on improving the outcomes of the African American men with prostate cancer. Recently, they have been working on translation research projects with the aim of using current genomic markers to guide treatment algorithms, as well as developing better and novel markers. The faculty actively recruits into clinical trials for the treatment of urologic cancers. Faculty in the department strive to create an environment to attract and nurture both physician and non-physician scientists with the goal of bridging basic, translational, clinical, and epidemiological research to improve the treatment of urologic diseases. The department has developed an expanding translational research portfolio focusing on prostate cancer, kidney cancer, and bladder cancer. Research collaborators span multiple departments, including medical oncology, radiation oncology, neurology, endocrinology, Women’s health, public health science, and pathology.

(b) Education mission

The mission of the residency program in the Department of Urology, Vattikuti Urology Institute (VUI) at Henry Ford Health is to train and educate residents to become local and national leaders, who excel in providing general urologic care and with knowledge in numerous urology subspecialty fields. They strive to provide patient-centered exceptional care to all patients. Faculty in the department respect and take pride in the diversity, equity, and inclusion of all patients. They provide training in service excellence to help residents optimize their relationships with patients. They strive to nurture scientific curiosity and lifelong learning and the pursuit of continual self-improvement. In addition, they foster a culture of giving back to the local and global community and engaging in global health opportunities.

The VUI Urology Residency offers three positions alternating with two positions yearly, (2-3-2-3 -2) for the 5-year residency program. Residents train with highly skilled clinical staff at three hospitals. VUI

residents receive an excellent experience in all facets of urology and learn the latest techniques. The clinical rotations are mainly at Henry Ford Hospital, West Bloomfield Hospital, and Children’s Hospital of Michigan, 10 minutes from Henry Ford Hospital. The program is successful in matching and graduating residents. About 50% of graduating residents enter fellowships. Medical student access to this program will help students interested in urology achieve their career goals.

The VUI’s strengths include a large ambulatory practice, a broad mix of minimally invasive and open surgery, oncology, pediatric urology, and basic research. The faculty are recognized and are involved nationally in developing resident training curriculum. The trainees benefit from being exposed to a large number and wide variety of patients, as they serve the metropolitan population of Detroit as well as the surrounding suburbs.

The urology program provides 3rd and 4th year rotations and attracts medical students both locally and nationally. During their clinical rotations, the students and residents are provided with a robust clinical experience and didactic curriculum. The department offers CME and faculty and resident development through weekly grand rounds and multiple conferences and symposiums.

(c) Service and outreach mission

The faculty is involved in numerous community service and outreach initiatives as a whole and individually. The faculty organizes and support PSA screening and community outreach. Internationally, Dr. Peabody has participated in annual medical service trips to Benin, Africa and has helped to organize trips with the resident to Honduras to provide urologic care. This has been an outstanding experience for those residents as they serve in these communities. They are also organizing a department service project this year to volunteer at a shelter in the Detroit community to help prepare and serve food for those in need.

Members of the department provide student mentoring and participate in pipeline programs to increase the number of underrepresented minorities in medicine. Faculty developed a bladder cancer advisory council that helps engage the bladder cancer patient community in areas including outreach and research. They also participate in running CME events and community events to raise awareness of urologic cancers. In addition, faculty and staff in the department of urology participate in the Game on Cancer event to raise awareness of urologic cancers and to support research.

(d) Clinical mission

The urology faculty have a tradition of providing outstanding clinical care. Over the last four years, the department of urology has added eight additional urologists and three additional APP’s covering all aspects of urology. The clinical patient volume at HFH sites exceeds 40,000 visits per year which occur at seven outpatient clinics and surgical centers. Twenty-one staff physicians and 13 residents care for the urology patients. They provide the inpatient consultations and teaching services for Urology at Henry Ford Hospitals in Detroit and West Bloomfield. The faculty provides general urology care for the community in addition to subspecialty clinics and is a referral center for numerous urologic conditions. They provide tertiary and quaternary care in all areas of urology and because of a focus on patient

centered care, innovation, and research, faculty in urology are leaders of surgical and medical management of urologic conditions. These faculty have also been leaders in developing multidisciplinary management of urologic disease that is demonstrated through our urologic cancer tumor boards, bladder cancer tumor boards, and genitourinary reconstruction multidisciplinary conferences.

Additional Goals include:

1. Contribute to system goal of NCI cancer center generation through NIH grant work.
2. With the leadership of Dr. Abdollah, continue to lead in outcomes research through an extremely productive lab for outcomes research.
3. Develop imaging guided targeted diagnostics and focal therapy options for prostate cancer with rapid diagnosis and treatment.

Benefits to Michigan State University

Overall, this new Department of Urology will strengthen and expand the academic environment of the college and MSU. Addition of this department will allow for curricular expansion of the College of Human Medicine and create additional academic homes for the expanding CHM faculty (both paid and no-pay faculty) across the state of Michigan.

The growth of the program and the faculty will bring several opportunities for strengthening and enriching educational and research activities for CHM, including: The opportunity to develop new areas of curriculum and offer highly desirable student experiences in disciplines not currently represented in other CHM campuses (e.g., MSU medical student urology clerkships). The ability to establish additional required experiences and competencies that would not be possible without the addition of qualified faculty. The enhancement of graduate medical education (e.g., post graduate urology residency program) throughout our system by the addition of programs in Henry Ford that we cannot currently offer at MSU (*see goals under education mission*). Strengthened subspecialty research, and clinical programs that will provide the necessary platform for translational and population-based research, as well as support the supply of well-trained physicians and physician scientists to meet future recruitment needs in all our communities across the state of Michigan.

The research focus of the MSU urology department will be broad in various areas of urology including cancer biology and outcomes research, and this will provide new and additional research training opportunities for undergraduate, graduate, and medical students in different biomedical programs at MSU. Importantly, faculty who are in the Henry Ford Urology department are funded by external funding (including NIH and DOD) and are involved in several funded clinical research studies. Addition of the department to MSU will increase NIH funding to MSU: (a) Addition to existing NIH funding from these faculty to MSU grant portfolio; (b) Increased collaborative research programs with existing MSU faculty leading to increase in NIH and other external funding. Together this will undoubtedly improve MSU funding and ranking overall. Expansion of the college to include this new department will help achieve MSU’s strategic goal for reaching $1 billion in research expenditures by 2030.

These urology faculty have received numerous honors and awards, and this will also significantly increase MSU faculty honorifics (another strategic goal for MSU). Lastly, CHM has an active and on-going relationship with several community partners and philanthropists. Addition of a MSU Urology Department will provide expanded opportunities for new endowments. Overall, creation of the MSU department of urology to the college of Human medicine will bring about several important benefits to the university and to the state of Michigan.

Programmatic, operational, and financial considerations

Alignment with existing departments/units in CHM and MSU

Addition of this Urology Department will provide research and educational collaborative opportunities across the College of Human Medicine and multiple colleges of MSU. There are already existing funding opportunities for collaborative research and education, through the Henry Ford-MSU partnership.

Faculty from both existing MSU departments and Henry Ford departments will be able to apply for internal and external grant programs collaboratively that will strengthen the grant portfolio of MSU faculty and significantly increase research expenditure.

There are multiple units in the college and the university that have faculty and students who do research in the areas of cancer biology including prostate cancer. The addition of the Department of Urology creates new opportunities and potential collaborations for these faculty and students. There is nothing about the department that would limit the ability of other colleges or departments from hiring urological faculty in their respective departments and/or research programs.

Department structure

MSU Department of Urology will be led by a department chair. Initially, the department will have an interim chair from faculty of the department that are already in place at Henry Ford. When the department has bylaws and voting faculty, there will be a search for a chair. This may be the same person who is the chair of the Henry Ford urology department or may be a different person depending on the outcome of the chair search.

The addition of this urology department will be an opportunity for the state’s Medicaid uplift. We expect significant funding to be available through this program, and we have pledged to use this money to support research, education, and scholarship in the MSU-Henry Ford collaborative efforts. At the present time, faculty employed in the Henry Ford Urology department will become part of the MSU Department of Urology. Thus, the Henry Ford Medical Group Chair of Urology will be the primary supervisor for these Henry Ford employed faculty for Henry Ford related issues. For MSU related issues, chair of the MSU Department of Urology will be the administrative leader. We will support this chair at 5-10%, either as a dually employed faculty or leased by CHM from Henry Ford. HFH is using the lease model to support the current position as chair (Dr. Rick Leach) for Ob/Gyn at Henry Ford Health. The interim chair of the MSU Department of Anesthesia is dually employed. This chair funding by MSU is essentially facilitating partnership development and we would request access to the “mission-support” funding provided through the partnership Definitive Agreement. Depending on the strategic needs of

the department, college and the university, the college may fund a few faculty positions in these departments as MSU employed faculty.

Faculty appointments

Faculty will be appointed in multiple ways. Faculty already in the Henry Ford urology department will be appointed as no-pay faculty in one of the following tracks depending on their role and contribution to the education and research missions of the college: Prefix, non-prefix, and research tracks. For these various faculty tracks, we will follow the same process we currently follow in the college. When funding is available for new MSU-based faculty positions, these will be done using existing faculty hiring processes. In addition to clinical and non-prefixed faculty from Henry Ford Health, there will be clinical and non-prefixed faculty in the discipline joining from other communities, including Lansing and Grand Rapids. Most of these faculty are engaged in elective clerkships for MS3 and MS4 students in our eight campuses across the state.

(New paragraph added in response to CAC request at their October 17, 2022 meeting). Upon establishment, new departments may initially not have voting-eligible, full- time faculty sufficient to participate as regular representatives to the CHM College Advisory Council (see CHM Bylaws Section 1.1.5.2.4. and 1.1.5.2.5. with referred definitions 1.1.1.). Departments with no eligible faculty with university level voting rights will send a CAC representative who will be granted voice but no vote, until such a time as they have eligible faculty to serve. It is expected that full -time MSU faculty will be added over time through enhanced Medicaid funding returned to MSU as well as new Henry Ford Health – MSU Health Science Center (HSC) funding. The college expects there will be 20-40 hires through these mechanisms. Priority will be given to addition and retention of at least two eligible faculty with university level voting rights (see CHM Bylaws Section 3.1.2.3.) within each department.

Chair selection

With creation of the MSU Department of Urology, the dean will first appoint an interim chair. After initial establishment of the department with faculty appointments, the dean (or designate) will work with the faculty and the interim chair to develop departmental bylaws that will go through appropriate approvals at the college and university levels. Once the bylaws are in place, the dean will work with the department to formulate a search for a founding chair and subsequent chairs using existing university guidelines. Depending on the strategic needs of the department and the faculty some of these searches will be national and some may be internal.

Department operations, governance, bylaws and RPT criteria

The department will operate in a manner consistent with other departments in the College of Human Medicine and will adopt a shared governance model. Shared governance with the existing faculty, staff, and students will follow the MSU Academic Governance policies. The interim chair will work with the dean to appoint a bylaws committee. The bylaws committee will include five faculty members and one outside faculty member with expertise in reviewing bylaws. Bylaws will be voted on and approved by a majority of department faculty before ratification. A scaffolding of the bylaws and major sections have

already been identified and minimally will include sections on organization; governance; committees; RPT; grievances and complaints; and faculty (e.g., composition, meetings, appointment, reappointment, promotion, tenure, responsibilities, etc.). Reappointment, promotion, and tenure criteria will align with the College of Human Medicine criteria which are written, well-specified, and available on the [CHM](https://humanmedicine.msu.edu/faculty-staff/faculty-affairs/promotion/index.html) [Faculty Affairs website.](https://humanmedicine.msu.edu/faculty-staff/faculty-affairs/promotion/index.html) An RPT committee will be established within the Department of Urology to work with the chair to manage the RPT processes.

Department Finance

Current Funding Status, Allocation, and Reserve Funds

The college is proposing a series of new departments based on faculty joining MSU and CHM from Henry Ford Health that complement the work of the college and university and highlight unique strengths of the HFH faculty. The health system, college, and partnership will provide support for the faculty and administration of the department. Most support will be in the form of faculty salary, which will come from the medical group within the health system. The Office of Health Sciences has committed financial resources from the overall MSU-HFHS partnership effort to support creation of departments. Discretionary funding will be used to support a small part of the salary and an administrative increment for the chair’s MSU employment. As the department integrates into the college, the department will enter the Medicaid uplift program providing additional support for the department and funding additional MSU faculty in the department. The department will accrue reserves and start-up funds as all other departments in the college do.

Projected financial needs and how financial obligations of the department, including administrative costs will be met

Projected financial needs are centered around ongoing recruitment and retention of high-caliber faculty to support our education, research, and service missions. The college will direct Medicaid uplift derived from HFH to use in the departments based out of HFH to fund new positions and programs in the departments and college.

The current college allocation and reserve funds more than meet the projected financial needs and financial obligations of the proposed department, including administrative costs. The college and the department expect additional philanthropy as well.

Oversight of the curriculum

The department will participate in the college’s educational programs as all other departments do. Electives and rotations in the MD curriculum will be approved and supervised by the CHM MD Curriculum Committee. All other courses and educational programs will be reviewed by the college’s Graduate Studies curriculum committee. The department’s residency and fellowship programs operate with oversight from the departmental residency committees consistent with the ACGME accreditation of Henry Ford Health. The department will have a clerkship committee to oversee its medical student

and any other educational programs not a part of the residency programs. For additional information on clerkships and residencies, see “Educational Mission” under “Goals of the Urology Department”.

Evaluation of departmental effectiveness

Internal reviews by Henry Ford Health and Hospital are performed through oversight from councils dedicated to quality, safety, clinical and operational excellence, and efficiency. Each Council has representation from all business units. One of the key tasks for each department is the oversight of maintaining privileges and upholding the bylaws set forth by the Henry Ford Medical Group Board of Governors and Henry Ford Hospital Medical Executive Committee.

Bi-annual reviews of the Urology Department are conducted by the HFMG Chair and Chief Operating Officer of HFMG. This review looks at operational effectiveness and performance of the department including finance, access, growth, patient and staff satisfaction/engagement, professional development, and programming. The outcomes of the most recent review were overall positive. Notable strengths included financial performance and growth with a noted 14% increase in patient visits and a 7% increase in OR cases across all HFH markets. Areas of opportunity included access for new patients and overall support staff engagement, with scores in alignment with the current trend across health care systems nationally. There are several surveys and evaluations as listed below:

1. *Focused Professional Performance Evaluations (FPPE – First two years of practice and/or remediation, bi-annual))*
2. *Ongoing Professional Performance Evaluations (OPPE – bi-annual)*
3. *Financial Reviews and Chair Performance reviews (bi-annual)*
4. *Peer Reviews (ad hoc and bi-annual)*
5. *Annual HFH resident survey (fall)*
6. *Annual ACGME Resident Survey (spring)*
7. *Annual ACGME Faculty Survey*
8. *Annual Program Evaluation by the program. Reviewed by the GME annually in the fall.*
9. *Semi Annual Faculty Evaluations by the residents*
10. *Annual Faculty Evaluations of the Program*
11. *Med Hub – Resident and faculty evaluation*
12. *APE – Annual Program Evaluation and meeting with entire teaching faculty and all residents from each year.*
13. *CCC meeting – All core teaching faculty evaluate residents*

**Accreditation/certification status of any educational programs including term, areas of excellence, non-compliance, and monitoring.**

The Urology Residency Program at the Vattikuti Urology Institute offers exceptional clinical training with exposure to a wide diversity of urologic conditions. It is a five-year program with a 2-3-2 -3-2 complement of residents. The urology residency has had continued accreditation by the ACGME. They

have 13 residents total and have a 100% first time boards pass rate for over 10 years. Dr. Humphrey Atiemo is the program director (PD) and Dr. Ali Dabaja is the associate PD.

The residency program's Program Evaluation Committee convenes annually and reviews the entire program with guidance from the HF Hospital GME. This is then peer reviewed by other program directors at HF Hospital and evaluated in detail by the Henry Ford Hospital Designated Institutional Official and GME office. Annual systematic updates are submitted to the ACGME Urology Review Committee and receive evaluations through an annual letter of notification. They are subject to their Self-Study process and periodic site visits; however, these plans are under review by the ACGME currently.

The Clinical Research Fellowship is a one-year non-accredited fellowship for applicants who have completed medical school and would like to explore research opportunities before applying for residency. The Clinical robotics fellowships is a non-accredited one-year fellowship for applicants who have completed urology training. The fellowship presents an opportunity to learn the latest techniques of robotic surgery and surgical management of urologic cancers and other conditions

**Existing system for annual faculty reviews**

Faculty reviews are performed bi-annually through Focused Professional Performance Evaluations (FPPE

– First two years of practice and/or remediation) as well as Ongoing Professional Performance Evaluations (OPPE). Reviews are done in person with written feedback/agreement on personal and professional performance goals. Patient satisfaction comments and scores are reviewed as well as metrics of professionalism including mandatory modules in Henry Ford University related to safety, patient care, and diversity and CME and participation in grand rounds and other departmental initiatives. Financial performance metrics are reviewed. Additionally, system engagement surveys are conducted and reviewed at faculty meetings, which occur bimonthly.

**Existing system for reviewing teaching performance of faculty, including areas of excellence and areas targeted for continuing development.**

Teaching performance of the core faculty is assessed twice year by the residents using the MedHub automated medical education software. The software specifically asks the resident to grade faculty on a Likert scale. The domains are:

1. Faculty member was a role model of professionalism
2. The faculty member demonstrated an interest in the education of residents/fellows
3. Faculty member created an environment of inquiry
4. Faculty member provided appropriate level of supervision, faculty member regularly participated in organized clinical discussions, rounds, journal clubs, and conferences
5. Faculty member demonstrated a commitment to the delivery of safe, quality, cost-effective, and patient-centered care
6. Faculty member reviewed the goals and objectives of the rotation with you at the beginning of the rotation
7. Faculty member provided sufficient instruction

There is also an area for text comments from the resident. This anonymous feedback is reviewed with the core faculty at their ongoing professional practice evaluation (OPPE) with the chair. When goal setting for the next six months, the core faculty are asked to identify areas for continuous growth,

incorporating resident feedback. If there are areas of concern, resources and opportunities for improvement are offered to the faculty. Throughout the academic year, courses on adult learning are offered through institutions and are circulated to the faculty for them to enroll for additional learning. Faculty development is a priority for the department and faculty are encouraged participation in different programs.

There is a weekly didactic session for residents and faculty. During this time, guest lecturers will give sessions on educational techniques on feedback, lecture preparation and setting goals for learning. They have recently upgraded the video conferencing system in the conference room to help facilitate having national and international experts deliver virtual lectures during Grand Rounds.

**Outreach and community service programs**

The faculty in the department are involved in several outreach and community service initiatives. For example, faculty have volunteered over the last several years for an Adopt A Family program to donate Holiday gifts for a family in need. In addition, the department organizes and support an annual free PSA screening drive for prostate cancer in the community. Dr. Peabody in department has participated in annual medical service trips to Benin, Africa and has helped to organize trips with the resident to Honduras to provide urologic care. This has been an outstanding experience for those residents as they serve in these communities. Faculty are also organizing a department service project this year to volunteer at a shelter in the Detroit community to help prepare and serve food for those in need. Members of the department also provide student mentoring and participate in pathway programs to increase the number of underrepresented minorities in medicine. Faculty developed a bladder cancer advisory council that helps engage the bladder cancer patient community in areas including outreach and research. They participate in running CME events and community events to raise awareness of urologic cancers as well as participate in the Game on Cancer event to raise awareness of urologic cancers and to support research. Evaluation of these programs will be based on the extent of community participation and feedback from the community.

Assurances

For the university and college, the creation of the Department of Urology will help solidify and expand the scholarly opportunities for students and faculty across the institution. With the addition of the department to MSU, it is expected that the unit will grow, adding to NIH funding in support of AAU metrics and building on the reputation of the existing faculty and programming. The leadership of the college has discussed the creation of the department with related departments and units including meetings with leadership and faculty. Many people across the university do work related to cancer biology, neuroscience, GI/GU-Hepatic/Cardiovascular/Pulmonary, immunity and inflammation, environmental toxicology, mass spectrometry, investigative histopathology, diabetes/obesity, and drug discovery, like many people across the university that do work related to other areas of medicine. The addition of the Department of Urology does not limit the scholarly opportunities of others in the university, and this department will not change or limit the activity of faculty interested in the above-mentioned research areas across the institution. In fact, the success and expansion of this department increases opportunities for all.

**Distribution of proposal for endorsement, assurances, or concerns:**

Distribution by email:

College of Osteopathic Medicine – Dean Andrea Amalfitano, October 7, 2022 See Attachment 6 Department of Surgery (CHM) – Interim Chair Sri Kavuturu, October 7, 2022

**College Advisory Council Summary**

* Recommendation/endorsement

The CHM CAC unanimously endorsed the proposal for a new Department of Urology on November 21, 2022.

**Attachment 1A**

**Description of Urology Faculty**

**FACULTY** (year joined department)

1. Craig G. Rogers, MD (2007), Department Chair
	1. Stanford University School of Medicine, CA, 2000
	2. Johns Hopkins University School of Med., Urology Residency, 2006
	3. National Cancer Institute, NIH, Bethesda, MD, Fellowship Urologic Oncology, 2007
2. James O. Peabody, MD (1990), Vice Chair Operations
	1. University of Michigan Medical School, 1985
	2. Henry Ford Department of Urology, Detroit MI, Urology Residency, 1990
3. Ali A. Dabaja, MD (2014), Vice Chair Clinical Affairs, Residency Program Associate Director
	1. Wayne State University School of Medicine, MI, 2007
	2. Henry Ford Department of Urology, Vattikuti Urology Institute, Urology Residency, 2012
	3. Weill Cornell Medical College, Fellowship Male Reproductive Medicine & Surgery, NY, 2014
4. Firas F. Abdollah, MD (2018), Vice Chair, Academics and Research
	1. University of Baghdad School of Medicine, 2003
	2. Vita Salute University, San Raffaele Hospital, Urology Residency, 2012

* + 1. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship Minimally Invasive Robotic Surgery, 2018
1. Humphrey O. Atiemo, MD (2011), Residency Program Director
	* 1. University of Maryland Medical School, 1999
		2. University of Maryland, Urology Residency, 2005
		3. Cleveland Clinic Foundation, Fellowship Female Pelvic Medicine and Reconstructive Surgery, 2007
2. Riad Farah, MD (1973)
	* 1. University of Damascus School of Medicine, 1966
		2. The University Hospital, Urology, 1968
		3. Mount Carmel Mercy Hospital, Surgery, MI, 1970
		4. Henry Ford Department of Urology, Urology Residency, 1973
3. Joseph A. Haddad, MD (2017)
	* 1. Wayne State University School of Medicine, MI, 2012
		2. Univ. of Oklahoma, Urology Residency, 2017
4. Frank B. Holloway, MD (1992)
	1. Indiana University School of Medicine, IN, 1987
	2. Wayne State University, Detroit, MI, Urology Residency, 1992



1. Wooju Jeong, MD (2013)
	* 1. Yonsei University School of Medicine, Seoul, South Korea, 1998
		2. Yonsei University, Urology Residency (KUA Board Certified), 2003
		3. Yonsei University, Fellowship Minimally Invasive Surgery, 2009
		4. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship in Robotic Urology, 2013
2. Naveen Kachroo, MD, PhD (2020)
	* 1. Newcastle University Faculty of Medical Sciences, 2004
		2. Newcastle University Faculty of Medical Sciences, Medicine & Surgery, 2006
		3. Newcastle University Faculty of Medical Sciences, Surgical, 2007
		4. Nottingham University Hospitals, Urology, 2009
		5. University of Cambridge, Urology, 2013
		6. Henry Ford Department of Urology, Vattikuti Urology Institute, Urology Residency, 2018
		7. Cleveland Clinic, Fellowship in Endourology, 2020
3. David A. Leavitt, MD (2015)
	* 1. University of Michigan Medical School, 2008
		2. University of Minnesota, Urology Residency, 2013
		3. The Smith Institute for Urology, New York, Fellowship Endourology/Laparoscopy, NY, 2015
4. Stephen A. Liroff, MD (1977)
	1. Georgetown University School of Medicine, 1971
	2. New York Presbyterian Hospital and North Shore University Hospitals, NY, General Surgery, NY, 1974



* 1. Wayne State University, Detroit, MI, Urology Residency, 1977
1. Ray H. Littleton, MD (1980)
	* + 1. University of Michigan Medical School, 1975
			2. Henry Ford Department of Urology, Urology Residency, 1980
2. Amit Patel, MD (2020)
	* + 1. University of Birmingham School of Medicine, 2005
			2. Kent/Surrey/Sussex Deanery, General Surgery, 2010
			3. Guys and St Thomas foundation NHS Trust, Urology, 2012
			4. Imperial College and the Royal Marsden Hospital, London, Urology specialty training, 2017
			5. Henry Ford Department of Urology, Vattikuti Urology Insititute, Fellowship in Robotic Urologic Oncology, MI, 2020
3. Samantha M. Raffee, MD (2020)
	* + 1.  Wayne State University School of Medicine, Detroit, MI, 2013
			2. Akron General Medical Center, OH, Urology Residency, 2018
			3. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship Female Pelvic Medicine and Reconstructive Surgery, 2020
4. Amarnath Rambhatla, MD (2019)
	* 1.  University of California Los Angeles School of Medicine, 2007
		2. Wayne State University School of Medicine, Urology Residency, 2012
		3. University of California Los Angeles, Fellowship Male Reproductive Medicine & Surgery, 2016

1. Kandis K. Rivers, MD (2000)
	1.  University of Michigan Medical School, 1993
	2. Henry Ford Department of Urology, Vattikuti Urology Institute, Detroit MI, Urology Residency, 2000
2. Nabeel A. Shakir, MD (2021)
	* 1.  University of Texas Southwestern Medical School, 2015
		2. University of Texas Southwestern Medical School, Urology Residency, 2020
		3. NYU Langone Medical Center, Fellowship Genitourinary Reconstructive Surgery, 2021
3. Hans Stricker, MD (1993)
	* 1.  University of Michigan Medical School, 1988
		2. University of Michigan, Urology Residency, 1993
4. Johar Syed Raza, MD (2020)
	* 1.  Baqai Medical College, 2002
		2. Baqai Medical University, General Surgery, 2007
		3. Aga Khan University, Urology, 2011
		4. Shaukat Khanum Cancer Hospital & Research Center, Urologic Oncology, 2013
		5. Roswell Park Cancer Institute, NY, Fellowship Urologic Oncology, 2015
		6. St. Louis University School of Medicine, MO, Urology Residency, 2020

1. Jeffrey L. Weingarten, MD (2021)
	1.  Saint Louis University, MO - School of Medicine, 1982
	2. Beaumont Hospital - Royal Oak, General Surgery, MI, 1985
	3. Albany Medical College, NY, Urology Residency, 1988

**Other Clinical Staff:**

Advanced Practice Practitioners 7

* 4 Nurse Practitioners
* 3 Physician Assistants

Basic Science Faculty 4

* Jagadananda Ghosh PhD
* Nallasivam Palanisamy PhD
* Sahn-Ho Kim PhD
* Mahendra Bhandari MD

Number of Total Faculty 32

Number of research Faculty 14

Number of Clinical Faculty 29

**Distribution of Rank at Henry Ford/WSU** -

|  |  |
| --- | --- |
| Craig Rogers, MD, Chair | Clinical Professor |
|  |  |
| James O. Peabody, MD, Vice- | Clinic Professor |
| Chair |  |
|  |  |
| Naveen Kachroo, MD | Clinical Assistant Professor |
|  |  |
| Frank Holloway, MD | Clinical Assistant Professor |
|  |  |
| Wooju Jeong, MD | Clinical Assistant Professor |
|  |  |
| Stephen Liroff, MD | Clinical Assistant Professor |
|  |  |
| Ray Littleton, MD | Clinical Assistant Professor |
|  |  |
| Kandis Rivers, MD | Clinical Assistant Professor |
|  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Abdollah Firas, MD |  |  | Clinical Associate Professor |
|  |  |  |  |
| Humphrey Atiemo, MD | Clinical Associate Professor |
|  |  |  |  |  |
| Ali A. Dabaja, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| Riad Farah, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| Hans Stricker, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| David Leavitt, MD |  |  | In process for Clinical Associate |
|  |  |  |  | Professor |
|  |  |  |  |  |
| Joseph Haddad, MD |  |  | In process for Clinical Associate |
|  |  |  |  | Professor |
|  | **Demographics (for DEI purposes)** |  |
|  | White | 1 |  |  |
|  |  | 2 |  |  |
|  | Black | 4 |  |  |
|  | Korean | 1 |  |  |
|  | Middle Eastern | 4 |  |  |
|  | Indian | 5 |  |  |
|  | Male | 2 |  |  |
|  |  | 0 |  |  |
|  | Female | 7 |  |  |

**Attachment 1B**

**Urology Faculty Picture Sheet**



**Attachment 2**

**Publications of department faculty over the last three years**

**Articles**

Agarwal A, Finelli R, Durairajanayagam D, Leisegang K, Henkel R, Salvio G, Aghamajidi A, Sengupta P, Crisóstomo L, Tsioulou PA, Roychoudhury S, Finocchi F, Darbandi M, Mottola F, Darbandi S, Iovine C, Santonastaso M, Zaker H, Kesari KK, Nomanzadeh A, Gugnani N, **Rambhatla A**, Duran MB, Ceyhan E, Kandil H, Arafa M, Saleh R, Shah R, Ko E, and BoitrelleF. Comprehensive Analysis of Global Research on Human Varicocele: A Scientometric Approach. *World J Mens Health* 2022. PMID: 35118839. doi.org/10.5534/wjmh.210202

Agarwal A, Gupta S, Sharma RK, Finelli R, Kuroda S, Vij SC, Boitrelle F, Kavoussi P, **Rambhatla A**, Saleh R, Chung E, Mostafa T, Zini A, Ko E, Parekh N, Martinez M, Arafa M,Tadros N, de la Rosette J, Le TV, Rajmil O, Kandil H, Blecher G, Liguori G, Caroppo E, Ho CCK, Altman A, Bajic P, Goldfarb D, Gill B, Zylbersztejn DS, Molina JMC, Gava MM,

Cardoso JPG, Kosgi R, Çeker G, Zilaitiene B, Pescatori E, Borges E, Duarsa GWK, Pinggera GM, Busetto GM, Balercia G, Franco G, Çalik G, Sallam HN, Park HJ, Ramsay J, Alvarez J, Khalafalla K, Bowa K, Hakim L, Simopoulou M, Rodriguez MG, Sabbaghian M, Elbardisi H, Timpano M, Altan M, Elkhouly M, Al-Marhoon MS, Sadighi Gilani MA, Soebadi MA, Nasr-Esfahani MH, Garrido N, Vogiatzi P, Birowo P, Patel P, Javed Q, Ambar RF, Adriansjah R, AlSaid S, Micic S, Lewis SE, Mutambirwa S, Fukuhara S, Parekattil S, Ahn ST, Jindal S, Takeshima T, Puigvert A, Amano T, Barrett T, Toprak T, Malhotra V, Atmoko W, Yumura Y, Morimoto Y, Lima TFN, Kunz Y, Kato Y, Umemoto Y, Colpi GM, Durairajanayagam D, and Shah R. Post-Vasectomy Semen Analysis: Optimizing Laboratory Procedures and Test Interpretation through a Clinical Audit and Global Survey of Practices. *World J Mens Health* 2022; 40(3):425-441. PMID: 35021311. doi.org/10.5534/wjmh.210191

Agarwal A, Sharma RK, Gupta S, Boitrelle F, Finelli R, Parekh N, Durairajanayagam D, Saleh R, Arafa M, Cho CL, Farkouh A, **Rambhatla A**, Henkel R, Vogiatzi P, Tadros N, Kavoussi P, Ko E, Leisegang K, Kandil H, Palani A, Salvio G, Mostafa T, Rajmil O, Banihani SA, Schon S, Le TV, Birowo P, Çeker G, Alvarez J, Molina JMC, Ho CCK, Calogero AE, Khalafalla K, Duran MB, Kuroda S, Colpi GM, Zini A, Anagnostopoulou C, Pescatori E, Chung E, Caroppo E, Dimitriadis F, Pinggera GM, Busetto GM, Balercia G, Elbardisi H, Taniguchi H, Park HJ, Maldonado Rosas I, de la Rosette J, Ramsay J, Bowa K, Simopoulou M, Rodriguez MG, Sabbaghian M, Martinez M, Gilani MAS, Al-Marhoon MS, Kosgi R, Cannarella R, Micic S, Fukuhara S, Parekattil S, Jindal S, Abdel-Meguid TA, Morimoto Y, and Shah R. Sperm Vitality and Necrozoospermia: Diagnosis, Management, and Results of a Global Survey of Clinical

Practice. *World J Mens Health* 2022; 40(2):228-242. PMID: 34666422.

doi.org/10.5534/wjmh.210149

Agochukwu-Mmonu N, Murali A, Wittmann D, Denton B, Dunn RL, Montie J, **Peabody J**, Miller D, and Singh K. Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative. *Eur Urol Open Sci* 2022; 40:1-8. PMID: 35638089. doi.org/10.1016/j.euros.2022.03.009

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, 3rd, and **Peabody J**. Patient- and Surgeon-Level Variation in Patient-Reported Sexual Function Outcomes Following Radical Prostatectomy Over 2 Years: Results From a Statewide Surgical Improvement Collaborative. *JAMA Surg* 2022; 157(2):136-144. PMID: 34851369. doi.org/10.1001/jamasurg.2021.6215

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, and **Peabody J**. Re: Patient- and Surgeon-Level Variation in Patient -Reported Sexual Function Outcomes following Radical Prostatectomy over 2 Years: Results from a Statewide Surgical Improvement Collaborative. *Journal of Urology* 2022; 207(4):928-928. PMID: Not assigned. doi.org/10.1097/ju.0000000000002413

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, and **Peabody J**. Re: Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. *Journal of Urology* 2022; 207(4):928-929. PMID: Not assigned.

Alanee S, Deebajah M, **Dabaja A**, **Peabody J**, and Menon M. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance. *Int Urol Nephrol* 2022; 54(4):799-803. PMID: 35138582. doi.org/10.1007/s11255-022-03136-1

**Atiemo HO**. EDITORIAL COMMENT. *Urology* 2022; 162:149-150. PMID: 35469606. doi.org/10.1016/j.urology.2021.01.056

**Atiemo HO**. Editorial Commentary. *Urology Practice* 2022; 9(4):312. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000307.01

Borchert A, Jamil M, Perkins S, **Raffee S**, and **Atiemo H**. Vaginal Free Graft Dorsal Onlay Urethroplasty. *Urology* 2022; 159:256. PMID: 34157342. doi.org/10.1016/j.urology.2021.06.004

Butaney M, Chan EM, and **Rambhatla A**. Editorial Comment. *J Urol* 2022; 207(1):51. PMID:

34633222. doi.org/10.1097/ju.0000000000002188.02

Butaney M, Chan EM, and **Rambhatla A**. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. *Journal of Urology* 2022; 207(1):51-51. PMID: Not assigned.

Butaney M, Levy AC, and **Rogers CG**. Robotic total and partial adrenalectomy: A step by step

approach. *Urology Video Journal* 2022; 13. PMID: Not assigned.

doi.org/10.1016/j.urolvj.2022.100138

Butaney M, and **Rambhatla A**. The impact of COVID-19 on urology office visits and adoption of telemedicine services. *Curr Opin Urol* 2022; 32(2):152-157. PMID: 34930885. doi.org/10.1097/mou.0000000000000957

Canvasser NE, River M, Bechis SK, Ingimarsson J, Knoedler J, Stern K, Stoughton CL, Wollin D, Borofsky M, Bhojani N, Tayeb ME, Kamphuis G, **Leavitt D**, Hsi RS, and Scotland KB. Over-the-counter alkali agents to raise urine pH and citrate excretion: a prospective crossover study in healthy adults. *Urology* 2022. PMID: 35843354. doi.org/10.1016/j.urology.2022.05.049

Chen I, Arora S, Alhayek K, **Leavitt D**, and **Dabaja A**. Diagnosis and management of testicular compartment syndrome caused by tension hydrocele. *Urol Case Rep* 2022; 43:102091. PMID: 35520029. doi.org/10.1016/j.eucr.2022.102091

Chen I, Perkins SQ, Schwartz SE, and **Leavitt D**. Nephrolithiasis associated with embolization material, Lipiodol®, following embolization of large renal angiomyolipoma. *Urol Case Rep* 2022; 40:101910. PMID: 34786344. doi.org/10.1016/j.eucr.2021.101910

Corsi NJ, Messing EM, Sood A, Keeley J, Bronkema C, Rakic N, Jamil M, Dalela D, Arora S, Piontkowski AJ, Majdalany SE, Butaney M, Rakic I, Li P, Menon M, **Rogers CG**, and **Abdollah F**. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free SurvivalRate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. *Clin Genitourin Cancer* 2022. PMID: 35871040. doi.org/10.1016/j.clgc.2022.06.015

Delto JC, Fleishman A, Chang P, Jiang DD, Hyde S, McAnally K, Crociani C, Jamil M, Patel HD, Pavlinec J, Budzyn J, Durant A, Eilender B, Gordon AO, Huang MM, Pierorazio PM, Raman JD, **Rogers C**, Su LM, and Wagner AA. Perioperative Aspirin Use Is Associated with Bleeding Complications during Robotic Partial Nephrectomy. *J Urol* 2022; 207(2):277-283. PMID: 34555934. doi.org/10.1097/ju.0000000000002240

Dielubanza EJ, Enemchukwu EA, and **Atiemo HO**. Workforce Diversity in Female Pelvic Medicine and Reconstructive Surgery: An Analysis of the American Urological Association Census Data. *Urology* 2022; 163:29-33. PMID: 34274388. doi.org/10.1016/j.urology.2021.06.031

ElKarami B, Deebajah M, Polk S, **Peabody J**, Shahrrava B, Menon M, Alkhateeb A, and Alanee S. Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance. *Urol Oncol* 2022; 40(5):191.e115-191.e120. PMID: 35307289. doi.org/10.1016/j.urolonc.2022.01.012

Elsayed AS, Ely HB, Abdelhakim MA, Saad IR, Jing Z, Iqbal U, Ramahi Y, Joseph J, Houenstein H, James G, **Peabody JO**, Razzak OA, Hussein AA, and Guru KA. Preservation of endopelvic fascia, puboprostatic ligaments, dorsal venous complex and hydrodissection of the neurovascular bundles during robot-assisted radical prostatectomy: a video demonstration and propensity score matched outcomes. *Urology Video Journal* 2022; 14. PMID: Not assigned. doi.org/10.1016/j.urolvj.2022.100143

Elsayed AS, Iqbal U, Jing Z, Houenstein HA, Wijburg C, Wiklund P, Kim E, Stöckle M, Kelly J, Dasgupta P, Wagner AA, Kaouk J, Badani KK, Redorta JP, Mottrie A, **Peabody JO**, Rouprêt M, Balbay D, Richstone L, Rha KH, Aboumohamed A, Li Q, Hussein AA, and Guru KA. Relapses Rates and Patterns for Pathological T0 After Robot -Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. *Urology* 2022; 166:177-181. PMID: 35461914. doi.org/10.1016/j.urology.2022.03.035

Goldenthal SB, Reimers MA, Singhal U, Farha M, Mehra R, Piert M, Tosoian JJ, Modi PK, Curci N, **Peabody J**, Kleer E, Smith DC, and Morgan TM. Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. *Urology* 2022. PMID: 35472327. doi.org/10.1016/j.urology.2022.04.002

Gopalakrishnan D, Elsayed AS, Hussein AA, Jing Z, Li Q, Wagner AA, Aboumohamed A, Roupret M, Balbay D, Wijburg C, Stockle M, Dasgupta P, Khan MS, Wiklund P, Hosseini A, **Peabody J**, Shigemura K, Trump D, Guru KA, and Chatta G. Impact of neoadjuvantchemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. *Int J Urol* 2022; 29(3):197-205. PMID: 34923677. doi.org/10.1111/iju.14749

Grauer R, Gorin MA, Sood A, Butaney M, Olson P, Farah G, Hanna Cole R, **Jeong W**, **Abdollah F**, and Menon M. Impact of prostate biopsy technique on outcomes of the precisionprostatectomy procedure. *BMJ Surg Interv Health Technol* 2022; 4(1):e000122. PMID: 35892060. doi.org/10.1136/bmjsit-2021-000122

Gupta S, Sharma R, Agarwal A, Boitrelle F, Finelli R, Farkouh A, Saleh R, Abdel-Meguid TA, Gül M, Zilaitiene B, Ko E, **Rambhatla A**, Zini A, Leisegang K, Kuroda S, Henkel R, Cannarella R, Palani A, Cho CL, Ho CCK, Zylbersztejn DS, Pescatori E, Chung E, Dimitriadis F, Pinggera GM, Busetto GM, Balercia G, Salvio G, Colpi GM, Çeker G, Taniguchi H, Kandil H, Park HJ, Maldonado Rosas I, de la Rosette J, Cardoso JPG, Ramsay J, Alvarez J, Molina JMC, Khalafalla K, Bowa K, Tremellen K, Evgeni E, Rocco L, Rodriguez Peña MG, Sabbaghian M, Martinez M, Arafa M, Al-Marhoon MS, Tadros N, Garrido N, Rajmil O, Sengupta P, Vogiatzi P, Kavoussi P, Birowo P, Kosgi R, Bani-Hani S, Micic S, Parekattil S, Jindal S, Le TV, Mostafa T, Toprak T, Morimoto Y, Malhotra V, Aghamajidi A, Durairajanayagam D, and Shah R. Antisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical Practices. *World J Mens Health* 2022; 40(3):380-398. PMID: 35021297. doi.org/10.5534/wjmh.210164

Hakimi K, Carbonara U, Djaladat H, Mehrazin R, Eun D, Reese A, Gonzalgo ML, Margulis V, Uzzo RG, Porter J, Sundaram CP, **Abdollah F**, Mottrie A, Tellini R, Ferro M, Walia A, Saidian A, Soliman S, Yuan J, Veccia A, Ghoreifi A, Cacciamani G, Bhattu AS, Meng X, Farrow JM, Jamil M, Minervini A, Rha KH, Wu Z, Simone G, Autorino R, and Derweesh IH. Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry. *J Urol* 2022; 208(2):268-276. PMID: 35377778. doi.org/10.1097/ju.0000000000002690

Hiller SC, Daignault-Newton S, Rakic I, Linsell S, Conrado B, Jafri SM, Rubenstein R, Abdelhady M, Fischer CP, Gimenez E, Sarle R, Roberts WW, Maitland C, Yousif R, Elgin R, Galejs L, Konheim J, **Leavitt D**, Stockall E, Fontera JR, Wolf JS, Hollingsworth JM, Dauw CA, and Ghani KR. Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease. *Urology Practice* 2022; 9(3):253-263. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000302

Iqbal U, Jing Z, Ahmed Y, Elsayed AS, **Rogers C**, Boris R, Porter J, Allaf M, Badani K, Stifelman M, Kaouk J, Terakawa T, Hinata N, Aboumohamed AA, Kauffman E, Li Q, Abaza R, Guru KA, Hussein AA, and Eun D. Development and Validation of an Objective Scoring Tool for Robot-Assisted Partial Nephrectomy: Scoring for Partial Nephrectomy. *J Endourol* 2022; 36(5):647-653. PMID: 34809491. doi.org/10.1089/end.2021.0706

Jaiswal A, Baliu-Souza T, Turner K, Nadiminty N, **Rambhatla A**, Agarwal A, Krawetz SA, Dupree JM, Saltzman B, Schon SB, and Avidor-Reiss T. Sperm centriole assessment identifies male factor infertility in couples with unexplained infertility - a pilot study. *Eur J Cell Biol* 2022; 101(3):151243. PMID: 35640396. doi.org/10.1016/j.ejcb.2022.151243

Jamil ML, Wurst H, Robinson P, Rubinfeld I, Suleyman G, Pollak E, and **Dabaja AA**. Urinary catheter alleviation navigator protocol (UCANP): Overview of protocol and review of initial experience. *Am J Infect Control* 2022; 50(1):81-85. PMID: 34273463. doi.org/10.1016/j.ajic.2021.06.019

**Kachroo N**, Monga M, and Miller AW. Comparative functional analysis of the urinary tract microbiome for individuals with or without calcium oxalate calculi. *Urolithiasis* 2022; 50(3):303-317. PMID: 35234986. doi.org/10.1007/s00240-022-01314-5

**Kachroo N**, **Rogers CG**, and **Peabody JO**. John Kelso Ormond - More Than a Syndrome. *Urology* 2022. PMID: 35369985. doi.org/10.1016/j.urology.2022.02.017

Kenigsberg AP, Carpinito G, Gold SA, Meng X, Ghoreifi A, Djaladat H, Minervini A, Jamil M, **Abdollah F**, Farrow JM, Sundaram C, Uzzo R, Ferro M, Meagher M, Derweesh I, Wu Z, PorterJ, Katims A, Mehrazin R, Mottrie A, Simone G, Reese AC, Eun DD, Bhattu AS, Gonzalgo ML, Carbonara U, Autorino R, and Margulis V. Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomy. *Urol Oncol* 2022. PMID: 35934609. doi.org/10.1016/j.urolonc.2022.06.006

Kim HJ, Yang SJ, **Jeong W**, Lee J, Na JC, Han WK, and Huh KH. The first robotic kidney transplantation in Korea: a case report. *Korean J Transplant* 2022; 36(1):61-66. PMID: 35769429. doi.org/10.4285/kjt.21.0023

König F, Grossmann NC, Soria F, D'Andrea D, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, **Abdollah F**, Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian SA, Rouprêt M, Rink M, Shariat SF, and Pradere B. Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. *Cancers (Basel)* 2022; 14(7). PMID: 35406553. doi.org/10.3390/cancers14071781

Majdalany S, and **Abdollah F**. Editorial Comment. *J Urol* 2022; 207(2):384. PMID: 34689605. doi.org/10.1097/ju.0000000000002250.02

Majdalany S, and **Abdollah F**. EDITORIAL COMMENTS. *Journal of Urology* 2022; 207(2):384. PMID: Not assigned. doi.org/10.1097/JU.0000000000002250.02

Majdalany S, and **Abdollah F**. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. *Journal of Urology* 2022; 207(2):384-384. PMID: Not assigned.

Modonutti D, Majdalany SE, Corsi N, Li P, Sood A, Dalela D, Jamil ML, Hwang C, Menon M, **Rogers CG**, Trinh QD, Novara G, and **Abdollah F**. A novel prognostic model predicting overallsurvival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis. *Prostate* 2022; 82(13):1293-1303. PMID: 35790016. doi.org/10.1002/pros.24403

Monga J, Adrianto I, **Rogers C**, Gadgeel S, Chitale D, Alumkal JJ, Beltran H, Zoubeidi A, and Ghosh J. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. *J Biol Chem* 2022; 298(2):101556. PMID: 34973338. doi.org/10.1016/j.jbc.2021.101556

Mora S, Qi J, Morgan TM, Brede CM, **Peabody J**, George A, and Lane BR. Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative. *Urol Oncol* 2022; 40(8):380.e381-380.e389. PMID: 35778348. doi.org/10.1016/j.urolonc.2022.05.029

Piontkowski AJ, Corsi N, Morisetty S, Majdalany S, Rakic I, Li P, Arora S, Jamil M, **Rogers C**, Autorino R, and **Abdollah F**. Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: Analysis of NCDB registry. *Urol Oncol* 2022. PMID:

35623996. doi.org/10.1016/j.urolonc.2022.04.015

Prebay ZJ, **Patel A**, Johnson A, Kim T, Fonshell C, Raman JD, Ginzburg S, Uzzo RG, **Rogers CG**, and Lane BR. Perspectives on the Role of Biopsy for Management of T1 Renal Masses:Survey Results From Two Regional Quality Improvement Collaboratives. *Urology* 2022; 165:206-211. PMID: 35143851. doi.org/10.1016/j.urology.2022.01.038

**Rogers C**. Laparoscopic vs Robotic Nephrectomy: A Debate Over Preferences. *J Endourol*

2022; 36(3):291. PMID: 34913727. doi.org/10.1089/end.2021.0910

Shah R, Agarwal A, Kavoussi P, **Rambhatla A**, Saleh R, Cannarella R, Harraz AM, Boitrelle F, Kuroda S, Hamoda TAA, Zini A, Ko E, Calik G, Toprak T, Kandil H, Gül M, Bakırcıoğlu ME, Parekh N, Russo GI, Tadros N, Kadioglu A, Arafa M, Chung E, Rajmil O, Dimitriadis F, Malhotra V, Salvio G, Henkel R, Le TV, Sogutdelen E, Vij S, Alarbid A, Gudeloglu A, Tsujimura A, Calogero AE, Meliegy AE, Crafa A, Kalkanli A, Baser A, Hazir B, Giulioni C, Cho CL, Ho CCK, Salzano C, Zylbersztejn DS, Tien DMB, Pescatori E, Borges E, Serefoglu EC, Saïs-Hamza E, Huyghe E, Ceyhan E, Caroppo E, Castiglioni F, Bahar F, Gokalp F, Lombardo F, Gadda F, Duarsa GWK, Pinggera GM, Busetto GM, Balercia G, Cito G, Blecher G, Franco G, Liguori G, Elbardisi H, Keskin H, Lin H, Taniguchi H, Park HJ, Ziouziou I, Rosette J, Hotaling J, Ramsay J, Molina JMC, Lo KL, Bocu K, Khalafalla K, Bowa K, Okada K, Nagao K, Chiba K, Hakim L, Makarounis K, Hehemann M, Peña MR, Falcone M, Bendayan M, Martinez M, Timpano M, Altan M, Fode M, Al-Marhoon MS, Gilani MAS, Soebadi MA, Gherabi N, Sofikitis N, Kahraman O, Birowo P, Kothari P, Sindhwani P, Javed Q, Ambar RF, Kosgi R, Ghayda RA, Adriansjah R, Condorelli RA, Vignera S, Micic S, Kim SHK, Fukuhara S, Ahn ST, Mostafa T, Ong TA, Takeshima T, Amano T, Barrett T, Arslan U, Karthikeyan VS, Atmoko W, Yumura Y, Yuan Y, Kato Y, Jezek D, Cheng BK, Hatzichristodoulou G, Dy J, Castañé ER, El-Sakka AI, Nguyen Q, Sarikaya S, Boeri L, Tan R, Moussa MA, El-Assmy A, Alali H, Alhathal N, Osman Y, Perovic D, Sajadi H, Akhavizadegan H, Vučinić M, Kattan S, Kattan MS, Mogharabian N, Phuoc NHV, Ngoo KS, Alkandari MH, Alsuhaibani S, Sokolakis I, Babaei M, King MS, Diemer T, Gava MM, Henrique R, Silva RSE, Paul GM, Mierzwa TC,

Glina S, Siddiqi K, Wu H, Wurzacher J, Farkouh A, Son H, Minhas S, Lee J, Magsanoc N, Capogrosso P, Albano GJ, Lewis SEM, Jayasena CN, Alvarez JG, Teo C, Smith RP, Chua JBM, Jensen CFS, Parekattil S, Finelli R, Durairajanayagam D, Karna KK, Ahmed A, Evenson D, Umemoto Y, Puigvert A, Çeker G, and Forum GMC. Consensus and Diversity in the Management of Varicocele for Male Infertility: Results of a Global Practice Survey and Comparison with Guidelines and Recommendations. *World J Mens Health* 2022. PMID: 35791302. doi.org/10.5534/wjmh.220048

Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M, Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, **Rogers C**, Mottrie A, Abaza R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, Capitanio U, Maes KK, Porpiglia F, Turkeri L, and Gautam G. Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database. *World J Urol* 2022. PMID: 35867142. doi.org/10.1007/s00345-022-04101-4

Sharma RK, Gupta S, Agarwal A, Finelli R, Kuroda S, Saleh R, Boitrelle F, Kavoussi P, Gül M, Tadros N, Ko E, Farkouh A, Henkel R, Arafa M, **Rambhatla A**, and Shah R. Role of Cytocentrifugation Combined with Nuclear Fast Picroindigocarmine Staining in Detecting Cryptozoospermia in Men Diagnosed with Azoospermia. *World J Mens Health* 2022. PMID: 35118836. doi.org/10.5534/wjmh.210210

Sood A, Grauer R, **Jeong W**, Butaney M, Mukkamala A, Borchert A, Baumgarten L, Hensley PJ, **Abdollah F**, and Menon M. Evaluating post radical prostatectomy mechanisms of early continence. *Prostate* 2022; 82(12):1186-1195. PMID: 35579026. doi.org/10.1002/pros.24371

Sood A, **Jeong W**, Palma-Zamora I, **Abdollah F**, Butaney M, Corsi N, Wurst H, Arora S, **Kachroo N**, Hassan O, Gupta N, Gorin MA, and Menon M. Description of Surgical Techniqueand Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study). *Eur Urol* 2022; 81(4):396-406. PMID: 34872786. doi.org/10.1016/j.eururo.2021.10.017

Sood A, Keeley J, Palma -Zamora I, Chien M, Corsi N, **Jeong W**, **Rogers CG**, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. Anti-Androgen Therapy Overcomes the Time Delayin Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. *Ann Surg Oncol* 2022:1-10. PMID: 35608801. doi.org/10.1245/s10434-022-11892-8

Sood A, Keeley J, Palma -Zamora I, Chien M, Corsi N, **Jeong W**, **Rogers CG**, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. ASO Visual Abstract: Anti-androgen TherapyOvercomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy-A Post Hoc Analysis of the RTOG 9601 Trial Data. *Annals of surgical oncology* 2022. PMID: Not assigned. doi.org/10.1245/s10434-022-11934-1

Sood A, Keeley J, Palma -Zamora I, Novara G, Elshaikh M, **Jeong W**, Hensley P, Navai N, **Peabody JO**, Trinh QD, **Rogers CG**, Menon M, and **Abdollah F**. High-intensity local treatmentof clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. *Urol Oncol* 2022; 40(2):62.e61-62.e11. PMID: 34348860. doi.org/10.1016/j.urolonc.2021.07.018

Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Optimizing anti-androgen treatment use among menwith pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. *Prostate Cancer Prostatic Dis* 2022. PMID: 35794359. doi.org/10.1038/s41391-022-00572-z

Veccia A, Carbonara U, Derweesh I, Mehrazin R, Porter J, **Abdollah F**, Mazzone E, Sundaram CP, Gonzalgo M, Mastroianni R, Ghoreifi A, Cacciamani GE, Patel D, Marcus J, Danno A, Steward J, Satish Bhattu A, Asghar A, Reese AC, Wu Z, Uzzo RG, Minervini A, Rha KH, Ferro M, Margulis V, Hampton LJ, Simone G, Eun DD, Djaladat H, Mottrie A, and Autorino R. Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. *Minerva Urol Nephrol* 2022; 74(2):233-241. PMID: 33781022. doi.org/10.23736/s2724-6051.21.04247-8

Veccia A, Carbonara U, Djaladat H, Mehazin R, Eun DD, Reese AC, Meng X, Uzzo R, Srivastava A, Porter J, Farrow JM, Jamil ML, Rosiello G, Tellini R, Mari A, Al-Qathani A, Rha KH, Wang L, Mastroianni R, Ferro M, De Cobelli O, Hakimi K, Crocerossa F, Ghoreifi A, Cacciamani G, Bhattu AS, Mottrie A, **Abdollah F**, Minervini A, Wu Z, Simone G, Derweesh I, Gonzalgo ML, Margulis V, Sundaram CP, and Autorino R. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group). *J Endourol* 2022; 36(6):752-759. PMID: 35019760. doi.org/10.1089/end.2021.0587

Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo RG, Sundaram CP, Rha KH, Gonzalgo ML, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi

A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu AS, Mottrie A, **Abdollah F**, Eun DD, Derweesh I, Veccia A, Autorino R, and Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). *Eur Urol Focus* 2022; 8(1):173-181. PMID: 33549537. doi.org/10.1016/j.euf.2021.01.014

Yaguchi G, Swavely N, Perkins SQ, and **Kachroo N**. Kidney stone depiction on fictional television: how accurate are they? *Urolithiasis* 2022; 50(2):167-175. PMID: 35050414. doi.org/10.1007/s00240-022-01303-8

Ahlawat R, Sood A, **Jeong W**, Ghosh P, Keeley J, **Abdollah F**, Kher V, Olson P, Farah G, Wurst H, Bhandari M, and Menon M. Robotic Kidney Transplantation with Regional Hypothermia versus Open Kidney Transplantation for Patients with End Stage Renal Disease: An Ideal Stage 2B Study. *J Urol* 2021; 205(2):595-602. PMID: 32941100. doi.org/10.1097/ju.0000000000001368

Alanee S, **Peabody J**, and Menon M. AUTHOR REPLY. *Urology* 2021; 148:317-318. PMID:

33279614. doi.org/10.1016/j.urology.2020.11.038

Alanee S, Sana S, El-Zawahry A, **Peabody J**, Pearce T, Adams N, Deebajah M, Crabtree J, Delfino K, McVary K, Robinson K, and Rao K. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment. *World J Urol* 2021; 39(10):3807-3813. PMID: 33966128. doi.org/10.1007/s00345-021-03716-3

Auffenberg GB, Qi J, Dunn RL, Linsell S, Kim T, Miller DC, Tosoian J, Sarle R, Johnston WK, 3rd, Kleer E, Ghani KR, Montie J, and **Peabody J**. Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. *JAMA Surg* 2021; 156(3):e206359. PMID: 33471043. doi.org/10.1001/jamasurg.2020.6359

Briskin R, and **Atiemo H**. Case - Unique complication of continent catheterizable stoma after bariatric surgery. *Can Urol Assoc J* 2021; 15(7): E370-e372. PMID: 33382367. doi.org/10.5489/cuaj.6773

Bronkema C, Arora S, Keeley J, Rakic N, Sood A, Dalela D, Jamil M, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Impact of treatment modality on overall survival in localizedductal prostate adenocarcinoma: A national cancer database analysis. *Urol Oncol* 2021; 39(6):366.e311-366.e318. PMID: 33223370. doi.org/10.1016/j.urolonc.2020.11.013

Budzyn J, and **Leavitt D**. Life threatening hepatic hemorrhage after shockwave lithotripsy - A case report and review of literature. *Urol Case Rep* 2021; 38:101724. PMID: 34136358. doi.org/10.1016/j.eucr.2021.101724

Butaney M, Dabaja A, and **Rambhatla A**. EDITORIAL COMMENT. *Urology* 2021; 157:56. PMID: 34895600. doi.org/10.1016/j.urology.2021.05.072

Butaney M, **Dabaja A**, and **Rambhatla A**. Anarcha, Lucy, and Betsey: The Mothers of Modern

Gynecology COMMENT. *Urology* 2021; 157:56-56. PMID: Not assigned.

doi.org/10.1016/j.urology.2021.05.072

Dalela D, and **Abdollah F**. Author Reply. *Urology* 2021; 153:361-362. PMID: 33823172. doi.org/10.1016/j.urology.2021.03.029

Dalela D, Arora S, **Peabody J**, and **Rogers C**. Re: Wilson et al. Outpatient Extraperitoneal

Single-Port Robotic Radical Prostatectomy. Urology 2020; 144: 142-146. *Urology* 2021;

152:203. PMID: 33600837. doi.org/10.1016/j.urology.2020.12.050

Dalela D, Palma-Zamora I, and **Rogers C**. Re: Fredrick Leidberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757-63. *Eur Urol* 2021; 79(4): e115-e116. PMID: 33487478. doi.org/10.1016/j.eururo.2021.01.009

Dalela D, Sood A, Keeley J, **Rogers C**, Menon M, and **Abdollah F**. Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis. *Urology* 2021; 148:1-3. PMID: 33221417. doi.org/10.1016/j.urology.2020.11.015

Elsayed AS, Gibson S, Jing Z, Wijburg C, Wagner AA, Mottrie A, Dasgupta P, **Peabody J**, Hussein AA, and Guru KA. Rates and Patterns of Recurrences and Survival Outcomes after

Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy

Consortium. *J Urol* 2021; 205(2):407-413. PMID: 32945729.

doi.org/10.1097/ju.0000000000001380

Fedrigon D, Faris A, **Kachroo N**, Jain R, Elia M, Wilkins L, Li J, De S, Noble M, Monga M, and Sivalingam S. SKOPE-Study of Ketorolac vs Opioid for Pain after Endoscopy: A Double-Blinded Randomized Control Trial in Patients Undergoing Ureteroscopy. *J Urol* 2021; 206(2):373-381. PMID: 33819072. doi.org/10.1097/ju.0000000000001772

Fedrigon D, Faris A, **Kachroo N**, Jain R, Elia M, Wilkins L, Li J, De S, Noble M, Monga M, and Sivalingam S. Reply by Authors. *J Urol* 2021; 206(2):381. PMID: 33983827. doi.org/10.1097/ju.0000000000001772.03

Gild P, Pompe RS, Seisen T, Keeley J, Tang HJ, Bossi A, Tilki D, Menon M, and **Abdollah F**. Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. *Eur Urol Oncol* 2021; 4(5):817-820. PMID: 31501084. doi.org/10.1016/j.euo.2019.08.005

Ginsburg KB, Johnson K, Moldovan T, Peabody H, Qi J, Dunn RL, **Rogers C**, Weizer A, Kaul S, Johnson A, Traver M, and Lane BR. A Statewide Quality Improvement Collaborative's Adherence to the 2017 American Urological Association Guidelines Regarding Initial Evaluation of Patients With Clinical T1 Renal Masses. *Urology* 2021; 158:117-124. PMID: 34499969. doi.org/10.1016/j.urology.2021.08.036

Hiller SC, Qi J, **Leavitt D**, Frontera JR, Jafri SM, Hollingsworth JM, Dauw CA, and Ghani KR. Ureteroscopy in Patients Taking Anticoagulant or Antiplatelet Therapy: Practice Patterns and Outcomes in a Surgical Collaborative. *J Urol* 2021; 205(3):833-840. PMID: 33035142. doi.org/10.1097/ju.0000000000001416

Jamil M, Etta P, and **Abdollah F**. AUTHOR REPLY. *Urology* 2021; 158:115-116. PMID:

34895624. doi.org/10.1016/j.urology.2021.04.077

Jamil M, Etta P, and **Abdollah F**. Renal Tumor Size and Presence of Synchronous Lung Metastasis at Time of Diagnosis: Implications for Chest Imaging REPLY. *Urology* 2021; 158:115-116. PMID: Not assigned. doi.org/10.1016/j.urology.2021.04.077

Jamil M, Hanna R, Sood A, Corsi N, Modonutti D, Keeley J, Etta P, Novara G, **Patel A**, **Rogers C**, and **Abdollah F**. Renal Tumor Size and Presence of Synchronous Lung Metastasis at Time ofDiagnosis: Implications for Chest Imaging. *Urology* 2021; 158:110-116. PMID: 34284011. doi.org/10.1016/j.urology.2021.04.070

Jamil M, Rakic N, Sood A, Keeley J, Modonutti D, Novara G, **Jeong W**, Menon M, **Rogers CG**, and **Abdollah F**. Impact of Lymphovascular Invasion on Overall Survival in Patients With Prostate Cancer Following Radical Prostatectomy: Stage-per-Stage Analysis. *Clin Genitourin Cancer* 2021; 19(5):e319-e325. PMID: 34154946. doi.org/10.1016/j.clgc.2021.04.009

Jiang T, Osadchiy V, Weinberger JM, Zheng MH, Owen MH, Leonard SA, Mills JN, **Kachroo N**, and Eleswarapu SV. Impact of the COVID-19 Pandemic on Patient Preferences and DecisionMaking for Symptomatic Urolithiasis. *J Endourol* 2021; 35(8):1250-1256. PMID: 33478351. doi.org/10.1089/end.2020.1141

Johnson K, Lane BR, Weizer AZ, Herrel LA, **Rogers CG**, Qi J, Johnson AM, Seifman BD, and Sarle RC. Partial nephrectomy should be classified as an inpatient procedure: Results from a statewide quality improvement collaborative. *Urol Oncol* 2021; 39(4):239.e239-239.e216. PMID: 33485765. doi.org/10.1016/j.urolonc.2021.01.001

**Kachroo N**, **Raffee S**, Elshatanoufy S, and **Atiemo H** . High uterosacral ligament hysteropexy for the management of pelvic organ prolapse. *Int Braz J Urol* 2021; 47(4):902-904. PMID: 33848087. doi.org/10.1590/s1677-5538.Ibju.2020.0384

Katims AB, Say R, Derweesh I, Uzzo R, Minervini A, Wu Z, **Abdollah F**, Sundaram C, Ferro M, Rha K, Mottrie A, Rosiello G, Simone G, Eun DD, Reese A, Kidd LC, Porter J, Bhattu AS, Gonzalgo ML, Margulis V, Marcus J, Danno A, Meagher M, Tellini R, Mari A, Veccia A, Ghoreifi A, Autorino R, Djaladat H, and Mehrazin R. Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). *J Urol* 2021; 206(3):568-576. PMID: 33881931. doi.org/10.1097/ju.0000000000001786

Lee DI, Shahait M, Dalela D, Keeley J, Lal P, Vapiwala N, and **Abdollah F**. External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. *World J Urol* 2021; 39(9):3217-3222. PMID: 33388922. doi.org/10.1007/s00345-020-03540-1

Malinzak L, McEvoy T, Denny J, Kim D, Stracke J, **Jeong W**, and Yoshida A. Robot-assisted Transplant Ureteral Repair to Treat Transplant Ureteral Strictures in Patients after Robot-assisted Kidney Transplant: A Case Series. *Urology* 2021; 156:141-146. PMID: 34058240. doi.org/10.1016/j.urology.2021.05.029

Nocera L, Collà Ruvolo C, Stolzenbach LF, Deuker M, Tian Z, Gandaglia G, Fossati N, **Abdollah F**, Suardi N, Mirone V, Graefen M, Chun FK, Saad F, Montorsi F, Briganti A, andKarakiewicz PI. Improving the stratification of intermediate risk prostate cancer. *Minerva Urol Nephrol* 2021. PMID: 33887893. doi.org/10.23736/s2724-6051.21.04314-7

**Patel AK**, Lane BR, Chintalapati P, Fouad L, Butaney M, Budzyn J, Johnson A, Qi J, Schervish E, and **Rogers CG**. Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative. *Eur Urol Open Sci* 2021; 30:37-43. PMID: 34337546. doi.org/10.1016/j.euros.2021.06.004

**Patel AK**, **Rogers CG**, Johnson A, Noyes SL, Qi J, Miller D, Shervish E, Stockton B, and Lane BR. Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative. *Eur Urol Open Sci* 2021; 23:13-19. PMID: 34337485. doi.org/10.1016/j.euros.2020.11.002

Raison N, Servian P, **Patel A**, Santhirasekaram A, Smith A, Yeung M, Lloyd J, Mannion E, Rockall A, Ahmed H, and Winkler M. Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer? *Prostate Cancer Prostatic Dis* 2021. PMID: 34845306. doi.org/10.1038/s41391-021-00468-4

Rakic N, Jamil M, Keeley J, Sood A, Vetterlein M, Dalela D, Arora S, Modonutti D, Bronkema C, Novara G, **Peabody J**, **Rogers C**, Menon M, and **Abdollah F**. Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. *Urol Oncol* 2021; 39(8):495.e491-495.e496. PMID: 33602620. doi.org/10.1016/j.urolonc.2021.01.007

**Rambhatla A**, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z, **Dabaja AA**, **Rogers CG**, **Liroff SA**, and **Abdollah F**. COVID-19 Infection in Men on Testosterone Replacement Therapy. *J Sex Med* 2021; 18(1):215-218. PMID: 33191186. doi.org/10.1016/j.jsxm.2020.09.013

**Rogers C**. Point/Counterpoint of Controversial Topics in Robotic Surgery Editorial Comment. *J Endourol* 2021; 35(8):1123. PMID: 33913740. doi.org/10.1089/end.2021.0342

**Shakir NA**. Letter to the Editor. *Can J Urol* 2021; 28(3):10657. PMID: 34129455.

**Shakir NA**. Re: Abramowitz et al. "Virtue male sling outcomes and application to a contemporary nomogram". *Canadian Journal of Urology* 2021; 28(3):10657-10657. PMID: Not assigned.

Shamaa T, Yoshida A, Borchert A, McEvoy T, **Jeong W**, and Malinzak L. Robot-assisted Transplant Ureteral Repair after Robot-assisted Kidney Transplant. *Urology Video Journal* 2021; 11. PMID: Not assigned. doi.org/10.1016/j.urolvj.2021.100099

Sood A, Butaney M, Olson P, Farah G, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. The Impact of the Price Transparency Mandate on Cost Reporting for Common Urological Services across the U.S. News Top 21 Hospitals. *Urology Practice* 2021; 8(6):657-660. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000264

Sood A, **Jeong W**, Keeley J, **Abdollah F**, Hassan O, Gupta N, and Menon M. Subtotal surgical therapy for localized prostate cancer: a single-center precision prostatectomy experience in 25 patients, and SEER-registry data analysis. *Transl Androl Urol* 2021; 10(7):3155-3166. PMID: 34430418. doi.org/10.21037/tau-20-1476

Sood A, Wong P, Borchert A, Budzyn J, Keeley J, Heilbronn C, Eilender B, **Littleton R**, and **Leavitt DA**. Use of ultra -low dose computed tomography versus abdominal plain film forassessment of stone-free rates after shock-wave lithotripsy: implications on emergency room visits, surgical procedures, and cost-effectiveness. *Urolithiasis* 2021; 49(6):591-598. PMID: 33993338. doi.org/10.1007/s00240-021-01273-3

Tandogdu Z, Collins J, Shaw G, Rohn J, Koves B, Sachdeva A, Ghazi A, Haese A, Mottrie A, Kumar A, Sivaraman A, Tewari A, Challacombe B, Rocco B, Giedelman C, Wagner C, **Rogers CG**, Murphy DG, Pushkar D, Ogaya-Pinies G, Porter J, Seetharam KR, Graefen M, Orvieto MA,Moschovas MC, Schatloff O, Wiklund P, Coelho R, Valero R, de Reijke TM, Ahlering T, Rogers T, van der Poel HG, Patel V, Artibani W, Wagenlehner F, Maes K, Rha KH, Nathan S, Bjerklund Johansen TE, Hawkey P, and Kelly J. Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international

accelerated consensus statement. *BJU Int* 2021; 127(6):729-741. PMID: 33185026. doi.org/10.1111/bju.15299

Wertheimer S, Budzyn J, Perkins S, Borchert A, **Rogers C**, and **Patel A**. Patient Tolerability With Office Transperineal Biopsy Using a Reusable Needle Guide. *Urology* 2021; 154:339-341. PMID: 34044025. doi.org/10.1016/j.urology.2021.05.018

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie J, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Reply to K.P. Weinfurt et al. *J Clin Oncol* 2020; 38(6):654-655. PMID: 31895615. doi.org/10.1200/jco.19.02642

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie J, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Assessing Patient-Reported Outcomes: A Negotiated Process Reply. *Journal of Clinical Oncology* 2020; 38(6):654-+. PMID: Not assigned. doi.org/10.1200/jco.19.02642

Ahmed Y, Hussein AA, May PR, Ahmad B, Khan A, Benkowski J, Durrani A, Khan S, Kozlowski J, Saar M, Wijburg CJ, Richstone L, Wagner A, Yuh B, Redorta JP, Dasgupta P, Khan MS, Menon M, **Peabody JO** , Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Tan WS, Maatman TJ, Poulakis V, Kaouk J, Canda AE, Balbay MD, Wiklund P, and Guru KA. Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *African Journal of Urology* 2020; 26(1). PMID: Not assigned. doi.org/10.1186/s12301-020-00031-y

Alanee S, Deebajah M, Taneja K, Cole D, Pantelic M, **Peabody J**, Williamson SR, Gupta N, **Dabaja A**, and Menon M. Post Prostatectomy Pathologic Findings of Patients With ClinicallySignificant Prostate Cancer and no Significant PI- RADS Lesions on Preoperative Magnetic Resonance Imaging. *Urology* 2020; 146:183-188. PMID: 32946907. doi.org/10.1016/j.urology.2020.07.068

Alanee S, **Peabody J**, and Menon M. AUTHOR REPLY. *Urology* 2020; 146:188. PMID:

33272426. doi.org/10.1016/j.urology.2020.07.071

Alanee S, **Peabody J**, and Menon M. Post Prostatectomy Pathologic Findings of Patients With Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative

Magnetic Resonance Imaging REPLY. *Urology* 2020; 146:188-188. PMID: Not assigned. doi.org/10.1016/j.urology.2020.07.071

Arora S, Bronkema C, Porter JR, Mottrie A, Dasgupta P, Challacombe B, Rha KH, Ahlawat RK, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Sivaraman A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Bhandari M, **Jeong W**, Menon M, **Rogers CG**, and **Abdollah F**. Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. *Urology* 2020; 146:125-132. PMID: 32941944. doi.org/10.1016/j.urology.2020.09.003

Arora S, Keeley J, **Patel A**, Eleswarapu SV, Bronkema C, Alanee S, and Menon M. Defining a "High Volume" Radical Cystectomy Hospital: Where Do We Draw the Line? *Eur Urol Focus* 2020; 6(5):975-981. PMID: 30772360. doi.org/10.1016/j.euf.2019.02.001

Baumgarten L, Borchert A, Sood A, Dalela D, Arora S, Keeley J, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort. *Urol Oncol* 2020; 38(2):38.e17-38.e22. PMID: 31653564. doi.org/10.1016/j.urolonc.2019.09.012

Bhandari M, Nallabasannagari AR, Reddiboina M, Porter JR, **Jeong W**, Mottrie A, Dasgupta P, Challacombe B, Abaza R, Rha KH, Parekh DJ, Ahlawat R, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Buffi NM, Sivaraman A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Meyyazhgan KR, Patil P, Menon M, and **Rogers C**. Predicting intra-operative and postoperative consequential events using machine-learning techniques in patients undergoing robot-assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. *BJU Int* 2020; 126(3):350-358. PMID: 32315504. doi.org/10.1111/bju.15087

Borchert A, Baumgarten L, Dalela D, Jamil M, Budzyn J, Kovacevic N, Yaguchi G, Palma-Zamora I, Perkins S, Bazzi M, Wong P, Sood A, **Peabody J**, **Rogers CG**, **Dabaja A**, and **Atiemo H**. Managing Urology Consultations During COVID-19 Pandemic: Application of aStructured Care Pathway. *Urology* 2020; 141:7-11. PMID: 32330531. doi.org/10.1016/j.urology.2020.04.059

Bronkema C, Arora S, Sood A, Dalela D, Keeley J, Borchert A, Baumgarten L, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. Rare Histological Variants of ProstateAdenocarcinoma: A National Cancer Database Analysis. *J Urol* 2020; 204(2):260-266. PMID: 32141804. doi.org/10.1097/ju.0000000000001011

Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Chitale D, Gupta N, Davis MB, Newman LA, **Rogers CG**, Paris PL, Li J, Rybicki BA, and Levin AM. Breast and prostate cancers harborcommon somatic copy number alterations that consistently differ by race and are associated with survival. *BMC Med Genomics* 2020; 13(1):116. PMID: 32819446. doi.org/10.1186/s12920-020-00765-2

Cheng PJ, Keihani S, Roth JD, Pariser JJ, Elliott SP, Bose S, Khavari R, Crescenze I, Stoffel JT, Velaer KN, Elliott CS, **Raffee SM**, **Atiemo HO**, Kennelly MJ, Lenherr SM, and Myers JB. Contemporary multicenter outcomes of continent cutaneous ileocecocystoplasty in the adult population over a 10-year period: A Neurogenic Bladder Research Group study. *Neurourol Urodyn* 2020; 39(6):1771-1780. PMID: 32506711. doi.org/10.1002/nau.24420

Dauw CA, Swarna K, Qi J, Kim T, **Leavitt D**, Leese J, Abdelhady M, Witzke K, Hollingsworth JM, and Ghani KR. Shockwave Lithotripsy Use in the State of Michigan: American Urological Association Guideline Adherence and Clinical Implications. *Urology* 2020; 137:38-44. PMID:

31843621. doi.org/10.1016/j.urology.2019.11.037

Dedigama-Arachchige P, Carskadon S, Li J, Loveless I, Alhamar M, **Peabody JO**, **Stricker H**, Chitale DA, **Rogers CG**, Menon M, Gupta NS, Bismar TA, Williamson SR, and Palanisamy N. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. *Mod Pathol* 2020; 33(9):1791-1801. PMID: 32238875. doi.org/10.1038/s41379-020-0525-0

Ginsburg KB, Schwabe JR, Cochrane JA, Tapper A, Burks F, and **Rambhatla A**. Low Serum Albumin Correlates With Adverse Events Following Surgery for Male Urinary Incontinence: Analysis of the American College of Surgeons National Surgical Quality Improvement Project. *Urology* 2020; 137:178-182. PMID: 31866523. doi.org/10.1016/j.urology.2019.12.004

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, **Peabody JO**, Wijburg CJ, Wagner A, Canda AE, Khan MS, Scherr D, Schanne F, Maatman TJ, Kim E, Mottrie A, Aboumohamed A, Gaboardi F, Pini G, Kaouk J, Yuh B, Rha KH, Hemal A, Palou Redorta J, Badani K, Saar M, Stockle M, Richstone L, Roupret M, Balbay D, Dasgupta P, Menon M, and Guru KA. A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *BJU Int* 2020; 126(2):265-272. PMID: 32306494. doi.org/10.1111/bju.15083

Jamil ML, Keeley J, Sood A, Dalela D, Arora S, **Peabody JO**, Trinh QD, Menon M, **Rogers CG**, and **Abdollah F**. Long-term Risk of Recurrence in Surgically Treated Renal CellCarcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. *Eur Urol* 2020; 77(2):277-281. PMID: 31703971. doi.org/10.1016/j.eururo.2019.10.028

Jamil ML, Keeley J, Sood A, Dalela D, Arora S, **Peabody JO**, Trinh QD, Menon M, **Rogers CG**, **Abdollah F**, and Laguna MP. Re: Long-Term Risk of Recurrence in Surgically TreatedRenal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. *Journal of Urology* 2020; 204(3):614-615. PMID: Not assigned. doi.org/10.1097/JU.0000000000001174

Johnson M, Perkins SQ, and **Leavitt D**. Alkaline- Encrusted Pyelitis Causing Renal Failure in a Transplant Kidney: Treatment with Percutaneous Nephrolithotomy and Urinary Acidification. *J Endourol Case Rep* 2020; 6(4):435-437. PMID: 33457694. doi.org/10.1089/cren.2020.0183

Kovacevic N, Lopes NN, **Raffee S**, and **Atiemo HO**. Predicting Upper Urinary Tract Risk in the Neurogenic Bladder Patient. *Current Bladder Dysfunction Reports* 2020; 15(2):66-71. PMID: Not assigned. doi.org/10.1007/s11884-020-00578-0

Lescay H, **Abdollah F**, Cher ML, Qi J, Linsell S, Miller DC, Montie JE, **Peabody J**, Kaffenberger S, Morgan T, Loeb A, and Lane BR. Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. *Urol Oncol* 2020; 38(4):198-203. PMID: 31740331. doi.org/10.1016/j.urolonc.2019.09.026

Lin JC, **Patel A**, and **Rogers CG**. Robot-assisted removal of inferior vena cava filter. *J Vasc Surg Cases Innov Tech* 2020; 6(2):311-312. PMID: 32566810.doi.org/10.1016/j.jvscit.2020.03.009

Lin JC, Ranasinghe B, **Patel A**, and **Rogers CG**. Robot-assisted laparoscopic placement of extravascular stent for nutcracker syndrome. *J Vasc Surg Cases Innov Tech* 2020; 6(3):346-347. PMID: 32715169. doi.org/10.1016/j.jvscit.2020.03.013

Lu Z, Williamson SR, Carskadon S, Arachchige PD, Dhamdhere G, Schultz DS, **Stricker H**, **Peabody JO**, **Jeong W**, Chitale DA, Bismar TA, **Rogers CG**, Menon M, Gupta NS, andPalanisamy N. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. *Prostate* 2020; 80(1):38-50. PMID: 31584209. doi.org/10.1002/pros.23914

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, Briganti A, Shariat SF, **Abdollah F**, Carmignani L, and Karakiewicz PI. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *Eur Urol Focus* 2020; 6(2):298-304. PMID: 30266210. doi.org/10.1016/j.euf.2018.09.007

Peabody H, **Patel A**, Johnson A, Mirza M, Noyes SL, Schervish E, Kaul S, **Rogers CG**, Lane BR, and Semerjian A. Development of a Novel Scoring System Quantifies Opportunities to Reduce Surgery for Benign Renal Neoplasms: A Retrospective Quality Improvement Analysis within the MUSIC-KIDNEY Collaborative. *J Urol* 2020; 204(6):1160-1165. PMID: 32628102. doi.org/10.1097/ju.0000000000001238

Perkins SQ, **Dabaja A**, and **Atiemo H**. Best Approaches to Evaluation and Feedback in Post-Graduate Medical Education. *Curr Urol Rep* 2020; 21(10):36. PMID: 32789759. doi.org/10.1007/s11934-020-00991-2

Rakic N, Keeley J, and **Abdollah F**. Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77:713-724: External Validity of the Updated Prostate Cancer Intervention Versus Observation Trial (PIVOT). *Eur Urol Oncol* 2020; 3(4):557-558. PMID: 32546347. doi.org/10.1016/j.euo.2020.05.002

Rakic N, Sood A, Dalela D, Arora S, Malovana U, Keeley J, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. *Clin Genitourin Cancer* 2020; 18(6):489-499.e486. PMID: 32595074. doi.org/10.1016/j.clgc.2020.05.001

**Rambhatla A**. Editorial Comment. *J Urol* 2020; 204(3):556. PMID: 32574513. doi.org/10.1097/ju.0000000000001016.01

Sood A, **Abdollah F**, Jeong W, and Menon M. The Precision Prostatectomy: "Waiting for

Godot". *Eur Urol Focus* 2020; 6(2):227-230. PMID: 31983662.

doi.org/10.1016/j.euf.2020.01.010

Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P, Hanna R, Cotter D, **Jeong W**, Elshaikh M, **Rogers CG**, **Peabody JO** , Menon M, and **Abdollah F**. Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data. *Urol Oncol* 2020; 38(6):599.e591-599.e598. PMID: 32229186. doi.org/10.1016/j.urolonc.2020.02.024

Sood A, Keeley J, Palma-Zamora I, Dalela D, Arora S, **Peabody JO**, **Rogers CG**, Montorsi F, Menon M, Briganti A, and **Abdollah F**. Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion. *BJU Int* 2020; 125(6):756-758. PMID: 32045096. doi.org/10.1111/bju.15034

Turner KA, **Rambhatla A**, Schon S, Agarwal A, Krawetz SA, Dupree JM, and Avidor-Reiss T. Male Infertility is a Women's Health Issue-Research and Clinical Evaluation of Male Infertility Is Needed. *Cells* 2020; 9(4). PMID: 32316195. doi.org/10.3390/cells9040990

Wu RC, Prebay ZJ, Patel P, Kim T, Qi J, Telang J, Linsell S, Kleer E, Miller DC, **Peabody JO**, Ghani KR, and Johnston WK, 3rd. Using video review to understand the technical variation of robot-assisted radical prostatectomy in a statewide surgical collaborative. *World J Urol* 2020; 38(7):1607-1613. PMID: 31444604. doi.org/10.1007/s00345-019-02906-4

Yaguchi G, Tang HJ, Deebajah M, Keeley J, Pantelic M, Williamson S, Gupta N, **Peabody JO** , Menon M, **Dabaja A**, and Alanee S. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance. *Urol Oncol* 2020; 38(6):599.e599-599.e513. PMID: 32265090. doi.org/10.1016/j.urolonc.2020.03.002

**Abdollah F**, Keeley J, and Menon M. Minimally Invasive or Abdominal Radical Hysterectomy for Cervical Cancer. *N Engl J Med* 2019; 380(8):793. PMID: 30786197. doi.org/10.1056/NEJMc1816590

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie JE, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Validity of the Patient -Reported Outcome Measurement Information System(PROMIS) sexual interest and satisfaction measures in men following radical prostatectomy. *Journal of Clinical Oncology* 2019; 37(23):2017-2027. PMID: Not assigned.doi.org/10.1200/JCO.18.01782

Alanee S, El-Zawahry A, Dynda D, **Dabaja A**, McVary K, Karr M, and Braundmeier-Fleming A. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. *Prostate* 2019; 79(1):81-87. PMID: 30117171. doi.org/10.1002/pros.23713

Arabi A, Deebajah M, Yaguchi G, Pantelic M, Williamson S, Gupta N, Park H, **Peabody J**, Menon M, **Dabaja A**, and Alanee S. Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer. *Urology* 2019; 134:168-172. PMID: 31479660. doi.org/10.1016/j.urology.2019.08.035

Arora S, Sood A, Dalela D, Tang HJ, **Patel A**, Keeley J, Trinh QD, **Rogers CG** , Menon M, and **Abdollah F**. Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENATrial to Real-world National Cancer Data Base Cases. *Eur Urol* 2019; 75(2):352-353. PMID: 30420256. doi.org/10.1016/j.eururo.2018.10.054

Auffenberg GB, Ghani KR, Ramani S, Usoro E, Denton B, **Rogers C**, Stockton B, Miller DC, and Singh K. askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men. *Eur Urol* 2019; 75(6):901-907. PMID: 30318331. doi.org/10.1016/j.eururo.2018.09.050

Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, **Abdollah F**, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, and Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. *Clin Genitourin Cancer* 2019; 17(1):72-78.e74. PMID: 30342845. doi.org/10.1016/j.clgc.2018.09.011

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, **Abdollah F**, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, and Karakiewicz PI.Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph

Node Metastatic Prostate Cancer Patients. *Eur Urol Focus* 2019; 5(3):381-388. PMID:

29366856. doi.org/10.1016/j.euf.2018.01.009

Bazzi M, Jamil ML, and **Dabaja AA**. Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections. *Curr Urol Rep* 2019; 20(8):42. PMID: 31201571. doi.org/10.1007/s11934-019-0910-8

Bronkema C, Rakic N, and **Abdollah F**. Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension. *Ann Transl Med* 2019; 7(Suppl 8):S291. PMID: 32016010. doi.org/10.21037/atm.2019.11.44

Budzyn J, Trinh H, **Raffee S**, and **Atiemo H**. Bladder Augmentation (Enterocystoplasty): the

Current State of a Historic Operation. *Curr Urol Rep* 2019; 20(9):50. PMID: 31342172. doi.org/10.1007/s11934-019-0919-z

Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, Sundaram SK, Li J, Wu KH, Chandrashekar DS, **Peabody JO**, **Stricker H**, Hwang C, Chitale DA, Williamson SR, Gupta NS, Navone NM, **Rogers C**, Menon M, Varambally S, and Palanisamy N. Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. *Neoplasia* 2019; 21(10):989-1002. PMID: 31446281. doi.org/10.1016/j.neo.2019.07.010

Dalela D, Sun M, Diaz M, Karabon P, Seisen T, Trinh QD, Menon M, and **Abdollah F**. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. *Eur Urol Focus* 2019; 5(1):77-80. PMID: 28753893. doi.org/10.1016/j.euf.2017.04.012

Deebajah M, Bazzi M, Walton E, Pantelic M, Park H, **Dabaja A**, and Alanee S. Prostate volume measured by magnetic resonance imaging is not a predictor of lower urinary tract symptoms. *J Family Med Prim Care* 2019; 8(4):1370-1373. PMID: 31143723.doi.org/10.4103/jfmpc.jfmpc\_94\_19

Deebajah M, Keeley J, Park H, Pantelic M, Gupta N, Williamson SR, **Peabody J**, Menon M, **Dabaja A**, and Alanee S. A propensity score matched analysis of the effects of AfricanAmerican race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate. *Urol Oncol* 2019; 37(8):531.e531-531.e535. PMID: 31005421. doi.org/10.1016/j.urolonc.2019.03.017

Friedlander DF, von Landenberg N, Löppenberg B, Noldus J, Lipsitz SR, Cole AP, **Abdollah F**, Nguyen PL, Choueiri TK, Kibel AS, and Trinh QD. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. *J Urol* 2019; 201(4):728-734. PMID: 30633112. doi.org/10.1097/ju.0000000000000006

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Osei J, Kaouk J, Redorta JP, Menon M, **Peabody J**, Dasgupta P, Khan MS, Mottrie A, Stöckle M, Hemal A, Richstone L, Hosseini A,Wiklund P, Schanne F, Kim E, Ho Rha K, and Guru KA. Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2019; 202(5):927-935. PMID: 31188729. doi.org/10.1097/ju.0000000000000386

Kryvenko ON, Wang Y, Sadasivan S, Gupta NS, **Rogers C**, Bobbitt K, Chitale DA, Rundle A, Tang D, and Rybicki BA. Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy. *Prostate* 2019; 79(10):1090-1098. PMID: 31045267. doi.org/10.1002/pros.23820

Macki M, Anand SK, Jaratli H, and **Dabaja AA**. Penile Lymphangioma: review of the literature

with a case presentation. *Basic Clin Androl* 2019; 29:1. PMID: 30705756.

doi.org/10.1186/s12610-018-0081-3

Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, **Abdollah F**, Tilki D, Briganti A, Montorsi F, Shariat SF, Schips L, and Karakiewicz PI. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *Eur Urol Focus* 2019; 5(3):467-473. PMID: 29398456. doi.org/10.1016/j.euf.2018.01.007

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, **Abdollah F**, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, and Karakiewicz PI. The effect of race on survival after local therapy in metastatic prostate cancer patients. *Can Urol Assoc J* 2019; 13(6):175-181. PMID: 30332592. doi.org/10.5489/cuaj.5399

Oh CK, Kim KH, **Jeong W**, Han WK, Rha KH, and Ahn B. Research on Patient Satisfaction of Robotic Telerounding: A Pilot Study in a Korean Population. *Urology* 2019; 130:205-208. PMID: 31059727. doi.org/10.1016/j.urology.2019.04.030

Prebay ZJ, **Peabody JO**, Miller DC, and Ghani KR. Video review for measuring and improving skill in urological surgery. *Nat Rev Urol* 2019; 16(4):261-267. PMID: 30622365. doi.org/10.1038/s41585-018-0138-2

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, **Abdollah F**, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, and Karakiewicz PI. TheImpact of Lymph Node Metastases Burden at Radical Prostatectomy. *Eur Urol Focus* 2019; 5(3):399-406. PMID: 29306731. doi.org/10.1016/j.euf.2017.12.009

**Raffee S**, and **Atiemo H**. Polydimethylsiloxane Erosion as a Cause for Recurrent Urinary Tract Infections. *J Endourol Case Rep* 2019; 5(3):117-119. PMID: 32775642. doi.org/10.1089/cren.2019.0007

Sood A, **Abdollah F**, and Menon M. Retzius-sparing robot-assisted radical prostatectomy. *BJU Int* 2019; 123(1):7-8. PMID: 30565400. doi.org/10.1111/bju.14518

Sood A, **Jeong W**, Taneja K, **Abdollah F**, Palma-Zamora I, Arora S, Gupta N, and Menon M. The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study. *BMJ Surg Interv Health Technol* 2019; 1(1):e000002. PMID: 35047770. doi.org/10.1136/bmjsit-2019-000002

Tam CA, Dauw CA, Ghani KR, Gunaseelan V, Kim T, **Leavitt DA**, Raisky J, Yan PL, and Hollingsworth JM. New Persistent Opioid Use After Outpatient Ureteroscopy for Upper Tract Stone Treatment. *Urology* 2019; 134:103-108. PMID: 31536742. doi.org/10.1016/j.urology.2019.08.042

Tan WS, Krimphove MJ, Cole AP, Marchese M, Berg S, Lipsitz SR, Löppenberg B, Nabi J, **Abdollah F**, Choueiri TK, Kibel AS, Sooriakumaran P, and Trinh QD. Variation in PositiveSurgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. *Clin Genitourin Cancer* 2019; 17(5):e1060-e1068. PMID: 31303561. doi.org/10.1016/j.clgc.2019.06.008

Trinh H, Irish V, Diaz M, and **Atiemo H**. Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation. *Int Neurourol J* 2019; 23(3):226-233. PMID: 31607102. doi.org/10.5213/inj.1938030.015

Ventimiglia E, Seisen T, **Abdollah F**, Briganti A, Fonteyne V, James N, Roach M, 3rd, Thalmann GN, Touijer K, Chen RC, and Cheng L. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. *Eur Urol Oncol* 2019; 2(3):294-301. PMID: 31200844. doi.org/10.1016/j.euo.2019.02.001

Walton E, Yaguchi G, Keeley J, Deebajah M, Menon M, **Peabody J**, **Dabaja A**, and Alanee S. Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans. *J Urol* 2019; 201(3):503-509. PMID: 30316896. doi.org/10.1016/j.juro.2018.10.003

Walton EL, Deebajah M, Keeley J, Fakhouri S, Yaguchi G, Pantelic M, **Rogers C**, Park H, Menon M, **Peabody JO**, **Dabaja A**, and Alanee S. Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. *Cancer Med* 2019; 8(8):3659-3665. PMID: 31111654. doi.org/10.1002/cam4.2149

**Abstracts**

**Abdollah F**, Piontkowski AJ, Morisetty S, Corsi N, Majdalany S, Rakic I, Sood A, Jamil M, Dalela D, Arora S, and **Rogers C**. The impact of adjuvant chemotherapy on overall survival in patients with node-positive Upper Tract Urothelial Carcinoma (UTUC): Improving precision in medicine with a risk-stratified approach. *European Urology* 2022; 81:S468-S468.

Butaney M, Johnson A, Bulusu A, Gandham D, Qi J, Jamil M, **Patel A**, Noyes S, Anema J, Levin M, Rosenberg B, Lane BR, **Rogers CG**, and Michigan Urological Surg I. Reducing post-operative emergency department visits and readmissions after nephrectomy: An initial evaluation of the MUSIC-KIDNEY registry. *European Urology* 2022; 81:S223-S224.

Butaney M, Johnson A, Qi J, **Patel A**, Noyes S, Brede C, Seifman B, Maatman T, **Rogers CG**, Lane BR, and Michigan Urological Surg I. Evaluation of an uncomplicated recovery after nephrectomy: MUSIC-KIDNEY NOTES (Notable Outcomes and Trackable Events after Surgery). *European Urology* 2022; 81:S219-S220.

Butaney M, **Patel A**, Qi J, Singh K, Johnson A, Levy A, Noyes S, Ghani K, **Rogers C**, Lane B, and Michigan Urological Surg I. Assessing renal mass management of patients with increased comorbidities: Results from a statewide registry. *European Urology* 2022; 81:S342-S343.

Corsi N, Majdalany SE, Rakic I, Friedman B, Corsi M, Butaney M, Malchow T, Piontkowski AJ, Ginsburg K, **Atiemo H**, and **Abdollah F**. Who is shaping the future of urology? A descriptive analysis of current urology residency program directors. *European Urology* 2022; 81:S145-S146.

Corsi N, Rakic I, Ginsburg K, Jamil M, Sood A, Dalela D, Piontkowski A, Majdalany SE, **Rogers C**, and **Abdollah F**. External validation of the Bladder Cancer Research Consortium(BCRC) nomogram for predicting survival after radical cystectomy. *European Urology* 2022; 81:S1327-S1328.

Hakimi K, Carbonara U, Djaladat H, Mehrazin R, Eun D, Reese A, Gonzalgo M, Margulis V, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Tellini R, Ferro M, Meagher M, Saidian A, Walia A, Veccia A, Ghoriefi A, Cacciamani G, Bhattu A, Minervini A, Autorino R, and Derweesh I. Impact of node count on survival outcomes of lymph node dissection in non-metastatic upper tract urothelial carcinoma: Analysis of the robuust registry. *European Urology* 2022; 81:S477-S478.

Ivan I, Rakic N, Corsi N, Piontkowski A, Majdalany S, Jamil M, Sood A, Dalela D, Arora S, **Rogers C**, and **Abdollah F**. Evaluation of the utility of lymph-vascular invasion as anindependent prognostic predictor of overall survival for patients with renal cell carcinoma that undergo nephrectomy. *European Urology* 2022; 81:S99-S99.

Katayama S, Pradere B, Grossmann NC, Potretzke AM, Boorjian SA, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene Z, D'Andrea D, Kikuchi E, Fujita K, Heindenreich A, Raman JD, Roumiguie M, **Abdollah F**, Marcus J, Breda A, Fontana M, Roupret M, Araki M, Nasu Y, and Shariat SF. Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma. *European Urology* 2022; 81:S460-S461.

Meagher MF, Autorino R, Mehrazin R, Eun D, Margulis V, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Minervini A, Ferro M, Dialadat H, Wu Z, Hakimi K, Saidian A, WaliaA, Tellini R, Veccia A, Mazzone E, Koon R, Gonzalgo M, and Derweesh I. Elevated hemoglobin: Creatinine ratio is a novel preoperative marker for worsened survival outcomes in

upper tract urothelial carcinoma: Analysis from the robuust registry. *European Urology* 2022;

81:S452-S453.

Piontkowski AJ, Corsi N, Morisetty S, Majdalany S, Rakic I, Arora S, Jamil M, Dalela D, **Rogers C**, and **Abdollah F**. Benefit of lymph node dissection in cn plus patients in the treatmentof upper tract urothelial carcinoma: Analysis of ncdb registry. *European Urology* 2022; 81:S459-S459.

Arora S, Bronkema C, Ranasinghe B, Wurst H, Keeley J, Sood A, Modonutti D, Novara G, Menon M, **Rogers C**, and **Abdollah F**. Impact of preexisting opioid-dependence on morbidity, length of stay, and inpatient cost of urologic oncologic surgery. *European Urology* 2021; 79:S768-S769. doi.org/10.1016/S0302-2838(21)00945-3

Briskin R, and **Atiemo H**. Evaluation of patient reported pain perception during office-based onabotulinumtoxina injection. *Neurourology and Urodynamics* 2021; 40(SUPPL 1):S216-S217. doi.org/10.1002/nau.24638

Briskin R, Etta P, **Raffee S**, Luck A, and **Atiemo H**. Comparison of urinary tract infection incidence following intradetrusor onabotulinumtoxina in clinic versus operating room settings. *Female Pelvic Medicine and Reconstructive Surgery* 2021; 27(10 SUPPL 1):S105.doi.org/10.1097/SPV.0000000000001103

Bronkema C, Arora S, Keeley J, Rakic N, Sood A, Dalela D, Stricker M, Olson P, **Rogers C**, Menon M, and **Abdollah F**. National Cancer Database analysis assessing the impact of treatment modalities on survival outcomes in localized neuroendocrine prostate adenocarcinoma. *European Urology* 2021; 79:S1542-S1543. doi.org/10.1016/S0302-2838(21)01461-5

Butaney M, **Patel A**, Lane B, Qi J, Johnson A, and **Rogers C**. Initial Management of Indeterminate Renal Masses in a Statewide Collaborative:a MUSICKIDNEY analysis. *Journal of Endourology* 2021; 35(SUPPL 1):A287. doi.org/10.1089/end.2021.35001.abstracts

Corsi N, Sood A, Keeley J, Dalela D, Bronkema C, Rakic N, Stricker M, Novara G, **Rogers C**, and **Abdollah F**. Recurrence-free survival following resection of low -grade, Non-Muscle-Invasive Urothelial Cancer (NMIBC): A Southwest Oncology Group (SWOG) S0337 post-hoc analysis. *European Urology* 2021; 79:S1032-S1033. doi.org/10.1016/S0302-2838(21)01124-6

Corsi N, Sood A, Keeley J, Dalela D, Bronkema C, Rakic N, Stricker M, Novara G, **Rogers C**, and **Abdollah F**. Estimating recurrence free survivability of Non-Muscle Invasive Bladder Cancer (NMIBC) after intravesical therapy: A clinical-based recursive partition analysis. *European Urology* 2021; 79:S1040. doi.org/10.1016/S0302-2838(21)01130-1

Dai Z, Jambor I, Taimen P, Pantelic M, Elshaikh MA, **Dabaja A**, **Rogers C**, Ettala O, Boström P, Aronen H, Merisaari H, and Wen N. Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth. *International Journal of Radiation Oncology Biology Physics* 2021; 111(3):S45. doi.org/10.1016/j.ijrobp.2021.07.123

Hakimi K, Autorino R, Meagher M, Soliman S, Yuan J, Stein R, Badani K, Mehrazin R, Eun D, Gonzalgo M, Margulis V, Li R, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Minervini A, Ferro M, Rha K, and Derweesh I. Outcomes of lymph node dissection in nephroureterectomy in treatment of upper tract urothelial carcinoma: Analysis of the robuust registry. *European Urology* 2021; 79:S1092-S1093. doi.org/10.1016/S0302-2838(21)01165-9

Jamil M, Hanna R, Sood A, Corsi N, Modonutti D, Keeley J, Novara G, **Patel A**, **Rogers C**, and **Abdollah F**. Renal mass size and presence of synchronous lung metastasis at time of diagnosis:Implications for chest imaging. *European Urology* 2021; 79:S880-S881. doi.org/10.1016/S0302-2838(21)01017-4

Kamphuis G, Canvasser N, Rivera M, Bechis S, Ingimarsson J, Knoedler J, Stern K, Stoughton C, Wollin D, Borofsky M, Bhojani N, El Tayeb M, **Leavitt D**, Hsi R, and Scotland K. Over-the-counter alkali agents to raise urine ph and citrate excretion: A randomized crossover study in healthy adults. *European Urology* 2021; 79:S381-S382. doi.org/10.1016/S0302-2838(21)00653-9

Modonutti D, Keeley J, Paciotti M, Hwang C, Menon M, Trinh Q, **Rogers C**, Novara G, and **Abdollah F**. A multi-trial based external validation of the Halabi nomogram in predicting theoverall survival of metastatic castration-resistant prostate cancer patients. *European Urology* 2021; 79:S1205. doi.org/10.1016/S0302-2838(21)01235-5

**Patel A**, Lane B, Butaney M, Johnson A, Qi J, and **Rogers C**. Building a roadmap for initial evaluation and follow up for surveillance of renal masses: Results from MUSIC consensus panel. *Journal of Endourology* 2021; 35(SUPPL 1):A105-A106. doi.org/10.1089/end.2021.35001.abstracts

**Patel A**, Lane B, Butaney M, Johnson A, Qi J, and **Rogers C**. Defining Patient Selection for Surveillance of Renal masses: Results from a MUSIC consensus panel. *Journal of Endourology* 2021; 35(SUPPL 1):A284. doi.org/10.1089/end.2021.35001.abstracts

Perkins S, **Patel A**, Butaney M, Johnson A, Qi J, **Rogers C**, and Lane B. Documentation of Nephrometry Scores for cT1 RenalMasses Correlates with Avoidance of Radical Nephrectomy Across the MUSIC-KIDNEY Statewide QI Collaborative. *Journal of Endourology* 2021; 35(SUPPL 1):A297. doi.org/10.1089/end.2021.35001.abstracts

Rakic N, Keeley J, Corsi N, Sood A, Bronkema C, Jamil M, Arora S, Palma-Zamora I, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Evaluation of the utility of lymphovascularinvasion as a complementary or independent prognostic predictor of overall survival after radical prostatectomy. *European Urology* 2021; 79:S1723. doi.org/10.1016/S0302-2838(21)01588-8

Sharrak A, Jamil M, Bazzi M, Timar R, Kovacevic N, and **Atiemo H**. Disparity in female pelvic examination in the evaluation of lower urinary tract symptoms. *Neurourology and Urodynamics* 2021; 40(SUPPL 1):S95-S96. doi.org/10.1002/nau.24638

Sood A, Keeley J, Palma-Zamora I, Chien M, Dalela D, Arora S, Jamil M, Kovacevic N, Corsi N, **Jeong W**, **Rogers C**, Trinh Q, **Peabody J**, Menon M, and **Abdollah F**. Anti-androgen therapy overcomes the time-delay in initiation of salvage radiation therapy and rescues the oncological outcomes in men with recurrent prostate cancer after radical prostatectomy: A post-hoc analysis of the RTOG 9601 trial data. *European Urology* 2021; 79:S1668. doi.org/10.1016/S0302-2838(21)01553-0

Zong WW, Carver E, Feldman A, Lee J, Sun Z, Xu LY, **Dabaja A**, and Wen N. Gleason grade group predictions from mp-MRI of prostate cancer patients using auto deep learning. *Cancer Research* 2021; 81(13).

**Abdollah F**, Shahait M, Dalela D, Kelly J, Vapiwala N, and Lee D. External validation of genomic classifier based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. *European Urology Open Science* 2020; 19:e1048-e1049. doi.org/10.1016/S2666-1683(20)33285-7

Alanee SR, Deebajah M, Roumayah Z, **Dabaja A**, **Peabody JO** , and Menon M. Detection of significant prostate cancer through magnetic resonance imaging targeted biopsy of PI-RADS3 lesions in African American patients based on prostate specific antigen density threshold of 0.15 ng/ml2: Analysis of patient population from the Vattikuti Urology Institute. *Journal of Clinical Oncology* 2020; 38(6). doi.org/10.1200/JCO.2020.38.6\_suppl.286

Alanee SR, Roumayah Z, Deebajah M, **Peabody JO**, Mora R, Guevara J, Francisco B, and Patterson BK. Adaptive genetic algorithms combined with high sensitivity single cell-based technology derived urine-based score to differentiate between high-grade and low-grade transitional cell carcinoma of the bladder. *Journal of Clinical Oncology* 2020; 38(6). doi.org/10.1200/JCO.2020.38.6\_suppl.572

Alhamar M, Gupta N, Oyedeji O, Hogan K, Sood A, Arora S, Schultz D, **Jeong W**, Williamson S, Menon M, and Hassan O. Precision prostatectomy: Analysis of surgical pathology findings of a promising and novel surgical approach for patients with low to intermediate-risk prostate cancer. *Modern Pathology* 2020; 33(3):850-852.

Alhamar M, Hassan O, Sood A, Arora S, **Jeong W**, Williamson S, Menon M, and Gupta N. Histopathologic features of prostate cancer in patients who underwent seminal vesicle-sparing radical prostatectomy: A novel surgical approach. *Modern Pathology* 2020; 33(3):849-850.

Arachchige PD, Carskadon S, Hu J, Fernando J, Chandrashekar DS, Gupta NS, Williamson SR, Chitale DA, **Rogers CG**, **Peabody JO**, Menon M, Bismar TA, Jiagge E, Varambally S, and Palanisamy N. Recurrent rearrangements of NAALADL2 in prostate, breast, cervical, head and neck and lung squamous cell carcinoma. *Cancer Research* 2020; 80(16 SUPPL). doi.org/10.1158/1538-7445.AM2020-2012

Arora S, **Rogers CG**, Arora K, Abou Shaar R, Kezlarian B, Modi M, Gupta N, and Williamson SR. Partial Nephrectomy For a Presumed Single Renal Mass Revealing Multiple Tumor Histologies: A Series of 4 Patients. *American Journal of Clinical Pathology* 2020; 154:S61-S61.

Baumgarten L, Irish V, **Raffee S**, and **Atiemo H**. Utilization of third line therapy in the urologic management of patients with multiple sclerosis. *Neurourology and Urodynamics* 2020; 39:S197-S198. doi.org/10.1002/nau.24307

Bhandari M, Nallabasannagari AR, Reddiboina M, Porter J, **Jeong W**, Mottrie A, Dasgupta P, Challacombe B, Abaza R, Rha KH, Parekh D, Ahlawat R, Capitanio U, Yuvaraja T, Rawal S, Moon D, Buffi's N, Sivaraman A, Maes K, Porpiglia F, Gautam G, Turkeri L, Preethi P, Menon M, and **Rogers C**. Predicting intraoperative complications and 30-days morbidity using machine learning techniques for patients undergoing robotic partial nephrectomy (RPN). *European Urology Open Science* 2020; 19:e1969-e1970. doi.org/10.1016/S2666-1683(20)33924-0

Bronkema C, Arora S, Rakic N, Sood A, Dalela D, Keeley J, Jamil M, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Impact of treatment modality on overall survival (OS) inlocalized ductal prostate adenocarcinoma (PCa): A national cancer database (NCDB) analysis. *European Urology Open Science* 2020; 19:e1659-e1660. doi.org/10.1016/S2666-1683(20)33709-5

Carskadon S, Diaz-Insua M, Gupta N, Williamson S, **Rogers C**, **Peabody J**, Menon M, and Palanisamy N. Comprehensive molecular mapping of prostate cancer-Approaching health disparities in molecular tumor heterogeneity perspective. *Cancer Epidemiology Biomarkers and Prevention* 2020; 29(6 SUPPL 1). doi.org/10.1158/1538-7755.DISP18-A113

Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Dhananjay C, Gupta N, Davis MB, Newman LA, **Rogers CG**, Paris PL, Li J, Rybicki BA, and Levin AM. Breast and prostate cancers harborcommon somatic copy number alterations thatconsistently differ by race and are associated with survival. *Cancer Epidemiology Biomarkers and Prevention* 2020; 29(6 SUPPL 2). doi.org/10.1158/1538-7755.DISP19-B066

Cone EB, Haeuser L, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh Q. Checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. *European Urology Open Science* 2020; 19:e1101. doi.org/10.1016/S2666-1683(20)33319-X

Cone EB, Modonutti D, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh QD. Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide. *European Urology Open Science* 2020; 19:e880. doi.org/10.1016/S2666-1683(20)33168-2

Cone EB, Modonutti D, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh QD. Lower odds of cardiac events for gonadotropic releasing hormone antagonists versus agonists. *European Urology Open Science* 2020; 19:e896. doi.org/10.1016/S2666-1683(20)33179-7

Dalela D, Sood A, Jamil M, Arora S, Keeley J, Palma-Zamora I, Rakic N, Bronkema C, **Peabody J**, **Rogers C**, Menon M, Elshaikh M, and **Abdollah F**. External validity of theStephenson nomogram predicting the outcomes of prostate cancer patients treated salvage radiotherapy after radical prostatectomy: The importance of genomic data. *European Urology Open Science* 2020; 19:e1058-e1059. doi.org/10.1016/S2666-1683(20)33292-4

Hiller SC, Swarna K, **Leavitt D**, Frontera JR, Jafri SM, Hollingsworth J, Dauw C, Ghani K, and For The Michigan Urological Surgery Improvement C. The risk of unplanned healthcare utilization in patients undergoing ureteroscopy with uncorrected bleeding diathesis in a surgical collaborative. *European Urology Open Science* 2020; 19:e850-e851. doi.org/10.1016/S2666-1683(20)33151-7

Jamil M, Keeley J, Sood A, Dalela D, Arora S, **Peabody J**, Trinh Q, Menon M, **Rogers C**, and **Abdollah F**. Long-term risk of recurrence in surgically treated renal cell carcinoma: A post-hocanalysis of the Eastern Cooperative Oncology Group - American College of Radiology Imaging Network E2805 Trial cohort. *European Urology Open Science* 2020; 19:e1962-e1964. doi.org/10.1016/S2666-1683(20)33920-3

Kovacevic N, Sood A, Keeley J, Dalela D, Arora S, Palma-Zamora I, Jamil M, **Jeong W**, Trinh QD, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Identifying patients that may benefit from addition of bicalutamide to salvage radiation therapy in the setting of biochemical failure after radical prostatectomy. *European Urology Open Science* 2020; 19:e1063. doi.org/10.1016/S2666-1683(20)33295-X

Lin JC, **Patel A**, and **Rogers CG**. Robot-assisted removal of inferior vena cava filter. *Journal of Vascular Surgery Cases and Innovative Techniques* 2020; 6(2):311-312.doi.org/10.1016/j.jvscit.2020.03.009

Lin JC, Ranasinghe B, **Patel A**, and **Rogers CG**. Robot -assisted laparoscopic placement of extravascular stent for nutcracker syndrome. *Journal of Vascular Surgery Cases and Innovative Techniques* 2020; 6(3):346-347. doi.org/10.1016/j.jvscit.2020.03.013

Maki G, **Abdollah F**, **Dabaja A**, and Suleyman G. Prevalence and outcome of asymptomatic procedural patients with COVID- 19 infection. *Open Forum Infectious Diseases* 2020; 7(SUPPL 1):S298. doi.org/10.1093/ofid/ofaa439.655

**Raffee S**, Griffin M, Massie L, Basheer A, Tundo K, Brown A, Air E, and **Atiemo H**. Lower urinary tract symptoms in women with spinal pathologies: A prospective prevalence study. *Neurourology and Urodynamics* 2020; 39:S198-S199. doi.org/10.1002/nau.24307

Sood A, Keeley J, Dalela D, Arora S, Palma-Zamora I, Jamil M, Kovacevic N, **Jeong W**, Trinh QD, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Does concomitant anti-androgen therapy improve outcomes in patients with recurrent prostate cancer undergoing early salvage radiation therapy. *European Urology Open Science* 2020; 19:e1062. doi.org/10.1016/S2666-1683(20)33294-8

Veccia A, Steward J, Derweesh I, Margulis V, Uzzo R, **Abdollah F**, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Riccardo T, Aron M, Mazzone E, Al -Qathani A, Asghar A, Sundaram C, and Autorino R. Robotic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) collaborative group. *European Urology Open Science* 2020; 19:e322-e324. doi.org/10.1016/S2666-1683(20)32772-5

Veccia A, Steward J, Derweesh I, Margulis V, Uzzo R, **Abdollah F**, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Tellini R, Aron M, Mazzone E, Al-Qathani A, Asghar A, Sundaram C, and Autorino R. Safety profile of robotic vs. laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) collaborative group. *European Urology Open Science* 2020; 19:e316-e318. doi.org/10.1016/S2666-1683(20)32769-5

**Abdollah F**, Betrus G, Cher M, Dalela D, Keeley J, Kim T, Lane B, Mansour S, Montie J, Schervish E, Sood A, Swama K, and **Peabody J**. Defining the indications for pelvic lymph node dissection (PLND)in prostate cancer (PCa)patients within a statewide quality improvement collaborative. *European Urology, Supplements* 2019; 18(1):e2050. doi.org/10.1016/S1569-9056(19)31484-8

**Abdollah F**, Dalela D, Sood A, Arora S, Tang HJ, Keeley J, Alanee S, **Rogers CG**, **Peabody JO**, and Menon M. Evaluating the impact of lead-time bias on the observed efficacy of early salvage radiation therapy in prostate cancer: A post -hoc analysis of the RTOG 9601 trial. *European Urology, Supplements* 2019; 18(1):e861. doi.org/10.1016/S1569-9056(19)30629-3

**Abdollah F**, **Jeong W**, Dalela D, Palma-Zamora I, Sood A, and Menon M. Menon-precision prostatectomy (MPP): An idea, development, exploration, assessment, long-term follow-up (IDEAL)stage 1 study. *European Urology, Supplements* 2019; 18(1):e622. doi.org/10.1016/S1569-9056(19)30460-9

Arachchige PD, Carskadon S, Dhamdhere G, Diaz-Insua M, Craig R, **Peabody J**, Menon M, Williamson S, Gupta N, and Palanisamy N. Evaluation of tumor heterogeneity in prostate biopsy samples. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-4688

Arachchige PD, Carskadon S, Dhamdhere G, Diaz-Insua M, **Stricker H**, **Rogers C**, **Peabody J**, Menon M, Williamson S, Gupta N, and Palanisamy N. Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNA in situ hybridization. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-4693

Arora S, Bronkema C, Porter JR, Mottrie A, Menon M, **Rogers CG**, **Jeong W**, Dasgupta P, Rha KH, Ahlawat RK, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Sivaramakrishnan A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Bhandari M, and **Abdollah F**. Feasibility of omitting outer (cortical)renorrhaphy during robotic partial nephrectomy - a multi-institutional analysis. *European Urology, Supplements* 2019; 18(1):e1605-e1606. doi.org/10.1016/S1569-9056(19)31161-3

Arora S, Sood A, Dalela D, Keeley J, Rakic N, Prokopiv U, Fotouhi A, **Peabody JO**, Mani M, and **Abdollah F**. Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States. *European Urology, Supplements* 2019; 18(1):e1392-e1393. doi.org/10.1016/S1569-9056(19)31007-3

Arora S, Sood A, Dalela D, **Patel A**, Keeley J, Trinh QD, Audrey F, Prokopiv U, Rakic N, **Rogers C**, Menon M, and Abdollah F. Testing the external validity of CARMENA trialcomparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *European Urology, Supplements* 2019; 18(1):e1178-e1179. doi.org/10.1016/S1569-9056(19)30849-8

Arora S, Sood A, Deepansh D, Keeley J, Borchert A, Baumgarten L, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e217-e218. doi.org/10.1016/S1569-9056(19)30159-9

Baumgarten LC, Borchert A, Delela D, Sood A, Arora S, Keeley J, Trinh Q, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Impact of timing on radiation therapy adverse eventsfollowing radical prostatectomy, an analysis of the RTOG 9601 cohort. *European Urology, Supplements* 2019; 18(1):e2200-e2201. doi.org/10.1016/S1569-9056(19)31591-X

Chakravarthi BVSK, Kalyana-Sundaram S, Arachchige PD, Carskadon S, Pathi SS, Diaz-Insua M, **Rogers C**, **Peabody J**, Hwang C, Menon M, Williamson S, Nilesh G, Varambally S, and Palanisamy N. Pseudogene-associated recurrent gene fusion in prostate cancer. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-915

Chopra V, Irish V, and **Atiemo H**. Outcomes of native tissue sacrospinous ligament fixation with unilateral deschamp needle suture ligature. *Neurourology and Urodynamics* 2019; 38:S239-S240. doi.org/10.1002/nau.23949

Fotouhi A, Borchert A, Dalela D, Sood A, Keeley J, Arora S, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. The changing face of surgically treated low-risk prostate cancer (PCa): A national cancer database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e2180. doi.org/10.1016/S1569-9056(19)31574-X

Gorgis S, Dabbagh M, Mawri S, Akoegbe G, Alanee S, **Alaswad K** , **Dabaja A**, and Rabbani B. RECURRENT SUPRAVENTRICULAR ARRHYTHMIA: WHEN ABLATION IS NOT THE ANSWER - A PERPLEXING CASE OF PHENOCHROMOCYTOMA. *Journal of the American College of Cardiology* 2019; 73(9):2941-2941. doi.org/10.1016/s0735-1097(19)33547-8

Jindal T, **Abdollah F**, and Menon M. Survival associated with radical prostatectomy vs radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis. *International Journal of Urology* 2019; 26:31. doi.org/10.1111/iju.14061

Lin JC, **Patel A**, and **Rogers C**. VS06. Robotic-Assisted Removal of Inferior Vena Cava Filter. *Journal of Vascular Surgery* 2019; 69(6):e193. doi.org/10.1016/j.jvs.2019.04.275

**Patel A**, Perkins S, Bazzi M, Arcot R, Johnson A, Qi J, Kim T, Ghani K, Schervish E, Lane B, and **Rogers C**. Patterns of renal mass biopsy across the MUSIC-KIDNEY statewide QI collaborative. *European Urology, Supplements* 2019; 18(1):e1231-e1232. doi.org/10.1016/S1569-9056(19)30884-X

**Raffee SM**, **Kachroo N**, Elshatanoufy S, and **Atiemo H**. Evaluation of transvaginal uterosacral ligament hysteropexy vs. uterosacral ligament suspension with hysterectomy: A retrospective comparison study with two year outcomes. *Neurourology and Urodynamics* 2019; 38:S241-S242. doi.org/10.1002/nau.23949

**Raffee SM**, Wong P, Palma-Zamora I, Irish V, and **Atiemo H**. Urologic care of a multiple sclerosis patient population-single provider experience. *Neurourology and Urodynamics* 2019; 38:S247-S248. doi.org/10.1002/nau.23949

Rakic N, Fotouhi A, Baumgarten L, Borchert A, Dalela D, Sood A, Arora S, Menon M, and **Abdollah F**. Persistent under-utilization of adjuvant radiotherapy in patients with adversepathological features at radical prostatectomy: A national cancer database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e969. doi.org/10.1016/S1569-9056(19)30703-1

Sood A, Eilender B, Wong P, and **Atiemo H**. Outcomes in patients with idiopathic overactive bladder undergoing augmentation cystoplasty in the era of onabotulinumtoxin-a and interstim. *Neurourology and Urodynamics* 2019; 38:S238-S239. doi.org/10.1002/nau.23949

Sood A, Keeley J, Arora S, Dalela D, **Jeong W**, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Rates and patterns of metastases in patients with node-negative prostate cancer at radicalprostatectomy that experience PSA failure: Post-hoc analysis of RTOG 9601 trial data. *European Urology, Supplements* 2019; 18(1):e865-e866. doi.org/10.1016/S1569-9056(19)30632-3

Sood A, Keeley J, Arora S, Dalela D, **Jeong W**, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Extended lymph node dissection is associated with improved overall survival in patients withvery high-risk prostate cancer: A national cancer database analysis. *European Urology, Supplements* 2019; 18(1):e2198. doi.org/10.1016/S1569-9056(19)31589-1

Tam C, Yan P, Raisky J, Gunaseelan V, Kim T, **Leavitt D**, Dauw C, and Hollingsworth JM. New persistent opioid use after ureteroscopy for stone treatment. *European Urology, Supplements* 2019; 18(1):e196-e197. doi.org/10.1016/S1569-9056(19)30146-0

Tan WS, Krimphove M, Cole A, Berg S, Marchese M, Lipsitz S, Loppenberg B, Nabi J, **Abdollah F**, Choueiri T, Kibel A, Sooriakumaran P, and Trinh QD. Variation in positivesurgical margin status following radical prostatectomy for pT2 prostate cancer. *Journal of Clinical Urology* 2019; 12(1):42-44. doi.org/10.1177/2051415819846081

Tan WS, Krimphove M, Cole A, Berg S, Marchese M, Lipsitz S, Loppenberg B, Nabi J, **Abdollah F**, Choueiri T, Kibel A, Sooriakumaran P, and Trinh QD. Variation in positivesurgical margin status following radical prostatectomy for pT2 prostate cancer. *European Urology, Supplements* 2019; 18(1):e294-e295. doi.org/10.1016/S1569-9056(19)30214-3

**Attachment 3**

**Urology Faculty Awards and Honors**

* **James O Peabody**
1. Distinguished Career Awards from the HF Alumni Association at the HFMG
	1. Elected to Chair of the Board of Governors of the Henry Ford Medical Group
	2. TopDoc HOUR magazine 2021
	3. Gold Humanism Honor Society, Wayne State University, 2020
	4. Resident Teaching Award, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI – 2018
	5. Resident Teaching Award, American Urology Association – 2013
	6. Shadow of a Leader Award – 2006
	7. Resident Teaching Award – 2004
	8. Joseph C. Cerny MD Resident Teaching Award – 1997
* **Craig G Rogers**
	1. President-elect, Society of Urologic Robotic Surgeons (term starting Fall 2022)
	2. TopDoc HOUR magazine 2010-2021
	3. Game on Cancer MVP Award, Henry Ford Cancer Institute – 2020
	4. Best poster AUA – 2020
	5. 2nd Prize, High Value Care Research, Henry Ford Medical Education Research Forum 2020
	6. 3rd Prize, Senior Clinical Research, Henry Ford Medical Education Research Forum 2020
	7. Best Poster Award, EAU Annual Meeting - 2019
	8. Best Poster Award, AUA Annual Meeting - 2018
	9. Best Abstract, AUA Annual Meeting - 2017
	10. Best Poster Award, EAU Annual Meeting - 2016
	11. 2nd Prize in Clinical Studies Poster, Wayne State University Medical Research - 2016
	12. Honorable Mention in Clinical Studies Oral Presentation, Wayne State University 2016
	13. Best Poster, British Association of Urological Surgeons Annual Meeting - 2015
	14. Excellence in Urology Seminar Faculty Award, Intermountain Urological Institute 2015
	15. 3rd Prize in Clinical Research, Research Symposium, Henry Ford Hospital - 2015
	16. Teaching Award Finalist, American Urological Association - 2014
1. Video Contest Winner, World Congress of Endourology - 2008, 2009, 2010

1. Video Contest Winner, European Robotic Urology Symposium - 2008, 2009,

2010, 2011

* 1. Video of the Year, European Urology Journal – 2012
	2. Poster Contest Winner, EAU – 2011, 2015
	3. Poster Contest Winner, EAU, European Robotic Urology Section Symposium – 2010
	4. Video Contest Winner, AUA Northcentral Section – 2010
	5. Abstract Award, Astellas/AUA Annual Meeting – 2006
	6. Clinical Research Essay Contest Prize Winner, AUA, Midatlantic - 2004, 2005
* **Ali D Dabaja**
	1. TopDoc HOUR magazine 2017-2022
	2. Elected to HF Medical Executive Committee
	3. NIH Trainee Travel Award - 2014
	4. First prize EAU Meeting, Paris -2012
	5. Media featured abstract AUA Washington DC. 2011 meeting (AAP Founded Grant Project) – 2011
	6. Second prize at the EAU Vienna – 2011
	7. First Place Michigan Urologic Society's annual Resident research day – 2010
* **Firas F Abdollah**
	1. Best Poster 95th annual NCS AUA 2021 Prostate Malignant Session - 2021
	2. Best Podium 95th annual NCS AUA 2021 Prostate Malignant Session - 2021
	3. Davidson Fellowship for Entrepreneurs in Digital Health Program
	4. Best Poster award AUA 2020
	5. Wayne State Medical student research fellowship – Mentor, 2020
	6. Winner of the Dykstra Foundation Grant 2017
	7. Excellence in Research Southeast Michigan Center for Medical Education – 2017
	8. First Place in the Slide Competition Southeast Michigan Center for Medical Education
	9. Outstanding reviewer for Cancer: ranked in the top 2% of reviewers for the period spanning September 1, 2016 to August 31, 2017
	10. First Prize for the Best Abstract, 33rd Annual EAU Congress – 2018
	11. Article of the Month BJUI March 2018
	12. 1st place fellow clinical research 25th annual medical education research form in Henry Ford Health System – 2018
	13. Best poster award AUA 2018
	14. Outstanding Fellow Award Nomination by Henry Ford Alumni Association - 2018
	15. Best poster award 34th EAU Congress
	16. Best Reviewer Journal of Urology 2018

1. Bronze Reviewer BJUI 2019
2. 1st place – High Value care research 27th annual medical education research form in Henry Ford Health System
3. 2nd place – High Value care research 27th annual medical education research

form in Henry Ford Health System

1. Article of the month BJUI -2015
	1. Best poster award 29th EAU Congress – 2014
	2. Best poster award 28th EAU Congress – 2013
	3. Reviewer of the month European Urology – 2012
	4. Best poster award 27th EAU Congress – 2012
* **Nabeel Shakir**
	1. AUA South Central Section Resident Essay Competition, 3rdPlace, 2019
	2. AUA South Central Section Resident Essay Competition,1stPlace, 2018
	3. John D. McConnell Award for Excellence in Urology, 2014
	4. Outstanding Poster (Oncology Section) and Podium Presentation, AUA 2014
	5. NIH-Medical Research Scholars Program Fellow, 2013—2014
	6. Alpha Omega Alpha, 2013
	7. Southwestern Medical Foundation Scholarship, 2010—2015
	8. Phillips Petroleum Award for Outstanding Research, 2010
	9. Robert C. Byrd Honors Scholarship, 2007—2010
* **Naveen Kachroo**
	1. Davidson Fellowship for Entrepreneurs in Digital Health 2021-2022 Program
	2. Best Poster prize HFHS basic science symposium (surgeon-scientist to receive that recognition)
	3. Consultant of the Year Award, Henry Ford Wyandotte, 2022
* **Hans Stricker**
	1. Elected to Chair of the Board of Governors of the Henry Ford Medical Group
	2. Best Doctors in America 2010, 2011, 2012, 2013
	3. Top Docs, Hour Magazine 2009, 2010, 2011, 2012, 2013
	4. Pfizer Academic Excellence in Urology 1998
	5. Joseph C. Cerny Resident Teaching Award 1998
* **Johar Raza Syed**
	1. 5th Place Resident Essay Competition, South-Central AUA annual meeting –

2018

1. Best Basic Science and Clinical Reports Roswell Park Cancer Institute - 2015 o Best Abstract EAU Robotic Urology Section meeting – 2014
2. Best Research Resident Department of Surgery, Aga Khan University – 2011

* 1. Société Internationale d'Urologie Travel Fellowship – 2011
	2. Best Poster Presentation, 21st Annual AUA meeting – 2011
	3. Gold Medal for Best Oral Presentation at JPMC symposium – 2010
	4. Young Investigator’s Award for Best Poster Presentation, UROCON – 2009
* **Humphrey O Atiemo**
	1. TopDoc HOUR magazine, 2021
1. Selected ABU examination committee
	1. Elected chair of DEI subcommittee of GME
* **Amit Patel**
	1. Davidson Fellowship for Entrepreneurs in Digital Health Program
* **Kandis K Rivers**
	1. TopDoc HOUR magazine, 2021
	2. Elected to the Board of Governors of the Henry Ford Medical Group
* **Joseph Haddad**
	1. TopDoc HOUR magazine, 2021
* **Janae Preece**
	1. TopDoc HOUR magazine, 2021

o

* **Kristina D Suson**
	1. TopDoc HOUR magazine, 2021
* **Yegappan Lakshmanan**
	1. TopDoc HOUR magazine, 2021

**Attachment 4**

**Grants**

**Current Federal**

* Genomics in Michigan to AdJust Outcomes in prostate canceR (G-MAJOR): A randomized controlled multi- center study for men with newly diagnosed favorable risk prostate cancer 2019-2022
* Tribbles 2: A Novel Molecular Target for Therapy of Aggressive Kidney Cancer. DoD 2021-2022 (Jagadananda Ghosh PhD)
* Tribbles 2, a Novel Target for Therapy of Enzalutamide Resistant, Neuroendocrine Prostate Cancer. DoD 2022-2025 (Jagadananda Ghosh PhD)
* DOD Prostate Cancer Research Program, Translational Science Award (W81XWH-22-1-0400): Co-targeting telomere integrity and repair of telomere damage for CRPC therapy 2022-2025 (Sahn-Ho Kim PhD)

**Current Non-Federal**

* Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES) 2022
* W029636 phase III, open-label, multicenter, randomized study of atezolizumab (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection 2017-2023
* A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) 2022-2024
* Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) 2019-2024
* Medtronic Evaluation of Implantable Tibial Neuromodulation (TITAN 2) Pivotal Study 2022 – 2025 (Humphrey Atiemo)
* Ambu Research Grant for evaluation of efficiency of disposable cystoscopes in clinic (Craig Rogers)
* ACS Pfizer Grant to improve PSA Screening among underrepresented men in Detroit (Firas Abdollah Co-PI)
* Development of novel small molecule inhibitors of Tribbles 2 using artificial intelligence. HFH-MSU Pilot Grant 2022-2023 (Jagadananda Ghosh PhD)
* Characterize the Tribbles 2 interactome to reveal actionable novel targets for therapy of enzalutamide-resistant, lethal prostate cancer. HFH-MSU Pilot Grant 2022-2023 (Jagadananda Ghosh PhD)
* Henry Ford Cancer Institute (HFCI) – Internal Funding for project development- ‘Evaluation of prostate cancer tumor heterogeneity in repeat biopsy samples’ (Nallasivam Palanisamy)
* Henry Ford Cancer Institute (HFCI) – Internal Funding for project development- ‘Characterization of a novel recurrent gene fusion in prostate cancer’(Nallasivam Palanisamy)
* Pfizer 2021 Global Medical Grant (01/2022 – 06/2023); Integrating Orthodox and Traditional Prostate Cancer Care and Treatment in Ghana: Evelyn Jiagge, PI, Eleanor Walker, Nallasivam Palanisamy, Clara Hwang and Sylvester Antwi

**Attachment 5**

**Practice Changing Contributions - Urology**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Practice Changing Contribution (brag point)** |  | **MD/Researc** |  | **Citation/Source** | **Add’l** |  |
| Ford Hospital which resulted in a remarkable milestone of significant | **her** |  |  | **Link** | **Comments** |  |
| Dabaja |  | 196- |  |  |  |
| CAUTI Reduction: • Dr. Dabaja led multidisciplinary initiative at Henry | Dr. Ali |  |  | urnal.org/article/S0 |  |  |
|  |  | https://www.ajicjo |  |  |
| reduction in catheter acquired UTI’s (CAUTI). He helped develop a |  |  |  | 6553(21)00459- |  |  |  |
| Urinary Catheter Alleviation Navigator Protocol (UCANP) to reduce the |  |  |  | 4/fulltext |  |  |
| use of indwelling catheters and unnecessary urine cultures to enhance |  |  |  |  |  |  |  |
| patient safety. This work has been published. |  |  |  |  |  |  |  |  |
| multidisciplinary robotic genitourinary reconstructive surgery |  | Shakir |  |  | [construction.org)](https://www.multidisciplinaryreconstruction.org/) |  |  |
| Gender affirming surgery using Single Port Robot. Hosted first |  | Dr. Nabil |  |  | [(multidisciplinaryre](https://www.multidisciplinaryreconstruction.org/) |  |  |
|  |  |  | [Home | MERGERS](https://www.multidisciplinaryreconstruction.org/) |  |  |
| symposium (MERGERS) with international audience. First Single port |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| robotic vaginoplasty in the Midwest. Collaboration with Plastic Surgery. |  |  |  |  |  |  |  |
| the first in the country to go "all in" on using disposable scopes during | Rogers |  |  |  |  |  |  |
| Leadership in use of reusable cystoscopes: Our department was one of | Dr. Craig |  |  |  |  |  |  |
| the pandemic and received recognition on a national podcast about how |  |  |  |  |  |  |  |
| using disposable scopes helped save clinic procedures when the Fairlane |  |  |  |  |  |  |  |
| clinic was displaced after the floods and when staffing shortages affected |  |  |  |  |  |  |  |
| our ability to do procedures. |  |  |  |  |  |  |  |  |
| (HIFU) Procedure for focal therapy of localized prostate cancer. Our |  | Rogers |  |  | nry-ford-health- |  |  |
| First in Michigan to offer fully robotic High Intensity Focused Ultrasound | Dr. Craig |  |  | etroit.com/news/he |  |  |
|  |  | https://www.fox2d |  |  |
| prostate HIFU program was recently featured in a press release and on |  |  |  | can-target-and- |  |  |
| Fox 2 news. One of first programs in the country to offer both robotic |  |  | treat-prostate- |  |  |
| HIFU and single port robotic surgery for prostate cancer. |  |  |  | cancer-through- |  |  |
| Helped build Robotic kidney transplant program in collaboration with | Dr. Wooju |  | robotic-technology |  |  |
| Henry Ford Transplant Institute that is now a highly successful program | Jeong / Dr. |  |  |  |  |  |
| for them |  | Atsi Yoshida |  |  |  |  |  |
| applicantsDEIJ:Urologytoourstaffprogramstarted andscholarshiptoprovidetomentorshiphelpattractopportunitiesresidency | to | Littleton,Dr.Ray | Dr. |  |  |  | AtiemoHumphreywas |  |
| college and high school students who are underrepresented in medicine. | Humphrey |  |  |  | voted as Chair |  |
| Dr. Abdollah featured in presentation about disparities in prostate cancer | Atiemo |  |  |  |  | of |  |
| and is part of grant with Dr. Walker and Dr. Hwang to reduce disparities |  |  |  |  |  | the Diversity E |  |
| in prostate cancer diagnosis in the community. |  |  |  |  |  |  | quity and |  |
|  |  |  |  |  |  |  | Inclusion (DEI) |  |
|  |  |  |  |  |  |  | sub-committee |  |
| Allegiance.Firstrobotic partial cystectomy and first targeted biopsies at HF |  | RanasingheBuddima |  |  |  | of the GME |  |
|  |  | Dr. Wooju |  |  |  |  |  |
|  |  | Jeong |  |  |  |  |  |  |
| diversion in our department and region |  | Syed Raza |  | [prostate-](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |
| First robotic cystectomy with intracorporeal “W-pouch” urinary |  | Dr. Johar |  |  | [ford.com/services/](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |
|  |  |  | https://www.henry |  |  |
|  |  |  |  |  | cancer/patient - |  |  |
| First health system in Michigan to perform Single Port (SP) robotic |  | Dr. Craig |  |  | [stories/donnel](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |  |
| prostatectomy surgeries, which includes both extraperitoneal and |  | Rogers / Dr. |  |  |  |  |  |
| intraperitoneal approaches, and facilitates same day discharges. |  | James |  |  |  |  |  |  |
|  |  | Peabody |  |  |  |  |  |  |
| in Michigan for patients with abdominal adhesions otherwise not eligible | Rogers/Dr. |  |  |  |  |  |
| First Transvesical single port simple and radical prostatectomy surgeries | Dr . Craig |  |  |  |  |  |
| for traditional surgical approaches |  | Wooju Jeong |  |  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| First in the country to enroll a patient in phase 2 clinical trial involving | Drs. Ali |  |  |
| MRI-guided targeted injections of nanoparticle paclitaxel directly into | Dabaja & |  |  |
| localized prostate cancer. This was followed by single port | Craig Rogers |  |  |
| extraperitoneal prostatectomy |  |  |  |
| Our targeted MRI fusion prostate biopsy results rank among the top in |  |  |  |
| the state over the past 3 years for detection of clinically significant |  |  |  |
| prostate cancer |  |  |  |
| 20th anniversary of the first robotic prostatectomy performed in the U.S., |  |  |  |
| leading to the first robotic prostate surgery program in the U.S. and the |  |  |  |
| foundation for robotic surgery in all other aspects of urology and other |  |  |  |
| specialties. 100th Urology Department anniversary celebrating legacy of |  |  |  |
| innovation in Urology in department |  |  |  |
| Innovations in prostate biopsy: Transperineal technique for prostate | Dr. Craig |  |  |
| biopsy in the office. One of first departments in the country to have | Rogers, Dr. |  |  |
| entire staff convert to transperineal approach for office biopsy, resulting | Amit Patel & |  |  |
| in a reduction in biopsy sepsis and bleeding complications as well as | Dr. Ali |  |  |
| antibiotic use. The Henry Ford biopsy technique has received | Dabaja |  |  |
| international attention and was recently published in the Urology 'Gold' |  |  |  |
| journal, featured in the AUA Core Curriculum and MUSIC websites, and |  |  |  |
| was presented at the AUA national meeting and the World Congress of |  |  |  |
| Endourology. Unique "Executive Biopsy" program with streamlined one - |  |  |  |
| stop diagnostic process for prostate cancer that can allow for a prostate |  |  |  |
| MRI targeted biopsy and pathology results in less than 48 hours. |  |  |  |
| Numerous publications, international meeting abstracts, and research | Dr. Firas |  |  |
| awards, led by VCORE research group, averaging about 50 publications | Abdollah |  |  |
| per year, with about 500 publications in the past 10 years |  |  |  |
| Leadership in Michigan Urologic Surgery Improvement Collaborative | Dr. Craig |  |  |
| (MUSIC): Led research on active surveillance and reducing ER | Rogers |  |  |
| readmissions after kidney surgery |  |  |  |
| Innovation Precision Prostatectomy technique to remove the cancer | Dr. Wooju |  |  |
| while preserving a thin rim of prostate capsule on the uninvolved side of | Jeong |  |  |
| the prostate opposite to the dominant lesion to help preserve sexual and |  |  |  |
| urinary function. Published largest experience in the world. First-in-the |  |  |  |
| world to perform procedure using a single-port robotic approach |  |  |  |
| through a small incision in the bladder. Dr. Abdollah performed first |  |  |  |
| precision prostatectomy at HF Macomb |  |  |  |
| endovascularCollaboration removalwithInterventionalofIVCtumorRadiology:thrombusFirstinpatientinworldwith metastaticperform |  |  |  |
| kidney cancer, facilitating a subsequent robotic cytoreductive |  |  |  |
| nephrectomy and enrollment in a clinical trial to make a vaccine from the |  |  |  |
| tumor. First in Michigan to offer prostate artery embolization for BPH |  |  |  |
| and super selective embolization of kidney tumors prior to nephrectomy. |  |  |  |
| Collaboration with Radiation Oncology: First in world to treat a patient |  |  |  |
| with prostate cancer using the combined MRI Linac technology for |  |  |  |
| precise radiation therapy. Same technology now offered for select |  |  |  |
| patients with kidney cancer. |  |  |  |
| Feaured on Channel 4 news discussing research linking COVID infections | Dr. |  |  |
| to an increased risk of ED. | Amarnath |  |  |
|  | Rambhatla |  |  |
| Dr. Peabody led recent JAMA surgery article about sexual function after | Dr. James |  |  |
| radical prostatectomy. | Peabody |  |  |
| Innovations in robotic kidney surgery: First in Michigan to perform | Dr. Craig |  |  |
| cooling of the kidney during robotic partial nephrectomy now used in | Rogers |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | robotic ultrasoundkidneytransplantprobe.forHelpedroboticdeveloppartialroboticnephrectomybulldog. clampsFirstliveand |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  | webcast of robotic partial nephrectomy in the US and first live |  |  |  |  |  |  |  |
|  | demonstration of robotic partial nephrectomy at the AUA National |  |  |  |  |  |  |  |
|  | meeting |  |  |  |  |  |  |  |
|  | EPIC that monitor stent implants and alert providers monthly when the | Dabaja |  | [Report Server](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  | Stent and Implant tracking. Currently we have algorithm build within | Dr. Ali |  | [n-V2 - Power BI](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  |  | [UrologyStentsAdmi](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  | implants are in place over 90 days |  |  |  |  |  |  |  |
|  |  | (hfhs.org) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | prostate cancer. Initial results are highly sensitive and specific to detect | Abdollah |  |  |  |  |  |  |
|  | Working on very innovative technique to isolate exosome specific for | Firas |  |  |  |  |  |  |
|  | not only prostate cancer, but its exact grading too. These are based on |  |  |  |  |  |  |  |
|  | urine and blood samples alone, without the need to obtain a biopsy. This |  |  |  |  |  |  |  |
|  | has the potential of totally changing the practice and the way we take |  |  |  |  |  |  |  |
|  | care of prostate cancer |  |  |  |  |  |  |  |
|  | with hope of identifying differences in exosomes among different races, | Abdollah |  |  |  |  |  |  |
|  | We are studying racial disparity in prostate cancer exosome expression, | Firas |  |  |  |  |  |  |
|  | and use that in designing specific biomarkers, and treatments |  |  |  |  |  |  |  |
|  | First to use Koelis machining to place SpaceOAR hydrogel | Firas |  |  |  |  |  |  |
|  |  | Abdollah |  |  |  |  |  |  |
|  | biopsy using Koelis machine along with MRI-fusion - working on | Abdollah |  |  |  |  |  |  |
|  | We are one of the few centers in Michigan to offer 3D US guided prostate | Firas |  |  |  |  |  |  |
|  | developing an AI model to decide the best biopsy scheme based on data |  |  |  |  |  |  |  |
|  | from these biopsies |  |  |  |  |  |  |  |
|  | Henry Ford providers going retrospectively to 20 years ago and | Abdollah |  |  |  |  |  |  |
|  | We developed a PSA testing/screening database based on EMRs from all | Firas |  |  |  |  |  |  |
|  | connected it to Michigan death certificates to obtain follow- up. This is a |  |  |  |  |  |  |  |
|  | unique source, which allows us for the first time to examine how PSA is |  |  |  |  |  |  |  |
|  | used in real practice (outside RCT), and the impact of that on patients’ |  |  |  |  |  |  |  |
|  | outcomes |  |  |  |  |  |  |  |
|  | country to address UTUC outcomes (the ROBUUST collaboration), which | Abdollah |  |  |  |  |  |  |
|  | Created new collaboration with several institutions from across the | Firas |  |  |  |  |  |  |
|  | has procedure 6 publications in high-impact factor journals in the last |  |  |  |  |  |  |  |
|  | year |  |  |  |  |  |  |  |

**Attachment 1A**

**Description of Urology Faculty**

**FACULTY** (year joined department)

1. Craig G. Rogers, MD (2007), Department Chair
	1. Stanford University School of Medicine, CA, 2000
	2. Johns Hopkins University School of Med., Urology Residency, 2006
	3. National Cancer Institute, NIH, Bethesda, MD, Fellowship Urologic Oncology, 2007
2. James O. Peabody, MD (1990), Vice Chair Operations
	1. University of Michigan Medical School, 1985
	2. Henry Ford Department of Urology, Detroit MI, Urology Residency, 1990
3. Ali A. Dabaja, MD (2014), Vice Chair Clinical Affairs, Residency Program Associate Director
	1. Wayne State University School of Medicine, MI, 2007
	2. Henry Ford Department of Urology, Vattikuti Urology Institute, Urology Residency, 2012
	3. Weill Cornell Medical College, Fellowship Male Reproductive Medicine & Surgery, NY, 2014
4. Firas F. Abdollah, MD (2018), Vice Chair, Academics and Research
	1. University of Baghdad School of Medicine, 2003
	2. Vita Salute University, San Raffaele Hospital, Urology Residency, 2012

* + 1. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship Minimally Invasive Robotic Surgery, 2018
1. Humphrey O. Atiemo, MD (2011), Residency Program Director
	* 1. University of Maryland Medical School, 1999
		2. University of Maryland, Urology Residency, 2005
		3. Cleveland Clinic Foundation, Fellowship Female Pelvic Medicine and Reconstructive Surgery, 2007
2. Riad Farah, MD (1973)
	* 1. University of Damascus School of Medicine, 1966
		2. The University Hospital, Urology, 1968
		3. Mount Carmel Mercy Hospital, Surgery, MI, 1970
		4. Henry Ford Department of Urology, Urology Residency, 1973
3. Joseph A. Haddad, MD (2017)
	* 1. Wayne State University School of Medicine, MI, 2012
		2. Univ. of Oklahoma, Urology Residency, 2017
4. Frank B. Holloway, MD (1992)
	1. Indiana University School of Medicine, IN, 1987
	2. Wayne State University, Detroit, MI, Urology Residency, 1992



1. Wooju Jeong, MD (2013)
	* 1. Yonsei University School of Medicine, Seoul, South Korea, 1998
		2. Yonsei University, Urology Residency (KUA Board Certified), 2003
		3. Yonsei University, Fellowship Minimally Invasive Surgery, 2009
		4. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship in Robotic Urology, 2013
2. Naveen Kachroo, MD, PhD (2020)
	* 1. Newcastle University Faculty of Medical Sciences, 2004
		2. Newcastle University Faculty of Medical Sciences, Medicine & Surgery, 2006
		3. Newcastle University Faculty of Medical Sciences, Surgical, 2007
		4. Nottingham University Hospitals, Urology, 2009
		5. University of Cambridge, Urology, 2013
		6. Henry Ford Department of Urology, Vattikuti Urology Institute, Urology Residency, 2018
		7. Cleveland Clinic, Fellowship in Endourology, 2020
3. David A. Leavitt, MD (2015)
	* 1. University of Michigan Medical School, 2008
		2. University of Minnesota, Urology Residency, 2013
		3. The Smith Institute for Urology, New York, Fellowship Endourology/Laparoscopy, NY, 2015
4. Stephen A. Liroff, MD (1977)
	1. Georgetown University School of Medicine, 1971
	2. New York Presbyterian Hospital and North Shore University Hospitals, NY, General Surgery, NY, 1974



* 1. Wayne State University, Detroit, MI, Urology Residency, 1977
1. Ray H. Littleton, MD (1980)
	* + 1. University of Michigan Medical School, 1975
			2. Henry Ford Department of Urology, Urology Residency, 1980
2. Amit Patel, MD (2020)
	* + 1. University of Birmingham School of Medicine, 2005
			2. Kent/Surrey/Sussex Deanery, General Surgery, 2010
			3. Guys and St Thomas foundation NHS Trust, Urology, 2012
			4. Imperial College and the Royal Marsden Hospital, London, Urology specialty training, 2017
			5. Henry Ford Department of Urology, Vattikuti Urology Insititute, Fellowship in Robotic Urologic Oncology, MI, 2020
3. Samantha M. Raffee, MD (2020)
	* + 1.  Wayne State University School of Medicine, Detroit, MI, 2013
			2. Akron General Medical Center, OH, Urology Residency, 2018
			3. Henry Ford Department of Urology, Vattikuti Urology Institute, Fellowship Female Pelvic Medicine and Reconstructive Surgery, 2020
4. Amarnath Rambhatla, MD (2019)
	* 1.  University of California Los Angeles School of Medicine, 2007
		2. Wayne State University School of Medicine, Urology Residency, 2012
		3. University of California Los Angeles, Fellowship Male Reproductive Medicine & Surgery, 2016

1. Kandis K. Rivers, MD (2000)
	1.  University of Michigan Medical School, 1993
	2. Henry Ford Department of Urology, Vattikuti Urology Institute, Detroit MI, Urology Residency, 2000
2. Nabeel A. Shakir, MD (2021)
	* 1.  University of Texas Southwestern Medical School, 2015
		2. University of Texas Southwestern Medical School, Urology Residency, 2020
		3. NYU Langone Medical Center, Fellowship Genitourinary Reconstructive Surgery, 2021
3. Hans Stricker, MD (1993)
	* 1.  University of Michigan Medical School, 1988
		2. University of Michigan, Urology Residency, 1993
4. Johar Syed Raza, MD (2020)
	* 1.  Baqai Medical College, 2002
		2. Baqai Medical University, General Surgery, 2007
		3. Aga Khan University, Urology, 2011
		4. Shaukat Khanum Cancer Hospital & Research Center, Urologic Oncology, 2013
		5. Roswell Park Cancer Institute, NY, Fellowship Urologic Oncology, 2015
		6. St. Louis University School of Medicine, MO, Urology Residency, 2020

1. Jeffrey L. Weingarten, MD (2021)
	1.  Saint Louis University, MO - School of Medicine, 1982
	2. Beaumont Hospital - Royal Oak, General Surgery, MI, 1985
	3. Albany Medical College, NY, Urology Residency, 1988

**Other Clinical Staff:**

Advanced Practice Practitioners 7

* 4 Nurse Practitioners
* 3 Physician Assistants

Basic Science Faculty 4

* Jagadananda Ghosh PhD
* Nallasivam Palanisamy PhD
* Sahn-Ho Kim PhD
* Mahendra Bhandari MD

Number of Total Faculty 32

Number of research Faculty 14

Number of Clinical Faculty 29

**Distribution of Rank at Henry Ford/WSU** -

|  |  |
| --- | --- |
| Craig Rogers, MD, Chair | Clinical Professor |
|  |  |
| James O. Peabody, MD, Vice- | Clinic Professor |
| Chair |  |
|  |  |
| Naveen Kachroo, MD | Clinical Assistant Professor |
|  |  |
| Frank Holloway, MD | Clinical Assistant Professor |
|  |  |
| Wooju Jeong, MD | Clinical Assistant Professor |
|  |  |
| Stephen Liroff, MD | Clinical Assistant Professor |
|  |  |
| Ray Littleton, MD | Clinical Assistant Professor |
|  |  |
| Kandis Rivers, MD | Clinical Assistant Professor |
|  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Abdollah Firas, MD |  |  | Clinical Associate Professor |
|  |  |  |  |
| Humphrey Atiemo, MD | Clinical Associate Professor |
|  |  |  |  |  |
| Ali A. Dabaja, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| Riad Farah, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| Hans Stricker, MD |  |  | Clinical Associate Professor |
|  |  |  |  |  |
| David Leavitt, MD |  |  | In process for Clinical Associate |
|  |  |  |  | Professor |
|  |  |  |  |  |
| Joseph Haddad, MD |  |  | In process for Clinical Associate |
|  |  |  |  | Professor |
|  | **Demographics (for DEI purposes)** |  |
|  | White | 1 |  |  |
|  |  | 2 |  |  |
|  | Black | 4 |  |  |
|  | Korean | 1 |  |  |
|  | Middle Eastern | 4 |  |  |
|  | Indian | 5 |  |  |
|  | Male | 2 |  |  |
|  |  | 0 |  |  |
|  | Female | 7 |  |  |

**Attachment 1B**

**Urology Faculty Picture Sheet**



**Attachment 2**

**Publications of department faculty over the last three years**

**Articles**

Agarwal A, Finelli R, Durairajanayagam D, Leisegang K, Henkel R, Salvio G, Aghamajidi A, Sengupta P, Crisóstomo L, Tsioulou PA, Roychoudhury S, Finocchi F, Darbandi M, Mottola F, Darbandi S, Iovine C, Santonastaso M, Zaker H, Kesari KK, Nomanzadeh A, Gugnani N, **Rambhatla A**, Duran MB, Ceyhan E, Kandil H, Arafa M, Saleh R, Shah R, Ko E, and BoitrelleF. Comprehensive Analysis of Global Research on Human Varicocele: A Scientometric Approach. *World J Mens Health* 2022. PMID: 35118839. doi.org/10.5534/wjmh.210202

Agarwal A, Gupta S, Sharma RK, Finelli R, Kuroda S, Vij SC, Boitrelle F, Kavoussi P, **Rambhatla A**, Saleh R, Chung E, Mostafa T, Zini A, Ko E, Parekh N, Martinez M, Arafa M,Tadros N, de la Rosette J, Le TV, Rajmil O, Kandil H, Blecher G, Liguori G, Caroppo E, Ho CCK, Altman A, Bajic P, Goldfarb D, Gill B, Zylbersztejn DS, Molina JMC, Gava MM,

Cardoso JPG, Kosgi R, Çeker G, Zilaitiene B, Pescatori E, Borges E, Duarsa GWK, Pinggera GM, Busetto GM, Balercia G, Franco G, Çalik G, Sallam HN, Park HJ, Ramsay J, Alvarez J, Khalafalla K, Bowa K, Hakim L, Simopoulou M, Rodriguez MG, Sabbaghian M, Elbardisi H, Timpano M, Altan M, Elkhouly M, Al-Marhoon MS, Sadighi Gilani MA, Soebadi MA, Nasr-Esfahani MH, Garrido N, Vogiatzi P, Birowo P, Patel P, Javed Q, Ambar RF, Adriansjah R, AlSaid S, Micic S, Lewis SE, Mutambirwa S, Fukuhara S, Parekattil S, Ahn ST, Jindal S, Takeshima T, Puigvert A, Amano T, Barrett T, Toprak T, Malhotra V, Atmoko W, Yumura Y, Morimoto Y, Lima TFN, Kunz Y, Kato Y, Umemoto Y, Colpi GM, Durairajanayagam D, and Shah R. Post-Vasectomy Semen Analysis: Optimizing Laboratory Procedures and Test Interpretation through a Clinical Audit and Global Survey of Practices. *World J Mens Health* 2022; 40(3):425-441. PMID: 35021311. doi.org/10.5534/wjmh.210191

Agarwal A, Sharma RK, Gupta S, Boitrelle F, Finelli R, Parekh N, Durairajanayagam D, Saleh R, Arafa M, Cho CL, Farkouh A, **Rambhatla A**, Henkel R, Vogiatzi P, Tadros N, Kavoussi P, Ko E, Leisegang K, Kandil H, Palani A, Salvio G, Mostafa T, Rajmil O, Banihani SA, Schon S, Le TV, Birowo P, Çeker G, Alvarez J, Molina JMC, Ho CCK, Calogero AE, Khalafalla K, Duran MB, Kuroda S, Colpi GM, Zini A, Anagnostopoulou C, Pescatori E, Chung E, Caroppo E, Dimitriadis F, Pinggera GM, Busetto GM, Balercia G, Elbardisi H, Taniguchi H, Park HJ, Maldonado Rosas I, de la Rosette J, Ramsay J, Bowa K, Simopoulou M, Rodriguez MG, Sabbaghian M, Martinez M, Gilani MAS, Al-Marhoon MS, Kosgi R, Cannarella R, Micic S, Fukuhara S, Parekattil S, Jindal S, Abdel-Meguid TA, Morimoto Y, and Shah R. Sperm Vitality and Necrozoospermia: Diagnosis, Management, and Results of a Global Survey of Clinical

Practice. *World J Mens Health* 2022; 40(2):228-242. PMID: 34666422.

doi.org/10.5534/wjmh.210149

Agochukwu-Mmonu N, Murali A, Wittmann D, Denton B, Dunn RL, Montie J, **Peabody J**, Miller D, and Singh K. Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative. *Eur Urol Open Sci* 2022; 40:1-8. PMID: 35638089. doi.org/10.1016/j.euros.2022.03.009

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, 3rd, and **Peabody J**. Patient- and Surgeon-Level Variation in Patient-Reported Sexual Function Outcomes Following Radical Prostatectomy Over 2 Years: Results From a Statewide Surgical Improvement Collaborative. *JAMA Surg* 2022; 157(2):136-144. PMID: 34851369. doi.org/10.1001/jamasurg.2021.6215

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, and **Peabody J**. Re: Patient- and Surgeon-Level Variation in Patient -Reported Sexual Function Outcomes following Radical Prostatectomy over 2 Years: Results from a Statewide Surgical Improvement Collaborative. *Journal of Urology* 2022; 207(4):928-928. PMID: Not assigned. doi.org/10.1097/ju.0000000000002413

Agochukwu-Mmonu N, Qi J, Dunn RL, Montie J, Wittmann D, Miller D, Martin R, Kim T, Johnston WK, and **Peabody J**. Re: Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. *Journal of Urology* 2022; 207(4):928-929. PMID: Not assigned.

Alanee S, Deebajah M, **Dabaja A**, **Peabody J**, and Menon M. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance. *Int Urol Nephrol* 2022; 54(4):799-803. PMID: 35138582. doi.org/10.1007/s11255-022-03136-1

**Atiemo HO**. EDITORIAL COMMENT. *Urology* 2022; 162:149-150. PMID: 35469606. doi.org/10.1016/j.urology.2021.01.056

**Atiemo HO**. Editorial Commentary. *Urology Practice* 2022; 9(4):312. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000307.01

Borchert A, Jamil M, Perkins S, **Raffee S**, and **Atiemo H**. Vaginal Free Graft Dorsal Onlay Urethroplasty. *Urology* 2022; 159:256. PMID: 34157342. doi.org/10.1016/j.urology.2021.06.004

Butaney M, Chan EM, and **Rambhatla A**. Editorial Comment. *J Urol* 2022; 207(1):51. PMID:

34633222. doi.org/10.1097/ju.0000000000002188.02

Butaney M, Chan EM, and **Rambhatla A**. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. *Journal of Urology* 2022; 207(1):51-51. PMID: Not assigned.

Butaney M, Levy AC, and **Rogers CG**. Robotic total and partial adrenalectomy: A step by step

approach. *Urology Video Journal* 2022; 13. PMID: Not assigned.

doi.org/10.1016/j.urolvj.2022.100138

Butaney M, and **Rambhatla A**. The impact of COVID-19 on urology office visits and adoption of telemedicine services. *Curr Opin Urol* 2022; 32(2):152-157. PMID: 34930885. doi.org/10.1097/mou.0000000000000957

Canvasser NE, River M, Bechis SK, Ingimarsson J, Knoedler J, Stern K, Stoughton CL, Wollin D, Borofsky M, Bhojani N, Tayeb ME, Kamphuis G, **Leavitt D**, Hsi RS, and Scotland KB. Over-the-counter alkali agents to raise urine pH and citrate excretion: a prospective crossover study in healthy adults. *Urology* 2022. PMID: 35843354. doi.org/10.1016/j.urology.2022.05.049

Chen I, Arora S, Alhayek K, **Leavitt D**, and **Dabaja A**. Diagnosis and management of testicular compartment syndrome caused by tension hydrocele. *Urol Case Rep* 2022; 43:102091. PMID: 35520029. doi.org/10.1016/j.eucr.2022.102091

Chen I, Perkins SQ, Schwartz SE, and **Leavitt D**. Nephrolithiasis associated with embolization material, Lipiodol®, following embolization of large renal angiomyolipoma. *Urol Case Rep* 2022; 40:101910. PMID: 34786344. doi.org/10.1016/j.eucr.2021.101910

Corsi NJ, Messing EM, Sood A, Keeley J, Bronkema C, Rakic N, Jamil M, Dalela D, Arora S, Piontkowski AJ, Majdalany SE, Butaney M, Rakic I, Li P, Menon M, **Rogers CG**, and **Abdollah F**. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free SurvivalRate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. *Clin Genitourin Cancer* 2022. PMID: 35871040. doi.org/10.1016/j.clgc.2022.06.015

Delto JC, Fleishman A, Chang P, Jiang DD, Hyde S, McAnally K, Crociani C, Jamil M, Patel HD, Pavlinec J, Budzyn J, Durant A, Eilender B, Gordon AO, Huang MM, Pierorazio PM, Raman JD, **Rogers C**, Su LM, and Wagner AA. Perioperative Aspirin Use Is Associated with Bleeding Complications during Robotic Partial Nephrectomy. *J Urol* 2022; 207(2):277-283. PMID: 34555934. doi.org/10.1097/ju.0000000000002240

Dielubanza EJ, Enemchukwu EA, and **Atiemo HO**. Workforce Diversity in Female Pelvic Medicine and Reconstructive Surgery: An Analysis of the American Urological Association Census Data. *Urology* 2022; 163:29-33. PMID: 34274388. doi.org/10.1016/j.urology.2021.06.031

ElKarami B, Deebajah M, Polk S, **Peabody J**, Shahrrava B, Menon M, Alkhateeb A, and Alanee S. Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance. *Urol Oncol* 2022; 40(5):191.e115-191.e120. PMID: 35307289. doi.org/10.1016/j.urolonc.2022.01.012

Elsayed AS, Ely HB, Abdelhakim MA, Saad IR, Jing Z, Iqbal U, Ramahi Y, Joseph J, Houenstein H, James G, **Peabody JO**, Razzak OA, Hussein AA, and Guru KA. Preservation of endopelvic fascia, puboprostatic ligaments, dorsal venous complex and hydrodissection of the neurovascular bundles during robot-assisted radical prostatectomy: a video demonstration and propensity score matched outcomes. *Urology Video Journal* 2022; 14. PMID: Not assigned. doi.org/10.1016/j.urolvj.2022.100143

Elsayed AS, Iqbal U, Jing Z, Houenstein HA, Wijburg C, Wiklund P, Kim E, Stöckle M, Kelly J, Dasgupta P, Wagner AA, Kaouk J, Badani KK, Redorta JP, Mottrie A, **Peabody JO**, Rouprêt M, Balbay D, Richstone L, Rha KH, Aboumohamed A, Li Q, Hussein AA, and Guru KA. Relapses Rates and Patterns for Pathological T0 After Robot -Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. *Urology* 2022; 166:177-181. PMID: 35461914. doi.org/10.1016/j.urology.2022.03.035

Goldenthal SB, Reimers MA, Singhal U, Farha M, Mehra R, Piert M, Tosoian JJ, Modi PK, Curci N, **Peabody J**, Kleer E, Smith DC, and Morgan TM. Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. *Urology* 2022. PMID: 35472327. doi.org/10.1016/j.urology.2022.04.002

Gopalakrishnan D, Elsayed AS, Hussein AA, Jing Z, Li Q, Wagner AA, Aboumohamed A, Roupret M, Balbay D, Wijburg C, Stockle M, Dasgupta P, Khan MS, Wiklund P, Hosseini A, **Peabody J**, Shigemura K, Trump D, Guru KA, and Chatta G. Impact of neoadjuvantchemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. *Int J Urol* 2022; 29(3):197-205. PMID: 34923677. doi.org/10.1111/iju.14749

Grauer R, Gorin MA, Sood A, Butaney M, Olson P, Farah G, Hanna Cole R, **Jeong W**, **Abdollah F**, and Menon M. Impact of prostate biopsy technique on outcomes of the precisionprostatectomy procedure. *BMJ Surg Interv Health Technol* 2022; 4(1):e000122. PMID: 35892060. doi.org/10.1136/bmjsit-2021-000122

Gupta S, Sharma R, Agarwal A, Boitrelle F, Finelli R, Farkouh A, Saleh R, Abdel-Meguid TA, Gül M, Zilaitiene B, Ko E, **Rambhatla A**, Zini A, Leisegang K, Kuroda S, Henkel R, Cannarella R, Palani A, Cho CL, Ho CCK, Zylbersztejn DS, Pescatori E, Chung E, Dimitriadis F, Pinggera GM, Busetto GM, Balercia G, Salvio G, Colpi GM, Çeker G, Taniguchi H, Kandil H, Park HJ, Maldonado Rosas I, de la Rosette J, Cardoso JPG, Ramsay J, Alvarez J, Molina JMC, Khalafalla K, Bowa K, Tremellen K, Evgeni E, Rocco L, Rodriguez Peña MG, Sabbaghian M, Martinez M, Arafa M, Al-Marhoon MS, Tadros N, Garrido N, Rajmil O, Sengupta P, Vogiatzi P, Kavoussi P, Birowo P, Kosgi R, Bani-Hani S, Micic S, Parekattil S, Jindal S, Le TV, Mostafa T, Toprak T, Morimoto Y, Malhotra V, Aghamajidi A, Durairajanayagam D, and Shah R. Antisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical Practices. *World J Mens Health* 2022; 40(3):380-398. PMID: 35021297. doi.org/10.5534/wjmh.210164

Hakimi K, Carbonara U, Djaladat H, Mehrazin R, Eun D, Reese A, Gonzalgo ML, Margulis V, Uzzo RG, Porter J, Sundaram CP, **Abdollah F**, Mottrie A, Tellini R, Ferro M, Walia A, Saidian A, Soliman S, Yuan J, Veccia A, Ghoreifi A, Cacciamani G, Bhattu AS, Meng X, Farrow JM, Jamil M, Minervini A, Rha KH, Wu Z, Simone G, Autorino R, and Derweesh IH. Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry. *J Urol* 2022; 208(2):268-276. PMID: 35377778. doi.org/10.1097/ju.0000000000002690

Hiller SC, Daignault-Newton S, Rakic I, Linsell S, Conrado B, Jafri SM, Rubenstein R, Abdelhady M, Fischer CP, Gimenez E, Sarle R, Roberts WW, Maitland C, Yousif R, Elgin R, Galejs L, Konheim J, **Leavitt D**, Stockall E, Fontera JR, Wolf JS, Hollingsworth JM, Dauw CA, and Ghani KR. Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease. *Urology Practice* 2022; 9(3):253-263. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000302

Iqbal U, Jing Z, Ahmed Y, Elsayed AS, **Rogers C**, Boris R, Porter J, Allaf M, Badani K, Stifelman M, Kaouk J, Terakawa T, Hinata N, Aboumohamed AA, Kauffman E, Li Q, Abaza R, Guru KA, Hussein AA, and Eun D. Development and Validation of an Objective Scoring Tool for Robot-Assisted Partial Nephrectomy: Scoring for Partial Nephrectomy. *J Endourol* 2022; 36(5):647-653. PMID: 34809491. doi.org/10.1089/end.2021.0706

Jaiswal A, Baliu-Souza T, Turner K, Nadiminty N, **Rambhatla A**, Agarwal A, Krawetz SA, Dupree JM, Saltzman B, Schon SB, and Avidor-Reiss T. Sperm centriole assessment identifies male factor infertility in couples with unexplained infertility - a pilot study. *Eur J Cell Biol* 2022; 101(3):151243. PMID: 35640396. doi.org/10.1016/j.ejcb.2022.151243

Jamil ML, Wurst H, Robinson P, Rubinfeld I, Suleyman G, Pollak E, and **Dabaja AA**. Urinary catheter alleviation navigator protocol (UCANP): Overview of protocol and review of initial experience. *Am J Infect Control* 2022; 50(1):81-85. PMID: 34273463. doi.org/10.1016/j.ajic.2021.06.019

**Kachroo N**, Monga M, and Miller AW. Comparative functional analysis of the urinary tract microbiome for individuals with or without calcium oxalate calculi. *Urolithiasis* 2022; 50(3):303-317. PMID: 35234986. doi.org/10.1007/s00240-022-01314-5

**Kachroo N**, **Rogers CG**, and **Peabody JO**. John Kelso Ormond - More Than a Syndrome. *Urology* 2022. PMID: 35369985. doi.org/10.1016/j.urology.2022.02.017

Kenigsberg AP, Carpinito G, Gold SA, Meng X, Ghoreifi A, Djaladat H, Minervini A, Jamil M, **Abdollah F**, Farrow JM, Sundaram C, Uzzo R, Ferro M, Meagher M, Derweesh I, Wu Z, PorterJ, Katims A, Mehrazin R, Mottrie A, Simone G, Reese AC, Eun DD, Bhattu AS, Gonzalgo ML, Carbonara U, Autorino R, and Margulis V. Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomy. *Urol Oncol* 2022. PMID: 35934609. doi.org/10.1016/j.urolonc.2022.06.006

Kim HJ, Yang SJ, **Jeong W**, Lee J, Na JC, Han WK, and Huh KH. The first robotic kidney transplantation in Korea: a case report. *Korean J Transplant* 2022; 36(1):61-66. PMID: 35769429. doi.org/10.4285/kjt.21.0023

König F, Grossmann NC, Soria F, D'Andrea D, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, **Abdollah F**, Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian SA, Rouprêt M, Rink M, Shariat SF, and Pradere B. Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. *Cancers (Basel)* 2022; 14(7). PMID: 35406553. doi.org/10.3390/cancers14071781

Majdalany S, and **Abdollah F**. Editorial Comment. *J Urol* 2022; 207(2):384. PMID: 34689605. doi.org/10.1097/ju.0000000000002250.02

Majdalany S, and **Abdollah F**. EDITORIAL COMMENTS. *Journal of Urology* 2022; 207(2):384. PMID: Not assigned. doi.org/10.1097/JU.0000000000002250.02

Majdalany S, and **Abdollah F**. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. *Journal of Urology* 2022; 207(2):384-384. PMID: Not assigned.

Modonutti D, Majdalany SE, Corsi N, Li P, Sood A, Dalela D, Jamil ML, Hwang C, Menon M, **Rogers CG**, Trinh QD, Novara G, and **Abdollah F**. A novel prognostic model predicting overallsurvival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis. *Prostate* 2022; 82(13):1293-1303. PMID: 35790016. doi.org/10.1002/pros.24403

Monga J, Adrianto I, **Rogers C**, Gadgeel S, Chitale D, Alumkal JJ, Beltran H, Zoubeidi A, and Ghosh J. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. *J Biol Chem* 2022; 298(2):101556. PMID: 34973338. doi.org/10.1016/j.jbc.2021.101556

Mora S, Qi J, Morgan TM, Brede CM, **Peabody J**, George A, and Lane BR. Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative. *Urol Oncol* 2022; 40(8):380.e381-380.e389. PMID: 35778348. doi.org/10.1016/j.urolonc.2022.05.029

Piontkowski AJ, Corsi N, Morisetty S, Majdalany S, Rakic I, Li P, Arora S, Jamil M, **Rogers C**, Autorino R, and **Abdollah F**. Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: Analysis of NCDB registry. *Urol Oncol* 2022. PMID:

35623996. doi.org/10.1016/j.urolonc.2022.04.015

Prebay ZJ, **Patel A**, Johnson A, Kim T, Fonshell C, Raman JD, Ginzburg S, Uzzo RG, **Rogers CG**, and Lane BR. Perspectives on the Role of Biopsy for Management of T1 Renal Masses:Survey Results From Two Regional Quality Improvement Collaboratives. *Urology* 2022; 165:206-211. PMID: 35143851. doi.org/10.1016/j.urology.2022.01.038

**Rogers C**. Laparoscopic vs Robotic Nephrectomy: A Debate Over Preferences. *J Endourol*

2022; 36(3):291. PMID: 34913727. doi.org/10.1089/end.2021.0910

Shah R, Agarwal A, Kavoussi P, **Rambhatla A**, Saleh R, Cannarella R, Harraz AM, Boitrelle F, Kuroda S, Hamoda TAA, Zini A, Ko E, Calik G, Toprak T, Kandil H, Gül M, Bakırcıoğlu ME, Parekh N, Russo GI, Tadros N, Kadioglu A, Arafa M, Chung E, Rajmil O, Dimitriadis F, Malhotra V, Salvio G, Henkel R, Le TV, Sogutdelen E, Vij S, Alarbid A, Gudeloglu A, Tsujimura A, Calogero AE, Meliegy AE, Crafa A, Kalkanli A, Baser A, Hazir B, Giulioni C, Cho CL, Ho CCK, Salzano C, Zylbersztejn DS, Tien DMB, Pescatori E, Borges E, Serefoglu EC, Saïs-Hamza E, Huyghe E, Ceyhan E, Caroppo E, Castiglioni F, Bahar F, Gokalp F, Lombardo F, Gadda F, Duarsa GWK, Pinggera GM, Busetto GM, Balercia G, Cito G, Blecher G, Franco G, Liguori G, Elbardisi H, Keskin H, Lin H, Taniguchi H, Park HJ, Ziouziou I, Rosette J, Hotaling J, Ramsay J, Molina JMC, Lo KL, Bocu K, Khalafalla K, Bowa K, Okada K, Nagao K, Chiba K, Hakim L, Makarounis K, Hehemann M, Peña MR, Falcone M, Bendayan M, Martinez M, Timpano M, Altan M, Fode M, Al-Marhoon MS, Gilani MAS, Soebadi MA, Gherabi N, Sofikitis N, Kahraman O, Birowo P, Kothari P, Sindhwani P, Javed Q, Ambar RF, Kosgi R, Ghayda RA, Adriansjah R, Condorelli RA, Vignera S, Micic S, Kim SHK, Fukuhara S, Ahn ST, Mostafa T, Ong TA, Takeshima T, Amano T, Barrett T, Arslan U, Karthikeyan VS, Atmoko W, Yumura Y, Yuan Y, Kato Y, Jezek D, Cheng BK, Hatzichristodoulou G, Dy J, Castañé ER, El-Sakka AI, Nguyen Q, Sarikaya S, Boeri L, Tan R, Moussa MA, El-Assmy A, Alali H, Alhathal N, Osman Y, Perovic D, Sajadi H, Akhavizadegan H, Vučinić M, Kattan S, Kattan MS, Mogharabian N, Phuoc NHV, Ngoo KS, Alkandari MH, Alsuhaibani S, Sokolakis I, Babaei M, King MS, Diemer T, Gava MM, Henrique R, Silva RSE, Paul GM, Mierzwa TC,

Glina S, Siddiqi K, Wu H, Wurzacher J, Farkouh A, Son H, Minhas S, Lee J, Magsanoc N, Capogrosso P, Albano GJ, Lewis SEM, Jayasena CN, Alvarez JG, Teo C, Smith RP, Chua JBM, Jensen CFS, Parekattil S, Finelli R, Durairajanayagam D, Karna KK, Ahmed A, Evenson D, Umemoto Y, Puigvert A, Çeker G, and Forum GMC. Consensus and Diversity in the Management of Varicocele for Male Infertility: Results of a Global Practice Survey and Comparison with Guidelines and Recommendations. *World J Mens Health* 2022. PMID: 35791302. doi.org/10.5534/wjmh.220048

Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M, Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, **Rogers C**, Mottrie A, Abaza R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, Capitanio U, Maes KK, Porpiglia F, Turkeri L, and Gautam G. Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database. *World J Urol* 2022. PMID: 35867142. doi.org/10.1007/s00345-022-04101-4

Sharma RK, Gupta S, Agarwal A, Finelli R, Kuroda S, Saleh R, Boitrelle F, Kavoussi P, Gül M, Tadros N, Ko E, Farkouh A, Henkel R, Arafa M, **Rambhatla A**, and Shah R. Role of Cytocentrifugation Combined with Nuclear Fast Picroindigocarmine Staining in Detecting Cryptozoospermia in Men Diagnosed with Azoospermia. *World J Mens Health* 2022. PMID: 35118836. doi.org/10.5534/wjmh.210210

Sood A, Grauer R, **Jeong W**, Butaney M, Mukkamala A, Borchert A, Baumgarten L, Hensley PJ, **Abdollah F**, and Menon M. Evaluating post radical prostatectomy mechanisms of early continence. *Prostate* 2022; 82(12):1186-1195. PMID: 35579026. doi.org/10.1002/pros.24371

Sood A, **Jeong W**, Palma-Zamora I, **Abdollah F**, Butaney M, Corsi N, Wurst H, Arora S, **Kachroo N**, Hassan O, Gupta N, Gorin MA, and Menon M. Description of Surgical Techniqueand Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study). *Eur Urol* 2022; 81(4):396-406. PMID: 34872786. doi.org/10.1016/j.eururo.2021.10.017

Sood A, Keeley J, Palma -Zamora I, Chien M, Corsi N, **Jeong W**, **Rogers CG**, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. Anti-Androgen Therapy Overcomes the Time Delayin Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. *Ann Surg Oncol* 2022:1-10. PMID: 35608801. doi.org/10.1245/s10434-022-11892-8

Sood A, Keeley J, Palma -Zamora I, Chien M, Corsi N, **Jeong W**, **Rogers CG**, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. ASO Visual Abstract: Anti-androgen TherapyOvercomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy-A Post Hoc Analysis of the RTOG 9601 Trial Data. *Annals of surgical oncology* 2022. PMID: Not assigned. doi.org/10.1245/s10434-022-11934-1

Sood A, Keeley J, Palma -Zamora I, Novara G, Elshaikh M, **Jeong W**, Hensley P, Navai N, **Peabody JO**, Trinh QD, **Rogers CG**, Menon M, and **Abdollah F**. High-intensity local treatmentof clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. *Urol Oncol* 2022; 40(2):62.e61-62.e11. PMID: 34348860. doi.org/10.1016/j.urolonc.2021.07.018

Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Optimizing anti-androgen treatment use among menwith pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. *Prostate Cancer Prostatic Dis* 2022. PMID: 35794359. doi.org/10.1038/s41391-022-00572-z

Veccia A, Carbonara U, Derweesh I, Mehrazin R, Porter J, **Abdollah F**, Mazzone E, Sundaram CP, Gonzalgo M, Mastroianni R, Ghoreifi A, Cacciamani GE, Patel D, Marcus J, Danno A, Steward J, Satish Bhattu A, Asghar A, Reese AC, Wu Z, Uzzo RG, Minervini A, Rha KH, Ferro M, Margulis V, Hampton LJ, Simone G, Eun DD, Djaladat H, Mottrie A, and Autorino R. Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. *Minerva Urol Nephrol* 2022; 74(2):233-241. PMID: 33781022. doi.org/10.23736/s2724-6051.21.04247-8

Veccia A, Carbonara U, Djaladat H, Mehazin R, Eun DD, Reese AC, Meng X, Uzzo R, Srivastava A, Porter J, Farrow JM, Jamil ML, Rosiello G, Tellini R, Mari A, Al-Qathani A, Rha KH, Wang L, Mastroianni R, Ferro M, De Cobelli O, Hakimi K, Crocerossa F, Ghoreifi A, Cacciamani G, Bhattu AS, Mottrie A, **Abdollah F**, Minervini A, Wu Z, Simone G, Derweesh I, Gonzalgo ML, Margulis V, Sundaram CP, and Autorino R. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group). *J Endourol* 2022; 36(6):752-759. PMID: 35019760. doi.org/10.1089/end.2021.0587

Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo RG, Sundaram CP, Rha KH, Gonzalgo ML, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi

A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu AS, Mottrie A, **Abdollah F**, Eun DD, Derweesh I, Veccia A, Autorino R, and Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). *Eur Urol Focus* 2022; 8(1):173-181. PMID: 33549537. doi.org/10.1016/j.euf.2021.01.014

Yaguchi G, Swavely N, Perkins SQ, and **Kachroo N**. Kidney stone depiction on fictional television: how accurate are they? *Urolithiasis* 2022; 50(2):167-175. PMID: 35050414. doi.org/10.1007/s00240-022-01303-8

Ahlawat R, Sood A, **Jeong W**, Ghosh P, Keeley J, **Abdollah F**, Kher V, Olson P, Farah G, Wurst H, Bhandari M, and Menon M. Robotic Kidney Transplantation with Regional Hypothermia versus Open Kidney Transplantation for Patients with End Stage Renal Disease: An Ideal Stage 2B Study. *J Urol* 2021; 205(2):595-602. PMID: 32941100. doi.org/10.1097/ju.0000000000001368

Alanee S, **Peabody J**, and Menon M. AUTHOR REPLY. *Urology* 2021; 148:317-318. PMID:

33279614. doi.org/10.1016/j.urology.2020.11.038

Alanee S, Sana S, El-Zawahry A, **Peabody J**, Pearce T, Adams N, Deebajah M, Crabtree J, Delfino K, McVary K, Robinson K, and Rao K. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment. *World J Urol* 2021; 39(10):3807-3813. PMID: 33966128. doi.org/10.1007/s00345-021-03716-3

Auffenberg GB, Qi J, Dunn RL, Linsell S, Kim T, Miller DC, Tosoian J, Sarle R, Johnston WK, 3rd, Kleer E, Ghani KR, Montie J, and **Peabody J**. Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. *JAMA Surg* 2021; 156(3):e206359. PMID: 33471043. doi.org/10.1001/jamasurg.2020.6359

Briskin R, and **Atiemo H**. Case - Unique complication of continent catheterizable stoma after bariatric surgery. *Can Urol Assoc J* 2021; 15(7): E370-e372. PMID: 33382367. doi.org/10.5489/cuaj.6773

Bronkema C, Arora S, Keeley J, Rakic N, Sood A, Dalela D, Jamil M, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Impact of treatment modality on overall survival in localizedductal prostate adenocarcinoma: A national cancer database analysis. *Urol Oncol* 2021; 39(6):366.e311-366.e318. PMID: 33223370. doi.org/10.1016/j.urolonc.2020.11.013

Budzyn J, and **Leavitt D**. Life threatening hepatic hemorrhage after shockwave lithotripsy - A case report and review of literature. *Urol Case Rep* 2021; 38:101724. PMID: 34136358. doi.org/10.1016/j.eucr.2021.101724

Butaney M, Dabaja A, and **Rambhatla A**. EDITORIAL COMMENT. *Urology* 2021; 157:56. PMID: 34895600. doi.org/10.1016/j.urology.2021.05.072

Butaney M, **Dabaja A**, and **Rambhatla A**. Anarcha, Lucy, and Betsey: The Mothers of Modern

Gynecology COMMENT. *Urology* 2021; 157:56-56. PMID: Not assigned.

doi.org/10.1016/j.urology.2021.05.072

Dalela D, and **Abdollah F**. Author Reply. *Urology* 2021; 153:361-362. PMID: 33823172. doi.org/10.1016/j.urology.2021.03.029

Dalela D, Arora S, **Peabody J**, and **Rogers C**. Re: Wilson et al. Outpatient Extraperitoneal

Single-Port Robotic Radical Prostatectomy. Urology 2020; 144: 142-146. *Urology* 2021;

152:203. PMID: 33600837. doi.org/10.1016/j.urology.2020.12.050

Dalela D, Palma-Zamora I, and **Rogers C**. Re: Fredrick Leidberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757-63. *Eur Urol* 2021; 79(4): e115-e116. PMID: 33487478. doi.org/10.1016/j.eururo.2021.01.009

Dalela D, Sood A, Keeley J, **Rogers C**, Menon M, and **Abdollah F**. Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis. *Urology* 2021; 148:1-3. PMID: 33221417. doi.org/10.1016/j.urology.2020.11.015

Elsayed AS, Gibson S, Jing Z, Wijburg C, Wagner AA, Mottrie A, Dasgupta P, **Peabody J**, Hussein AA, and Guru KA. Rates and Patterns of Recurrences and Survival Outcomes after

Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy

Consortium. *J Urol* 2021; 205(2):407-413. PMID: 32945729.

doi.org/10.1097/ju.0000000000001380

Fedrigon D, Faris A, **Kachroo N**, Jain R, Elia M, Wilkins L, Li J, De S, Noble M, Monga M, and Sivalingam S. SKOPE-Study of Ketorolac vs Opioid for Pain after Endoscopy: A Double-Blinded Randomized Control Trial in Patients Undergoing Ureteroscopy. *J Urol* 2021; 206(2):373-381. PMID: 33819072. doi.org/10.1097/ju.0000000000001772

Fedrigon D, Faris A, **Kachroo N**, Jain R, Elia M, Wilkins L, Li J, De S, Noble M, Monga M, and Sivalingam S. Reply by Authors. *J Urol* 2021; 206(2):381. PMID: 33983827. doi.org/10.1097/ju.0000000000001772.03

Gild P, Pompe RS, Seisen T, Keeley J, Tang HJ, Bossi A, Tilki D, Menon M, and **Abdollah F**. Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. *Eur Urol Oncol* 2021; 4(5):817-820. PMID: 31501084. doi.org/10.1016/j.euo.2019.08.005

Ginsburg KB, Johnson K, Moldovan T, Peabody H, Qi J, Dunn RL, **Rogers C**, Weizer A, Kaul S, Johnson A, Traver M, and Lane BR. A Statewide Quality Improvement Collaborative's Adherence to the 2017 American Urological Association Guidelines Regarding Initial Evaluation of Patients With Clinical T1 Renal Masses. *Urology* 2021; 158:117-124. PMID: 34499969. doi.org/10.1016/j.urology.2021.08.036

Hiller SC, Qi J, **Leavitt D**, Frontera JR, Jafri SM, Hollingsworth JM, Dauw CA, and Ghani KR. Ureteroscopy in Patients Taking Anticoagulant or Antiplatelet Therapy: Practice Patterns and Outcomes in a Surgical Collaborative. *J Urol* 2021; 205(3):833-840. PMID: 33035142. doi.org/10.1097/ju.0000000000001416

Jamil M, Etta P, and **Abdollah F**. AUTHOR REPLY. *Urology* 2021; 158:115-116. PMID:

34895624. doi.org/10.1016/j.urology.2021.04.077

Jamil M, Etta P, and **Abdollah F**. Renal Tumor Size and Presence of Synchronous Lung Metastasis at Time of Diagnosis: Implications for Chest Imaging REPLY. *Urology* 2021; 158:115-116. PMID: Not assigned. doi.org/10.1016/j.urology.2021.04.077

Jamil M, Hanna R, Sood A, Corsi N, Modonutti D, Keeley J, Etta P, Novara G, **Patel A**, **Rogers C**, and **Abdollah F**. Renal Tumor Size and Presence of Synchronous Lung Metastasis at Time ofDiagnosis: Implications for Chest Imaging. *Urology* 2021; 158:110-116. PMID: 34284011. doi.org/10.1016/j.urology.2021.04.070

Jamil M, Rakic N, Sood A, Keeley J, Modonutti D, Novara G, **Jeong W**, Menon M, **Rogers CG**, and **Abdollah F**. Impact of Lymphovascular Invasion on Overall Survival in Patients With Prostate Cancer Following Radical Prostatectomy: Stage-per-Stage Analysis. *Clin Genitourin Cancer* 2021; 19(5):e319-e325. PMID: 34154946. doi.org/10.1016/j.clgc.2021.04.009

Jiang T, Osadchiy V, Weinberger JM, Zheng MH, Owen MH, Leonard SA, Mills JN, **Kachroo N**, and Eleswarapu SV. Impact of the COVID-19 Pandemic on Patient Preferences and DecisionMaking for Symptomatic Urolithiasis. *J Endourol* 2021; 35(8):1250-1256. PMID: 33478351. doi.org/10.1089/end.2020.1141

Johnson K, Lane BR, Weizer AZ, Herrel LA, **Rogers CG**, Qi J, Johnson AM, Seifman BD, and Sarle RC. Partial nephrectomy should be classified as an inpatient procedure: Results from a statewide quality improvement collaborative. *Urol Oncol* 2021; 39(4):239.e239-239.e216. PMID: 33485765. doi.org/10.1016/j.urolonc.2021.01.001

**Kachroo N**, **Raffee S**, Elshatanoufy S, and **Atiemo H** . High uterosacral ligament hysteropexy for the management of pelvic organ prolapse. *Int Braz J Urol* 2021; 47(4):902-904. PMID: 33848087. doi.org/10.1590/s1677-5538.Ibju.2020.0384

Katims AB, Say R, Derweesh I, Uzzo R, Minervini A, Wu Z, **Abdollah F**, Sundaram C, Ferro M, Rha K, Mottrie A, Rosiello G, Simone G, Eun DD, Reese A, Kidd LC, Porter J, Bhattu AS, Gonzalgo ML, Margulis V, Marcus J, Danno A, Meagher M, Tellini R, Mari A, Veccia A, Ghoreifi A, Autorino R, Djaladat H, and Mehrazin R. Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). *J Urol* 2021; 206(3):568-576. PMID: 33881931. doi.org/10.1097/ju.0000000000001786

Lee DI, Shahait M, Dalela D, Keeley J, Lal P, Vapiwala N, and **Abdollah F**. External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. *World J Urol* 2021; 39(9):3217-3222. PMID: 33388922. doi.org/10.1007/s00345-020-03540-1

Malinzak L, McEvoy T, Denny J, Kim D, Stracke J, **Jeong W**, and Yoshida A. Robot-assisted Transplant Ureteral Repair to Treat Transplant Ureteral Strictures in Patients after Robot-assisted Kidney Transplant: A Case Series. *Urology* 2021; 156:141-146. PMID: 34058240. doi.org/10.1016/j.urology.2021.05.029

Nocera L, Collà Ruvolo C, Stolzenbach LF, Deuker M, Tian Z, Gandaglia G, Fossati N, **Abdollah F**, Suardi N, Mirone V, Graefen M, Chun FK, Saad F, Montorsi F, Briganti A, andKarakiewicz PI. Improving the stratification of intermediate risk prostate cancer. *Minerva Urol Nephrol* 2021. PMID: 33887893. doi.org/10.23736/s2724-6051.21.04314-7

**Patel AK**, Lane BR, Chintalapati P, Fouad L, Butaney M, Budzyn J, Johnson A, Qi J, Schervish E, and **Rogers CG**. Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative. *Eur Urol Open Sci* 2021; 30:37-43. PMID: 34337546. doi.org/10.1016/j.euros.2021.06.004

**Patel AK**, **Rogers CG**, Johnson A, Noyes SL, Qi J, Miller D, Shervish E, Stockton B, and Lane BR. Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative. *Eur Urol Open Sci* 2021; 23:13-19. PMID: 34337485. doi.org/10.1016/j.euros.2020.11.002

Raison N, Servian P, **Patel A**, Santhirasekaram A, Smith A, Yeung M, Lloyd J, Mannion E, Rockall A, Ahmed H, and Winkler M. Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer? *Prostate Cancer Prostatic Dis* 2021. PMID: 34845306. doi.org/10.1038/s41391-021-00468-4

Rakic N, Jamil M, Keeley J, Sood A, Vetterlein M, Dalela D, Arora S, Modonutti D, Bronkema C, Novara G, **Peabody J**, **Rogers C**, Menon M, and **Abdollah F**. Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. *Urol Oncol* 2021; 39(8):495.e491-495.e496. PMID: 33602620. doi.org/10.1016/j.urolonc.2021.01.007

**Rambhatla A**, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z, **Dabaja AA**, **Rogers CG**, **Liroff SA**, and **Abdollah F**. COVID-19 Infection in Men on Testosterone Replacement Therapy. *J Sex Med* 2021; 18(1):215-218. PMID: 33191186. doi.org/10.1016/j.jsxm.2020.09.013

**Rogers C**. Point/Counterpoint of Controversial Topics in Robotic Surgery Editorial Comment. *J Endourol* 2021; 35(8):1123. PMID: 33913740. doi.org/10.1089/end.2021.0342

**Shakir NA**. Letter to the Editor. *Can J Urol* 2021; 28(3):10657. PMID: 34129455.

**Shakir NA**. Re: Abramowitz et al. "Virtue male sling outcomes and application to a contemporary nomogram". *Canadian Journal of Urology* 2021; 28(3):10657-10657. PMID: Not assigned.

Shamaa T, Yoshida A, Borchert A, McEvoy T, **Jeong W**, and Malinzak L. Robot-assisted Transplant Ureteral Repair after Robot-assisted Kidney Transplant. *Urology Video Journal* 2021; 11. PMID: Not assigned. doi.org/10.1016/j.urolvj.2021.100099

Sood A, Butaney M, Olson P, Farah G, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. The Impact of the Price Transparency Mandate on Cost Reporting for Common Urological Services across the U.S. News Top 21 Hospitals. *Urology Practice* 2021; 8(6):657-660. PMID: Not assigned. doi.org/10.1097/UPJ.0000000000000264

Sood A, **Jeong W**, Keeley J, **Abdollah F**, Hassan O, Gupta N, and Menon M. Subtotal surgical therapy for localized prostate cancer: a single-center precision prostatectomy experience in 25 patients, and SEER-registry data analysis. *Transl Androl Urol* 2021; 10(7):3155-3166. PMID: 34430418. doi.org/10.21037/tau-20-1476

Sood A, Wong P, Borchert A, Budzyn J, Keeley J, Heilbronn C, Eilender B, **Littleton R**, and **Leavitt DA**. Use of ultra -low dose computed tomography versus abdominal plain film forassessment of stone-free rates after shock-wave lithotripsy: implications on emergency room visits, surgical procedures, and cost-effectiveness. *Urolithiasis* 2021; 49(6):591-598. PMID: 33993338. doi.org/10.1007/s00240-021-01273-3

Tandogdu Z, Collins J, Shaw G, Rohn J, Koves B, Sachdeva A, Ghazi A, Haese A, Mottrie A, Kumar A, Sivaraman A, Tewari A, Challacombe B, Rocco B, Giedelman C, Wagner C, **Rogers CG**, Murphy DG, Pushkar D, Ogaya-Pinies G, Porter J, Seetharam KR, Graefen M, Orvieto MA,Moschovas MC, Schatloff O, Wiklund P, Coelho R, Valero R, de Reijke TM, Ahlering T, Rogers T, van der Poel HG, Patel V, Artibani W, Wagenlehner F, Maes K, Rha KH, Nathan S, Bjerklund Johansen TE, Hawkey P, and Kelly J. Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international

accelerated consensus statement. *BJU Int* 2021; 127(6):729-741. PMID: 33185026. doi.org/10.1111/bju.15299

Wertheimer S, Budzyn J, Perkins S, Borchert A, **Rogers C**, and **Patel A**. Patient Tolerability With Office Transperineal Biopsy Using a Reusable Needle Guide. *Urology* 2021; 154:339-341. PMID: 34044025. doi.org/10.1016/j.urology.2021.05.018

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie J, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Reply to K.P. Weinfurt et al. *J Clin Oncol* 2020; 38(6):654-655. PMID: 31895615. doi.org/10.1200/jco.19.02642

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie J, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Assessing Patient-Reported Outcomes: A Negotiated Process Reply. *Journal of Clinical Oncology* 2020; 38(6):654-+. PMID: Not assigned. doi.org/10.1200/jco.19.02642

Ahmed Y, Hussein AA, May PR, Ahmad B, Khan A, Benkowski J, Durrani A, Khan S, Kozlowski J, Saar M, Wijburg CJ, Richstone L, Wagner A, Yuh B, Redorta JP, Dasgupta P, Khan MS, Menon M, **Peabody JO** , Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Tan WS, Maatman TJ, Poulakis V, Kaouk J, Canda AE, Balbay MD, Wiklund P, and Guru KA. Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *African Journal of Urology* 2020; 26(1). PMID: Not assigned. doi.org/10.1186/s12301-020-00031-y

Alanee S, Deebajah M, Taneja K, Cole D, Pantelic M, **Peabody J**, Williamson SR, Gupta N, **Dabaja A**, and Menon M. Post Prostatectomy Pathologic Findings of Patients With ClinicallySignificant Prostate Cancer and no Significant PI- RADS Lesions on Preoperative Magnetic Resonance Imaging. *Urology* 2020; 146:183-188. PMID: 32946907. doi.org/10.1016/j.urology.2020.07.068

Alanee S, **Peabody J**, and Menon M. AUTHOR REPLY. *Urology* 2020; 146:188. PMID:

33272426. doi.org/10.1016/j.urology.2020.07.071

Alanee S, **Peabody J**, and Menon M. Post Prostatectomy Pathologic Findings of Patients With Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative

Magnetic Resonance Imaging REPLY. *Urology* 2020; 146:188-188. PMID: Not assigned. doi.org/10.1016/j.urology.2020.07.071

Arora S, Bronkema C, Porter JR, Mottrie A, Dasgupta P, Challacombe B, Rha KH, Ahlawat RK, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Sivaraman A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Bhandari M, **Jeong W**, Menon M, **Rogers CG**, and **Abdollah F**. Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. *Urology* 2020; 146:125-132. PMID: 32941944. doi.org/10.1016/j.urology.2020.09.003

Arora S, Keeley J, **Patel A**, Eleswarapu SV, Bronkema C, Alanee S, and Menon M. Defining a "High Volume" Radical Cystectomy Hospital: Where Do We Draw the Line? *Eur Urol Focus* 2020; 6(5):975-981. PMID: 30772360. doi.org/10.1016/j.euf.2019.02.001

Baumgarten L, Borchert A, Sood A, Dalela D, Arora S, Keeley J, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort. *Urol Oncol* 2020; 38(2):38.e17-38.e22. PMID: 31653564. doi.org/10.1016/j.urolonc.2019.09.012

Bhandari M, Nallabasannagari AR, Reddiboina M, Porter JR, **Jeong W**, Mottrie A, Dasgupta P, Challacombe B, Abaza R, Rha KH, Parekh DJ, Ahlawat R, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Buffi NM, Sivaraman A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Meyyazhgan KR, Patil P, Menon M, and **Rogers C**. Predicting intra-operative and postoperative consequential events using machine-learning techniques in patients undergoing robot-assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. *BJU Int* 2020; 126(3):350-358. PMID: 32315504. doi.org/10.1111/bju.15087

Borchert A, Baumgarten L, Dalela D, Jamil M, Budzyn J, Kovacevic N, Yaguchi G, Palma-Zamora I, Perkins S, Bazzi M, Wong P, Sood A, **Peabody J**, **Rogers CG**, **Dabaja A**, and **Atiemo H**. Managing Urology Consultations During COVID-19 Pandemic: Application of aStructured Care Pathway. *Urology* 2020; 141:7-11. PMID: 32330531. doi.org/10.1016/j.urology.2020.04.059

Bronkema C, Arora S, Sood A, Dalela D, Keeley J, Borchert A, Baumgarten L, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. Rare Histological Variants of ProstateAdenocarcinoma: A National Cancer Database Analysis. *J Urol* 2020; 204(2):260-266. PMID: 32141804. doi.org/10.1097/ju.0000000000001011

Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Chitale D, Gupta N, Davis MB, Newman LA, **Rogers CG**, Paris PL, Li J, Rybicki BA, and Levin AM. Breast and prostate cancers harborcommon somatic copy number alterations that consistently differ by race and are associated with survival. *BMC Med Genomics* 2020; 13(1):116. PMID: 32819446. doi.org/10.1186/s12920-020-00765-2

Cheng PJ, Keihani S, Roth JD, Pariser JJ, Elliott SP, Bose S, Khavari R, Crescenze I, Stoffel JT, Velaer KN, Elliott CS, **Raffee SM**, **Atiemo HO**, Kennelly MJ, Lenherr SM, and Myers JB. Contemporary multicenter outcomes of continent cutaneous ileocecocystoplasty in the adult population over a 10-year period: A Neurogenic Bladder Research Group study. *Neurourol Urodyn* 2020; 39(6):1771-1780. PMID: 32506711. doi.org/10.1002/nau.24420

Dauw CA, Swarna K, Qi J, Kim T, **Leavitt D**, Leese J, Abdelhady M, Witzke K, Hollingsworth JM, and Ghani KR. Shockwave Lithotripsy Use in the State of Michigan: American Urological Association Guideline Adherence and Clinical Implications. *Urology* 2020; 137:38-44. PMID:

31843621. doi.org/10.1016/j.urology.2019.11.037

Dedigama-Arachchige P, Carskadon S, Li J, Loveless I, Alhamar M, **Peabody JO**, **Stricker H**, Chitale DA, **Rogers CG**, Menon M, Gupta NS, Bismar TA, Williamson SR, and Palanisamy N. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. *Mod Pathol* 2020; 33(9):1791-1801. PMID: 32238875. doi.org/10.1038/s41379-020-0525-0

Ginsburg KB, Schwabe JR, Cochrane JA, Tapper A, Burks F, and **Rambhatla A**. Low Serum Albumin Correlates With Adverse Events Following Surgery for Male Urinary Incontinence: Analysis of the American College of Surgeons National Surgical Quality Improvement Project. *Urology* 2020; 137:178-182. PMID: 31866523. doi.org/10.1016/j.urology.2019.12.004

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, **Peabody JO**, Wijburg CJ, Wagner A, Canda AE, Khan MS, Scherr D, Schanne F, Maatman TJ, Kim E, Mottrie A, Aboumohamed A, Gaboardi F, Pini G, Kaouk J, Yuh B, Rha KH, Hemal A, Palou Redorta J, Badani K, Saar M, Stockle M, Richstone L, Roupret M, Balbay D, Dasgupta P, Menon M, and Guru KA. A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *BJU Int* 2020; 126(2):265-272. PMID: 32306494. doi.org/10.1111/bju.15083

Jamil ML, Keeley J, Sood A, Dalela D, Arora S, **Peabody JO**, Trinh QD, Menon M, **Rogers CG**, and **Abdollah F**. Long-term Risk of Recurrence in Surgically Treated Renal CellCarcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. *Eur Urol* 2020; 77(2):277-281. PMID: 31703971. doi.org/10.1016/j.eururo.2019.10.028

Jamil ML, Keeley J, Sood A, Dalela D, Arora S, **Peabody JO**, Trinh QD, Menon M, **Rogers CG**, **Abdollah F**, and Laguna MP. Re: Long-Term Risk of Recurrence in Surgically TreatedRenal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. *Journal of Urology* 2020; 204(3):614-615. PMID: Not assigned. doi.org/10.1097/JU.0000000000001174

Johnson M, Perkins SQ, and **Leavitt D**. Alkaline- Encrusted Pyelitis Causing Renal Failure in a Transplant Kidney: Treatment with Percutaneous Nephrolithotomy and Urinary Acidification. *J Endourol Case Rep* 2020; 6(4):435-437. PMID: 33457694. doi.org/10.1089/cren.2020.0183

Kovacevic N, Lopes NN, **Raffee S**, and **Atiemo HO**. Predicting Upper Urinary Tract Risk in the Neurogenic Bladder Patient. *Current Bladder Dysfunction Reports* 2020; 15(2):66-71. PMID: Not assigned. doi.org/10.1007/s11884-020-00578-0

Lescay H, **Abdollah F**, Cher ML, Qi J, Linsell S, Miller DC, Montie JE, **Peabody J**, Kaffenberger S, Morgan T, Loeb A, and Lane BR. Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. *Urol Oncol* 2020; 38(4):198-203. PMID: 31740331. doi.org/10.1016/j.urolonc.2019.09.026

Lin JC, **Patel A**, and **Rogers CG**. Robot-assisted removal of inferior vena cava filter. *J Vasc Surg Cases Innov Tech* 2020; 6(2):311-312. PMID: 32566810.doi.org/10.1016/j.jvscit.2020.03.009

Lin JC, Ranasinghe B, **Patel A**, and **Rogers CG**. Robot-assisted laparoscopic placement of extravascular stent for nutcracker syndrome. *J Vasc Surg Cases Innov Tech* 2020; 6(3):346-347. PMID: 32715169. doi.org/10.1016/j.jvscit.2020.03.013

Lu Z, Williamson SR, Carskadon S, Arachchige PD, Dhamdhere G, Schultz DS, **Stricker H**, **Peabody JO**, **Jeong W**, Chitale DA, Bismar TA, **Rogers CG**, Menon M, Gupta NS, andPalanisamy N. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. *Prostate* 2020; 80(1):38-50. PMID: 31584209. doi.org/10.1002/pros.23914

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, Briganti A, Shariat SF, **Abdollah F**, Carmignani L, and Karakiewicz PI. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *Eur Urol Focus* 2020; 6(2):298-304. PMID: 30266210. doi.org/10.1016/j.euf.2018.09.007

Peabody H, **Patel A**, Johnson A, Mirza M, Noyes SL, Schervish E, Kaul S, **Rogers CG**, Lane BR, and Semerjian A. Development of a Novel Scoring System Quantifies Opportunities to Reduce Surgery for Benign Renal Neoplasms: A Retrospective Quality Improvement Analysis within the MUSIC-KIDNEY Collaborative. *J Urol* 2020; 204(6):1160-1165. PMID: 32628102. doi.org/10.1097/ju.0000000000001238

Perkins SQ, **Dabaja A**, and **Atiemo H**. Best Approaches to Evaluation and Feedback in Post-Graduate Medical Education. *Curr Urol Rep* 2020; 21(10):36. PMID: 32789759. doi.org/10.1007/s11934-020-00991-2

Rakic N, Keeley J, and **Abdollah F**. Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77:713-724: External Validity of the Updated Prostate Cancer Intervention Versus Observation Trial (PIVOT). *Eur Urol Oncol* 2020; 3(4):557-558. PMID: 32546347. doi.org/10.1016/j.euo.2020.05.002

Rakic N, Sood A, Dalela D, Arora S, Malovana U, Keeley J, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. *Clin Genitourin Cancer* 2020; 18(6):489-499.e486. PMID: 32595074. doi.org/10.1016/j.clgc.2020.05.001

**Rambhatla A**. Editorial Comment. *J Urol* 2020; 204(3):556. PMID: 32574513. doi.org/10.1097/ju.0000000000001016.01

Sood A, **Abdollah F**, Jeong W, and Menon M. The Precision Prostatectomy: "Waiting for

Godot". *Eur Urol Focus* 2020; 6(2):227-230. PMID: 31983662.

doi.org/10.1016/j.euf.2020.01.010

Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P, Hanna R, Cotter D, **Jeong W**, Elshaikh M, **Rogers CG**, **Peabody JO** , Menon M, and **Abdollah F**. Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data. *Urol Oncol* 2020; 38(6):599.e591-599.e598. PMID: 32229186. doi.org/10.1016/j.urolonc.2020.02.024

Sood A, Keeley J, Palma-Zamora I, Dalela D, Arora S, **Peabody JO**, **Rogers CG**, Montorsi F, Menon M, Briganti A, and **Abdollah F**. Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion. *BJU Int* 2020; 125(6):756-758. PMID: 32045096. doi.org/10.1111/bju.15034

Turner KA, **Rambhatla A**, Schon S, Agarwal A, Krawetz SA, Dupree JM, and Avidor-Reiss T. Male Infertility is a Women's Health Issue-Research and Clinical Evaluation of Male Infertility Is Needed. *Cells* 2020; 9(4). PMID: 32316195. doi.org/10.3390/cells9040990

Wu RC, Prebay ZJ, Patel P, Kim T, Qi J, Telang J, Linsell S, Kleer E, Miller DC, **Peabody JO**, Ghani KR, and Johnston WK, 3rd. Using video review to understand the technical variation of robot-assisted radical prostatectomy in a statewide surgical collaborative. *World J Urol* 2020; 38(7):1607-1613. PMID: 31444604. doi.org/10.1007/s00345-019-02906-4

Yaguchi G, Tang HJ, Deebajah M, Keeley J, Pantelic M, Williamson S, Gupta N, **Peabody JO** , Menon M, **Dabaja A**, and Alanee S. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance. *Urol Oncol* 2020; 38(6):599.e599-599.e513. PMID: 32265090. doi.org/10.1016/j.urolonc.2020.03.002

**Abdollah F**, Keeley J, and Menon M. Minimally Invasive or Abdominal Radical Hysterectomy for Cervical Cancer. *N Engl J Med* 2019; 380(8):793. PMID: 30786197. doi.org/10.1056/NEJMc1816590

Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie JE, Kim T, Miller DC, **Peabody J**, and Carlozzi NE. Validity of the Patient -Reported Outcome Measurement Information System(PROMIS) sexual interest and satisfaction measures in men following radical prostatectomy. *Journal of Clinical Oncology* 2019; 37(23):2017-2027. PMID: Not assigned.doi.org/10.1200/JCO.18.01782

Alanee S, El-Zawahry A, Dynda D, **Dabaja A**, McVary K, Karr M, and Braundmeier-Fleming A. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. *Prostate* 2019; 79(1):81-87. PMID: 30117171. doi.org/10.1002/pros.23713

Arabi A, Deebajah M, Yaguchi G, Pantelic M, Williamson S, Gupta N, Park H, **Peabody J**, Menon M, **Dabaja A**, and Alanee S. Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer. *Urology* 2019; 134:168-172. PMID: 31479660. doi.org/10.1016/j.urology.2019.08.035

Arora S, Sood A, Dalela D, Tang HJ, **Patel A**, Keeley J, Trinh QD, **Rogers CG** , Menon M, and **Abdollah F**. Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENATrial to Real-world National Cancer Data Base Cases. *Eur Urol* 2019; 75(2):352-353. PMID: 30420256. doi.org/10.1016/j.eururo.2018.10.054

Auffenberg GB, Ghani KR, Ramani S, Usoro E, Denton B, **Rogers C**, Stockton B, Miller DC, and Singh K. askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men. *Eur Urol* 2019; 75(6):901-907. PMID: 30318331. doi.org/10.1016/j.eururo.2018.09.050

Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, **Abdollah F**, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, and Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. *Clin Genitourin Cancer* 2019; 17(1):72-78.e74. PMID: 30342845. doi.org/10.1016/j.clgc.2018.09.011

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, **Abdollah F**, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, and Karakiewicz PI.Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph

Node Metastatic Prostate Cancer Patients. *Eur Urol Focus* 2019; 5(3):381-388. PMID:

29366856. doi.org/10.1016/j.euf.2018.01.009

Bazzi M, Jamil ML, and **Dabaja AA**. Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections. *Curr Urol Rep* 2019; 20(8):42. PMID: 31201571. doi.org/10.1007/s11934-019-0910-8

Bronkema C, Rakic N, and **Abdollah F**. Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension. *Ann Transl Med* 2019; 7(Suppl 8):S291. PMID: 32016010. doi.org/10.21037/atm.2019.11.44

Budzyn J, Trinh H, **Raffee S**, and **Atiemo H**. Bladder Augmentation (Enterocystoplasty): the

Current State of a Historic Operation. *Curr Urol Rep* 2019; 20(9):50. PMID: 31342172. doi.org/10.1007/s11934-019-0919-z

Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, Sundaram SK, Li J, Wu KH, Chandrashekar DS, **Peabody JO**, **Stricker H**, Hwang C, Chitale DA, Williamson SR, Gupta NS, Navone NM, **Rogers C**, Menon M, Varambally S, and Palanisamy N. Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. *Neoplasia* 2019; 21(10):989-1002. PMID: 31446281. doi.org/10.1016/j.neo.2019.07.010

Dalela D, Sun M, Diaz M, Karabon P, Seisen T, Trinh QD, Menon M, and **Abdollah F**. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. *Eur Urol Focus* 2019; 5(1):77-80. PMID: 28753893. doi.org/10.1016/j.euf.2017.04.012

Deebajah M, Bazzi M, Walton E, Pantelic M, Park H, **Dabaja A**, and Alanee S. Prostate volume measured by magnetic resonance imaging is not a predictor of lower urinary tract symptoms. *J Family Med Prim Care* 2019; 8(4):1370-1373. PMID: 31143723.doi.org/10.4103/jfmpc.jfmpc\_94\_19

Deebajah M, Keeley J, Park H, Pantelic M, Gupta N, Williamson SR, **Peabody J**, Menon M, **Dabaja A**, and Alanee S. A propensity score matched analysis of the effects of AfricanAmerican race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate. *Urol Oncol* 2019; 37(8):531.e531-531.e535. PMID: 31005421. doi.org/10.1016/j.urolonc.2019.03.017

Friedlander DF, von Landenberg N, Löppenberg B, Noldus J, Lipsitz SR, Cole AP, **Abdollah F**, Nguyen PL, Choueiri TK, Kibel AS, and Trinh QD. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. *J Urol* 2019; 201(4):728-734. PMID: 30633112. doi.org/10.1097/ju.0000000000000006

Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Osei J, Kaouk J, Redorta JP, Menon M, **Peabody J**, Dasgupta P, Khan MS, Mottrie A, Stöckle M, Hemal A, Richstone L, Hosseini A,Wiklund P, Schanne F, Kim E, Ho Rha K, and Guru KA. Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2019; 202(5):927-935. PMID: 31188729. doi.org/10.1097/ju.0000000000000386

Kryvenko ON, Wang Y, Sadasivan S, Gupta NS, **Rogers C**, Bobbitt K, Chitale DA, Rundle A, Tang D, and Rybicki BA. Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy. *Prostate* 2019; 79(10):1090-1098. PMID: 31045267. doi.org/10.1002/pros.23820

Macki M, Anand SK, Jaratli H, and **Dabaja AA**. Penile Lymphangioma: review of the literature

with a case presentation. *Basic Clin Androl* 2019; 29:1. PMID: 30705756.

doi.org/10.1186/s12610-018-0081-3

Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, **Abdollah F**, Tilki D, Briganti A, Montorsi F, Shariat SF, Schips L, and Karakiewicz PI. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *Eur Urol Focus* 2019; 5(3):467-473. PMID: 29398456. doi.org/10.1016/j.euf.2018.01.007

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, **Abdollah F**, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, and Karakiewicz PI. The effect of race on survival after local therapy in metastatic prostate cancer patients. *Can Urol Assoc J* 2019; 13(6):175-181. PMID: 30332592. doi.org/10.5489/cuaj.5399

Oh CK, Kim KH, **Jeong W**, Han WK, Rha KH, and Ahn B. Research on Patient Satisfaction of Robotic Telerounding: A Pilot Study in a Korean Population. *Urology* 2019; 130:205-208. PMID: 31059727. doi.org/10.1016/j.urology.2019.04.030

Prebay ZJ, **Peabody JO**, Miller DC, and Ghani KR. Video review for measuring and improving skill in urological surgery. *Nat Rev Urol* 2019; 16(4):261-267. PMID: 30622365. doi.org/10.1038/s41585-018-0138-2

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, **Abdollah F**, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, and Karakiewicz PI. TheImpact of Lymph Node Metastases Burden at Radical Prostatectomy. *Eur Urol Focus* 2019; 5(3):399-406. PMID: 29306731. doi.org/10.1016/j.euf.2017.12.009

**Raffee S**, and **Atiemo H**. Polydimethylsiloxane Erosion as a Cause for Recurrent Urinary Tract Infections. *J Endourol Case Rep* 2019; 5(3):117-119. PMID: 32775642. doi.org/10.1089/cren.2019.0007

Sood A, **Abdollah F**, and Menon M. Retzius-sparing robot-assisted radical prostatectomy. *BJU Int* 2019; 123(1):7-8. PMID: 30565400. doi.org/10.1111/bju.14518

Sood A, **Jeong W**, Taneja K, **Abdollah F**, Palma-Zamora I, Arora S, Gupta N, and Menon M. The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study. *BMJ Surg Interv Health Technol* 2019; 1(1):e000002. PMID: 35047770. doi.org/10.1136/bmjsit-2019-000002

Tam CA, Dauw CA, Ghani KR, Gunaseelan V, Kim T, **Leavitt DA**, Raisky J, Yan PL, and Hollingsworth JM. New Persistent Opioid Use After Outpatient Ureteroscopy for Upper Tract Stone Treatment. *Urology* 2019; 134:103-108. PMID: 31536742. doi.org/10.1016/j.urology.2019.08.042

Tan WS, Krimphove MJ, Cole AP, Marchese M, Berg S, Lipsitz SR, Löppenberg B, Nabi J, **Abdollah F**, Choueiri TK, Kibel AS, Sooriakumaran P, and Trinh QD. Variation in PositiveSurgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. *Clin Genitourin Cancer* 2019; 17(5):e1060-e1068. PMID: 31303561. doi.org/10.1016/j.clgc.2019.06.008

Trinh H, Irish V, Diaz M, and **Atiemo H**. Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation. *Int Neurourol J* 2019; 23(3):226-233. PMID: 31607102. doi.org/10.5213/inj.1938030.015

Ventimiglia E, Seisen T, **Abdollah F**, Briganti A, Fonteyne V, James N, Roach M, 3rd, Thalmann GN, Touijer K, Chen RC, and Cheng L. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. *Eur Urol Oncol* 2019; 2(3):294-301. PMID: 31200844. doi.org/10.1016/j.euo.2019.02.001

Walton E, Yaguchi G, Keeley J, Deebajah M, Menon M, **Peabody J**, **Dabaja A**, and Alanee S. Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans. *J Urol* 2019; 201(3):503-509. PMID: 30316896. doi.org/10.1016/j.juro.2018.10.003

Walton EL, Deebajah M, Keeley J, Fakhouri S, Yaguchi G, Pantelic M, **Rogers C**, Park H, Menon M, **Peabody JO**, **Dabaja A**, and Alanee S. Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. *Cancer Med* 2019; 8(8):3659-3665. PMID: 31111654. doi.org/10.1002/cam4.2149

**Abstracts**

**Abdollah F**, Piontkowski AJ, Morisetty S, Corsi N, Majdalany S, Rakic I, Sood A, Jamil M, Dalela D, Arora S, and **Rogers C**. The impact of adjuvant chemotherapy on overall survival in patients with node-positive Upper Tract Urothelial Carcinoma (UTUC): Improving precision in medicine with a risk-stratified approach. *European Urology* 2022; 81:S468-S468.

Butaney M, Johnson A, Bulusu A, Gandham D, Qi J, Jamil M, **Patel A**, Noyes S, Anema J, Levin M, Rosenberg B, Lane BR, **Rogers CG**, and Michigan Urological Surg I. Reducing post-operative emergency department visits and readmissions after nephrectomy: An initial evaluation of the MUSIC-KIDNEY registry. *European Urology* 2022; 81:S223-S224.

Butaney M, Johnson A, Qi J, **Patel A**, Noyes S, Brede C, Seifman B, Maatman T, **Rogers CG**, Lane BR, and Michigan Urological Surg I. Evaluation of an uncomplicated recovery after nephrectomy: MUSIC-KIDNEY NOTES (Notable Outcomes and Trackable Events after Surgery). *European Urology* 2022; 81:S219-S220.

Butaney M, **Patel A**, Qi J, Singh K, Johnson A, Levy A, Noyes S, Ghani K, **Rogers C**, Lane B, and Michigan Urological Surg I. Assessing renal mass management of patients with increased comorbidities: Results from a statewide registry. *European Urology* 2022; 81:S342-S343.

Corsi N, Majdalany SE, Rakic I, Friedman B, Corsi M, Butaney M, Malchow T, Piontkowski AJ, Ginsburg K, **Atiemo H**, and **Abdollah F**. Who is shaping the future of urology? A descriptive analysis of current urology residency program directors. *European Urology* 2022; 81:S145-S146.

Corsi N, Rakic I, Ginsburg K, Jamil M, Sood A, Dalela D, Piontkowski A, Majdalany SE, **Rogers C**, and **Abdollah F**. External validation of the Bladder Cancer Research Consortium(BCRC) nomogram for predicting survival after radical cystectomy. *European Urology* 2022; 81:S1327-S1328.

Hakimi K, Carbonara U, Djaladat H, Mehrazin R, Eun D, Reese A, Gonzalgo M, Margulis V, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Tellini R, Ferro M, Meagher M, Saidian A, Walia A, Veccia A, Ghoriefi A, Cacciamani G, Bhattu A, Minervini A, Autorino R, and Derweesh I. Impact of node count on survival outcomes of lymph node dissection in non-metastatic upper tract urothelial carcinoma: Analysis of the robuust registry. *European Urology* 2022; 81:S477-S478.

Ivan I, Rakic N, Corsi N, Piontkowski A, Majdalany S, Jamil M, Sood A, Dalela D, Arora S, **Rogers C**, and **Abdollah F**. Evaluation of the utility of lymph-vascular invasion as anindependent prognostic predictor of overall survival for patients with renal cell carcinoma that undergo nephrectomy. *European Urology* 2022; 81:S99-S99.

Katayama S, Pradere B, Grossmann NC, Potretzke AM, Boorjian SA, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene Z, D'Andrea D, Kikuchi E, Fujita K, Heindenreich A, Raman JD, Roumiguie M, **Abdollah F**, Marcus J, Breda A, Fontana M, Roupret M, Araki M, Nasu Y, and Shariat SF. Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma. *European Urology* 2022; 81:S460-S461.

Meagher MF, Autorino R, Mehrazin R, Eun D, Margulis V, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Minervini A, Ferro M, Dialadat H, Wu Z, Hakimi K, Saidian A, WaliaA, Tellini R, Veccia A, Mazzone E, Koon R, Gonzalgo M, and Derweesh I. Elevated hemoglobin: Creatinine ratio is a novel preoperative marker for worsened survival outcomes in

upper tract urothelial carcinoma: Analysis from the robuust registry. *European Urology* 2022;

81:S452-S453.

Piontkowski AJ, Corsi N, Morisetty S, Majdalany S, Rakic I, Arora S, Jamil M, Dalela D, **Rogers C**, and **Abdollah F**. Benefit of lymph node dissection in cn plus patients in the treatmentof upper tract urothelial carcinoma: Analysis of ncdb registry. *European Urology* 2022; 81:S459-S459.

Arora S, Bronkema C, Ranasinghe B, Wurst H, Keeley J, Sood A, Modonutti D, Novara G, Menon M, **Rogers C**, and **Abdollah F**. Impact of preexisting opioid-dependence on morbidity, length of stay, and inpatient cost of urologic oncologic surgery. *European Urology* 2021; 79:S768-S769. doi.org/10.1016/S0302-2838(21)00945-3

Briskin R, and **Atiemo H**. Evaluation of patient reported pain perception during office-based onabotulinumtoxina injection. *Neurourology and Urodynamics* 2021; 40(SUPPL 1):S216-S217. doi.org/10.1002/nau.24638

Briskin R, Etta P, **Raffee S**, Luck A, and **Atiemo H**. Comparison of urinary tract infection incidence following intradetrusor onabotulinumtoxina in clinic versus operating room settings. *Female Pelvic Medicine and Reconstructive Surgery* 2021; 27(10 SUPPL 1):S105.doi.org/10.1097/SPV.0000000000001103

Bronkema C, Arora S, Keeley J, Rakic N, Sood A, Dalela D, Stricker M, Olson P, **Rogers C**, Menon M, and **Abdollah F**. National Cancer Database analysis assessing the impact of treatment modalities on survival outcomes in localized neuroendocrine prostate adenocarcinoma. *European Urology* 2021; 79:S1542-S1543. doi.org/10.1016/S0302-2838(21)01461-5

Butaney M, **Patel A**, Lane B, Qi J, Johnson A, and **Rogers C**. Initial Management of Indeterminate Renal Masses in a Statewide Collaborative:a MUSICKIDNEY analysis. *Journal of Endourology* 2021; 35(SUPPL 1):A287. doi.org/10.1089/end.2021.35001.abstracts

Corsi N, Sood A, Keeley J, Dalela D, Bronkema C, Rakic N, Stricker M, Novara G, **Rogers C**, and **Abdollah F**. Recurrence-free survival following resection of low -grade, Non-Muscle-Invasive Urothelial Cancer (NMIBC): A Southwest Oncology Group (SWOG) S0337 post-hoc analysis. *European Urology* 2021; 79:S1032-S1033. doi.org/10.1016/S0302-2838(21)01124-6

Corsi N, Sood A, Keeley J, Dalela D, Bronkema C, Rakic N, Stricker M, Novara G, **Rogers C**, and **Abdollah F**. Estimating recurrence free survivability of Non-Muscle Invasive Bladder Cancer (NMIBC) after intravesical therapy: A clinical-based recursive partition analysis. *European Urology* 2021; 79:S1040. doi.org/10.1016/S0302-2838(21)01130-1

Dai Z, Jambor I, Taimen P, Pantelic M, Elshaikh MA, **Dabaja A**, **Rogers C**, Ettala O, Boström P, Aronen H, Merisaari H, and Wen N. Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth. *International Journal of Radiation Oncology Biology Physics* 2021; 111(3):S45. doi.org/10.1016/j.ijrobp.2021.07.123

Hakimi K, Autorino R, Meagher M, Soliman S, Yuan J, Stein R, Badani K, Mehrazin R, Eun D, Gonzalgo M, Margulis V, Li R, Uzzo R, Porter J, Sundaram C, **Abdollah F**, Mottrie A, Minervini A, Ferro M, Rha K, and Derweesh I. Outcomes of lymph node dissection in nephroureterectomy in treatment of upper tract urothelial carcinoma: Analysis of the robuust registry. *European Urology* 2021; 79:S1092-S1093. doi.org/10.1016/S0302-2838(21)01165-9

Jamil M, Hanna R, Sood A, Corsi N, Modonutti D, Keeley J, Novara G, **Patel A**, **Rogers C**, and **Abdollah F**. Renal mass size and presence of synchronous lung metastasis at time of diagnosis:Implications for chest imaging. *European Urology* 2021; 79:S880-S881. doi.org/10.1016/S0302-2838(21)01017-4

Kamphuis G, Canvasser N, Rivera M, Bechis S, Ingimarsson J, Knoedler J, Stern K, Stoughton C, Wollin D, Borofsky M, Bhojani N, El Tayeb M, **Leavitt D**, Hsi R, and Scotland K. Over-the-counter alkali agents to raise urine ph and citrate excretion: A randomized crossover study in healthy adults. *European Urology* 2021; 79:S381-S382. doi.org/10.1016/S0302-2838(21)00653-9

Modonutti D, Keeley J, Paciotti M, Hwang C, Menon M, Trinh Q, **Rogers C**, Novara G, and **Abdollah F**. A multi-trial based external validation of the Halabi nomogram in predicting theoverall survival of metastatic castration-resistant prostate cancer patients. *European Urology* 2021; 79:S1205. doi.org/10.1016/S0302-2838(21)01235-5

**Patel A**, Lane B, Butaney M, Johnson A, Qi J, and **Rogers C**. Building a roadmap for initial evaluation and follow up for surveillance of renal masses: Results from MUSIC consensus panel. *Journal of Endourology* 2021; 35(SUPPL 1):A105-A106. doi.org/10.1089/end.2021.35001.abstracts

**Patel A**, Lane B, Butaney M, Johnson A, Qi J, and **Rogers C**. Defining Patient Selection for Surveillance of Renal masses: Results from a MUSIC consensus panel. *Journal of Endourology* 2021; 35(SUPPL 1):A284. doi.org/10.1089/end.2021.35001.abstracts

Perkins S, **Patel A**, Butaney M, Johnson A, Qi J, **Rogers C**, and Lane B. Documentation of Nephrometry Scores for cT1 RenalMasses Correlates with Avoidance of Radical Nephrectomy Across the MUSIC-KIDNEY Statewide QI Collaborative. *Journal of Endourology* 2021; 35(SUPPL 1):A297. doi.org/10.1089/end.2021.35001.abstracts

Rakic N, Keeley J, Corsi N, Sood A, Bronkema C, Jamil M, Arora S, Palma-Zamora I, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Evaluation of the utility of lymphovascularinvasion as a complementary or independent prognostic predictor of overall survival after radical prostatectomy. *European Urology* 2021; 79:S1723. doi.org/10.1016/S0302-2838(21)01588-8

Sharrak A, Jamil M, Bazzi M, Timar R, Kovacevic N, and **Atiemo H**. Disparity in female pelvic examination in the evaluation of lower urinary tract symptoms. *Neurourology and Urodynamics* 2021; 40(SUPPL 1):S95-S96. doi.org/10.1002/nau.24638

Sood A, Keeley J, Palma-Zamora I, Chien M, Dalela D, Arora S, Jamil M, Kovacevic N, Corsi N, **Jeong W**, **Rogers C**, Trinh Q, **Peabody J**, Menon M, and **Abdollah F**. Anti-androgen therapy overcomes the time-delay in initiation of salvage radiation therapy and rescues the oncological outcomes in men with recurrent prostate cancer after radical prostatectomy: A post-hoc analysis of the RTOG 9601 trial data. *European Urology* 2021; 79:S1668. doi.org/10.1016/S0302-2838(21)01553-0

Zong WW, Carver E, Feldman A, Lee J, Sun Z, Xu LY, **Dabaja A**, and Wen N. Gleason grade group predictions from mp-MRI of prostate cancer patients using auto deep learning. *Cancer Research* 2021; 81(13).

**Abdollah F**, Shahait M, Dalela D, Kelly J, Vapiwala N, and Lee D. External validation of genomic classifier based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. *European Urology Open Science* 2020; 19:e1048-e1049. doi.org/10.1016/S2666-1683(20)33285-7

Alanee SR, Deebajah M, Roumayah Z, **Dabaja A**, **Peabody JO** , and Menon M. Detection of significant prostate cancer through magnetic resonance imaging targeted biopsy of PI-RADS3 lesions in African American patients based on prostate specific antigen density threshold of 0.15 ng/ml2: Analysis of patient population from the Vattikuti Urology Institute. *Journal of Clinical Oncology* 2020; 38(6). doi.org/10.1200/JCO.2020.38.6\_suppl.286

Alanee SR, Roumayah Z, Deebajah M, **Peabody JO**, Mora R, Guevara J, Francisco B, and Patterson BK. Adaptive genetic algorithms combined with high sensitivity single cell-based technology derived urine-based score to differentiate between high-grade and low-grade transitional cell carcinoma of the bladder. *Journal of Clinical Oncology* 2020; 38(6). doi.org/10.1200/JCO.2020.38.6\_suppl.572

Alhamar M, Gupta N, Oyedeji O, Hogan K, Sood A, Arora S, Schultz D, **Jeong W**, Williamson S, Menon M, and Hassan O. Precision prostatectomy: Analysis of surgical pathology findings of a promising and novel surgical approach for patients with low to intermediate-risk prostate cancer. *Modern Pathology* 2020; 33(3):850-852.

Alhamar M, Hassan O, Sood A, Arora S, **Jeong W**, Williamson S, Menon M, and Gupta N. Histopathologic features of prostate cancer in patients who underwent seminal vesicle-sparing radical prostatectomy: A novel surgical approach. *Modern Pathology* 2020; 33(3):849-850.

Arachchige PD, Carskadon S, Hu J, Fernando J, Chandrashekar DS, Gupta NS, Williamson SR, Chitale DA, **Rogers CG**, **Peabody JO**, Menon M, Bismar TA, Jiagge E, Varambally S, and Palanisamy N. Recurrent rearrangements of NAALADL2 in prostate, breast, cervical, head and neck and lung squamous cell carcinoma. *Cancer Research* 2020; 80(16 SUPPL). doi.org/10.1158/1538-7445.AM2020-2012

Arora S, **Rogers CG**, Arora K, Abou Shaar R, Kezlarian B, Modi M, Gupta N, and Williamson SR. Partial Nephrectomy For a Presumed Single Renal Mass Revealing Multiple Tumor Histologies: A Series of 4 Patients. *American Journal of Clinical Pathology* 2020; 154:S61-S61.

Baumgarten L, Irish V, **Raffee S**, and **Atiemo H**. Utilization of third line therapy in the urologic management of patients with multiple sclerosis. *Neurourology and Urodynamics* 2020; 39:S197-S198. doi.org/10.1002/nau.24307

Bhandari M, Nallabasannagari AR, Reddiboina M, Porter J, **Jeong W**, Mottrie A, Dasgupta P, Challacombe B, Abaza R, Rha KH, Parekh D, Ahlawat R, Capitanio U, Yuvaraja T, Rawal S, Moon D, Buffi's N, Sivaraman A, Maes K, Porpiglia F, Gautam G, Turkeri L, Preethi P, Menon M, and **Rogers C**. Predicting intraoperative complications and 30-days morbidity using machine learning techniques for patients undergoing robotic partial nephrectomy (RPN). *European Urology Open Science* 2020; 19:e1969-e1970. doi.org/10.1016/S2666-1683(20)33924-0

Bronkema C, Arora S, Rakic N, Sood A, Dalela D, Keeley J, Jamil M, **Peabody JO**, **Rogers CG**, Menon M, and **Abdollah F**. Impact of treatment modality on overall survival (OS) inlocalized ductal prostate adenocarcinoma (PCa): A national cancer database (NCDB) analysis. *European Urology Open Science* 2020; 19:e1659-e1660. doi.org/10.1016/S2666-1683(20)33709-5

Carskadon S, Diaz-Insua M, Gupta N, Williamson S, **Rogers C**, **Peabody J**, Menon M, and Palanisamy N. Comprehensive molecular mapping of prostate cancer-Approaching health disparities in molecular tumor heterogeneity perspective. *Cancer Epidemiology Biomarkers and Prevention* 2020; 29(6 SUPPL 1). doi.org/10.1158/1538-7755.DISP18-A113

Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Dhananjay C, Gupta N, Davis MB, Newman LA, **Rogers CG**, Paris PL, Li J, Rybicki BA, and Levin AM. Breast and prostate cancers harborcommon somatic copy number alterations thatconsistently differ by race and are associated with survival. *Cancer Epidemiology Biomarkers and Prevention* 2020; 29(6 SUPPL 2). doi.org/10.1158/1538-7755.DISP19-B066

Cone EB, Haeuser L, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh Q. Checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. *European Urology Open Science* 2020; 19:e1101. doi.org/10.1016/S2666-1683(20)33319-X

Cone EB, Modonutti D, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh QD. Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide. *European Urology Open Science* 2020; 19:e880. doi.org/10.1016/S2666-1683(20)33168-2

Cone EB, Modonutti D, Reese S, Marchese M, Nabi J, **Abdollah F**, Kilbridge K, and Trinh QD. Lower odds of cardiac events for gonadotropic releasing hormone antagonists versus agonists. *European Urology Open Science* 2020; 19:e896. doi.org/10.1016/S2666-1683(20)33179-7

Dalela D, Sood A, Jamil M, Arora S, Keeley J, Palma-Zamora I, Rakic N, Bronkema C, **Peabody J**, **Rogers C**, Menon M, Elshaikh M, and **Abdollah F**. External validity of theStephenson nomogram predicting the outcomes of prostate cancer patients treated salvage radiotherapy after radical prostatectomy: The importance of genomic data. *European Urology Open Science* 2020; 19:e1058-e1059. doi.org/10.1016/S2666-1683(20)33292-4

Hiller SC, Swarna K, **Leavitt D**, Frontera JR, Jafri SM, Hollingsworth J, Dauw C, Ghani K, and For The Michigan Urological Surgery Improvement C. The risk of unplanned healthcare utilization in patients undergoing ureteroscopy with uncorrected bleeding diathesis in a surgical collaborative. *European Urology Open Science* 2020; 19:e850-e851. doi.org/10.1016/S2666-1683(20)33151-7

Jamil M, Keeley J, Sood A, Dalela D, Arora S, **Peabody J**, Trinh Q, Menon M, **Rogers C**, and **Abdollah F**. Long-term risk of recurrence in surgically treated renal cell carcinoma: A post-hocanalysis of the Eastern Cooperative Oncology Group - American College of Radiology Imaging Network E2805 Trial cohort. *European Urology Open Science* 2020; 19:e1962-e1964. doi.org/10.1016/S2666-1683(20)33920-3

Kovacevic N, Sood A, Keeley J, Dalela D, Arora S, Palma-Zamora I, Jamil M, **Jeong W**, Trinh QD, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Identifying patients that may benefit from addition of bicalutamide to salvage radiation therapy in the setting of biochemical failure after radical prostatectomy. *European Urology Open Science* 2020; 19:e1063. doi.org/10.1016/S2666-1683(20)33295-X

Lin JC, **Patel A**, and **Rogers CG**. Robot-assisted removal of inferior vena cava filter. *Journal of Vascular Surgery Cases and Innovative Techniques* 2020; 6(2):311-312.doi.org/10.1016/j.jvscit.2020.03.009

Lin JC, Ranasinghe B, **Patel A**, and **Rogers CG**. Robot -assisted laparoscopic placement of extravascular stent for nutcracker syndrome. *Journal of Vascular Surgery Cases and Innovative Techniques* 2020; 6(3):346-347. doi.org/10.1016/j.jvscit.2020.03.013

Maki G, **Abdollah F**, **Dabaja A**, and Suleyman G. Prevalence and outcome of asymptomatic procedural patients with COVID- 19 infection. *Open Forum Infectious Diseases* 2020; 7(SUPPL 1):S298. doi.org/10.1093/ofid/ofaa439.655

**Raffee S**, Griffin M, Massie L, Basheer A, Tundo K, Brown A, Air E, and **Atiemo H**. Lower urinary tract symptoms in women with spinal pathologies: A prospective prevalence study. *Neurourology and Urodynamics* 2020; 39:S198-S199. doi.org/10.1002/nau.24307

Sood A, Keeley J, Dalela D, Arora S, Palma-Zamora I, Jamil M, Kovacevic N, **Jeong W**, Trinh QD, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Does concomitant anti-androgen therapy improve outcomes in patients with recurrent prostate cancer undergoing early salvage radiation therapy. *European Urology Open Science* 2020; 19:e1062. doi.org/10.1016/S2666-1683(20)33294-8

Veccia A, Steward J, Derweesh I, Margulis V, Uzzo R, **Abdollah F**, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Riccardo T, Aron M, Mazzone E, Al -Qathani A, Asghar A, Sundaram C, and Autorino R. Robotic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) collaborative group. *European Urology Open Science* 2020; 19:e322-e324. doi.org/10.1016/S2666-1683(20)32772-5

Veccia A, Steward J, Derweesh I, Margulis V, Uzzo R, **Abdollah F**, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Tellini R, Aron M, Mazzone E, Al-Qathani A, Asghar A, Sundaram C, and Autorino R. Safety profile of robotic vs. laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) collaborative group. *European Urology Open Science* 2020; 19:e316-e318. doi.org/10.1016/S2666-1683(20)32769-5

**Abdollah F**, Betrus G, Cher M, Dalela D, Keeley J, Kim T, Lane B, Mansour S, Montie J, Schervish E, Sood A, Swama K, and **Peabody J**. Defining the indications for pelvic lymph node dissection (PLND)in prostate cancer (PCa)patients within a statewide quality improvement collaborative. *European Urology, Supplements* 2019; 18(1):e2050. doi.org/10.1016/S1569-9056(19)31484-8

**Abdollah F**, Dalela D, Sood A, Arora S, Tang HJ, Keeley J, Alanee S, **Rogers CG**, **Peabody JO**, and Menon M. Evaluating the impact of lead-time bias on the observed efficacy of early salvage radiation therapy in prostate cancer: A post -hoc analysis of the RTOG 9601 trial. *European Urology, Supplements* 2019; 18(1):e861. doi.org/10.1016/S1569-9056(19)30629-3

**Abdollah F**, **Jeong W**, Dalela D, Palma-Zamora I, Sood A, and Menon M. Menon-precision prostatectomy (MPP): An idea, development, exploration, assessment, long-term follow-up (IDEAL)stage 1 study. *European Urology, Supplements* 2019; 18(1):e622. doi.org/10.1016/S1569-9056(19)30460-9

Arachchige PD, Carskadon S, Dhamdhere G, Diaz-Insua M, Craig R, **Peabody J**, Menon M, Williamson S, Gupta N, and Palanisamy N. Evaluation of tumor heterogeneity in prostate biopsy samples. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-4688

Arachchige PD, Carskadon S, Dhamdhere G, Diaz-Insua M, **Stricker H**, **Rogers C**, **Peabody J**, Menon M, Williamson S, Gupta N, and Palanisamy N. Evaluation of prostate tumor molecular heterogeneity using whole mount radical prostatectomy by dual immunohistochemistry and dual RNA in situ hybridization. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-4693

Arora S, Bronkema C, Porter JR, Mottrie A, Menon M, **Rogers CG**, **Jeong W**, Dasgupta P, Rha KH, Ahlawat RK, Capitanio U, Yuvaraja TB, Rawal S, Moon DA, Sivaramakrishnan A, Maes KK, Porpiglia F, Gautam G, Turkeri L, Bhandari M, and **Abdollah F**. Feasibility of omitting outer (cortical)renorrhaphy during robotic partial nephrectomy - a multi-institutional analysis. *European Urology, Supplements* 2019; 18(1):e1605-e1606. doi.org/10.1016/S1569-9056(19)31161-3

Arora S, Sood A, Dalela D, Keeley J, Rakic N, Prokopiv U, Fotouhi A, **Peabody JO**, Mani M, and **Abdollah F**. Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States. *European Urology, Supplements* 2019; 18(1):e1392-e1393. doi.org/10.1016/S1569-9056(19)31007-3

Arora S, Sood A, Dalela D, **Patel A**, Keeley J, Trinh QD, Audrey F, Prokopiv U, Rakic N, **Rogers C**, Menon M, and Abdollah F. Testing the external validity of CARMENA trialcomparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *European Urology, Supplements* 2019; 18(1):e1178-e1179. doi.org/10.1016/S1569-9056(19)30849-8

Arora S, Sood A, Deepansh D, Keeley J, Borchert A, Baumgarten L, **Rogers CG**, **Peabody JO**, Menon M, and **Abdollah F**. Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e217-e218. doi.org/10.1016/S1569-9056(19)30159-9

Baumgarten LC, Borchert A, Delela D, Sood A, Arora S, Keeley J, Trinh Q, **Rogers CG** , **Peabody JO**, Menon M, and **Abdollah F**. Impact of timing on radiation therapy adverse eventsfollowing radical prostatectomy, an analysis of the RTOG 9601 cohort. *European Urology, Supplements* 2019; 18(1):e2200-e2201. doi.org/10.1016/S1569-9056(19)31591-X

Chakravarthi BVSK, Kalyana-Sundaram S, Arachchige PD, Carskadon S, Pathi SS, Diaz-Insua M, **Rogers C**, **Peabody J**, Hwang C, Menon M, Williamson S, Nilesh G, Varambally S, and Palanisamy N. Pseudogene-associated recurrent gene fusion in prostate cancer. *Cancer Research* 2019; 79(13). doi.org/10.1158/1538-7445.SABCS18-915

Chopra V, Irish V, and **Atiemo H**. Outcomes of native tissue sacrospinous ligament fixation with unilateral deschamp needle suture ligature. *Neurourology and Urodynamics* 2019; 38:S239-S240. doi.org/10.1002/nau.23949

Fotouhi A, Borchert A, Dalela D, Sood A, Keeley J, Arora S, Trinh QD, **Peabody JO**, Menon M, and **Abdollah F**. The changing face of surgically treated low-risk prostate cancer (PCa): A national cancer database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e2180. doi.org/10.1016/S1569-9056(19)31574-X

Gorgis S, Dabbagh M, Mawri S, Akoegbe G, Alanee S, **Alaswad K** , **Dabaja A**, and Rabbani B. RECURRENT SUPRAVENTRICULAR ARRHYTHMIA: WHEN ABLATION IS NOT THE ANSWER - A PERPLEXING CASE OF PHENOCHROMOCYTOMA. *Journal of the American College of Cardiology* 2019; 73(9):2941-2941. doi.org/10.1016/s0735-1097(19)33547-8

Jindal T, **Abdollah F**, and Menon M. Survival associated with radical prostatectomy vs radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis. *International Journal of Urology* 2019; 26:31. doi.org/10.1111/iju.14061

Lin JC, **Patel A**, and **Rogers C**. VS06. Robotic-Assisted Removal of Inferior Vena Cava Filter. *Journal of Vascular Surgery* 2019; 69(6):e193. doi.org/10.1016/j.jvs.2019.04.275

**Patel A**, Perkins S, Bazzi M, Arcot R, Johnson A, Qi J, Kim T, Ghani K, Schervish E, Lane B, and **Rogers C**. Patterns of renal mass biopsy across the MUSIC-KIDNEY statewide QI collaborative. *European Urology, Supplements* 2019; 18(1):e1231-e1232. doi.org/10.1016/S1569-9056(19)30884-X

**Raffee SM**, **Kachroo N**, Elshatanoufy S, and **Atiemo H**. Evaluation of transvaginal uterosacral ligament hysteropexy vs. uterosacral ligament suspension with hysterectomy: A retrospective comparison study with two year outcomes. *Neurourology and Urodynamics* 2019; 38:S241-S242. doi.org/10.1002/nau.23949

**Raffee SM**, Wong P, Palma-Zamora I, Irish V, and **Atiemo H**. Urologic care of a multiple sclerosis patient population-single provider experience. *Neurourology and Urodynamics* 2019; 38:S247-S248. doi.org/10.1002/nau.23949

Rakic N, Fotouhi A, Baumgarten L, Borchert A, Dalela D, Sood A, Arora S, Menon M, and **Abdollah F**. Persistent under-utilization of adjuvant radiotherapy in patients with adversepathological features at radical prostatectomy: A national cancer database (NCDB)analysis. *European Urology, Supplements* 2019; 18(1):e969. doi.org/10.1016/S1569-9056(19)30703-1

Sood A, Eilender B, Wong P, and **Atiemo H**. Outcomes in patients with idiopathic overactive bladder undergoing augmentation cystoplasty in the era of onabotulinumtoxin-a and interstim. *Neurourology and Urodynamics* 2019; 38:S238-S239. doi.org/10.1002/nau.23949

Sood A, Keeley J, Arora S, Dalela D, **Jeong W**, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Rates and patterns of metastases in patients with node-negative prostate cancer at radicalprostatectomy that experience PSA failure: Post-hoc analysis of RTOG 9601 trial data. *European Urology, Supplements* 2019; 18(1):e865-e866. doi.org/10.1016/S1569-9056(19)30632-3

Sood A, Keeley J, Arora S, Dalela D, **Jeong W**, **Rogers C**, **Peabody J**, Menon M, and **Abdollah F**. Extended lymph node dissection is associated with improved overall survival in patients withvery high-risk prostate cancer: A national cancer database analysis. *European Urology, Supplements* 2019; 18(1):e2198. doi.org/10.1016/S1569-9056(19)31589-1

Tam C, Yan P, Raisky J, Gunaseelan V, Kim T, **Leavitt D**, Dauw C, and Hollingsworth JM. New persistent opioid use after ureteroscopy for stone treatment. *European Urology, Supplements* 2019; 18(1):e196-e197. doi.org/10.1016/S1569-9056(19)30146-0

Tan WS, Krimphove M, Cole A, Berg S, Marchese M, Lipsitz S, Loppenberg B, Nabi J, **Abdollah F**, Choueiri T, Kibel A, Sooriakumaran P, and Trinh QD. Variation in positivesurgical margin status following radical prostatectomy for pT2 prostate cancer. *Journal of Clinical Urology* 2019; 12(1):42-44. doi.org/10.1177/2051415819846081

Tan WS, Krimphove M, Cole A, Berg S, Marchese M, Lipsitz S, Loppenberg B, Nabi J, **Abdollah F**, Choueiri T, Kibel A, Sooriakumaran P, and Trinh QD. Variation in positivesurgical margin status following radical prostatectomy for pT2 prostate cancer. *European Urology, Supplements* 2019; 18(1):e294-e295. doi.org/10.1016/S1569-9056(19)30214-3

**Attachment 3**

**Urology Faculty Awards and Honors**

* **James O Peabody**
1. Distinguished Career Awards from the HF Alumni Association at the HFMG
	1. Elected to Chair of the Board of Governors of the Henry Ford Medical Group
	2. TopDoc HOUR magazine 2021
	3. Gold Humanism Honor Society, Wayne State University, 2020
	4. Resident Teaching Award, Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI – 2018
	5. Resident Teaching Award, American Urology Association – 2013
	6. Shadow of a Leader Award – 2006
	7. Resident Teaching Award – 2004
	8. Joseph C. Cerny MD Resident Teaching Award – 1997
* **Craig G Rogers**
	1. President-elect, Society of Urologic Robotic Surgeons (term starting Fall 2022)
	2. TopDoc HOUR magazine 2010-2021
	3. Game on Cancer MVP Award, Henry Ford Cancer Institute – 2020
	4. Best poster AUA – 2020
	5. 2nd Prize, High Value Care Research, Henry Ford Medical Education Research Forum 2020
	6. 3rd Prize, Senior Clinical Research, Henry Ford Medical Education Research Forum 2020
	7. Best Poster Award, EAU Annual Meeting - 2019
	8. Best Poster Award, AUA Annual Meeting - 2018
	9. Best Abstract, AUA Annual Meeting - 2017
	10. Best Poster Award, EAU Annual Meeting - 2016
	11. 2nd Prize in Clinical Studies Poster, Wayne State University Medical Research - 2016
	12. Honorable Mention in Clinical Studies Oral Presentation, Wayne State University 2016
	13. Best Poster, British Association of Urological Surgeons Annual Meeting - 2015
	14. Excellence in Urology Seminar Faculty Award, Intermountain Urological Institute 2015
	15. 3rd Prize in Clinical Research, Research Symposium, Henry Ford Hospital - 2015
	16. Teaching Award Finalist, American Urological Association - 2014
1. Video Contest Winner, World Congress of Endourology - 2008, 2009, 2010

1. Video Contest Winner, European Robotic Urology Symposium - 2008, 2009,

2010, 2011

* 1. Video of the Year, European Urology Journal – 2012
	2. Poster Contest Winner, EAU – 2011, 2015
	3. Poster Contest Winner, EAU, European Robotic Urology Section Symposium – 2010
	4. Video Contest Winner, AUA Northcentral Section – 2010
	5. Abstract Award, Astellas/AUA Annual Meeting – 2006
	6. Clinical Research Essay Contest Prize Winner, AUA, Midatlantic - 2004, 2005
* **Ali D Dabaja**
	1. TopDoc HOUR magazine 2017-2022
	2. Elected to HF Medical Executive Committee
	3. NIH Trainee Travel Award - 2014
	4. First prize EAU Meeting, Paris -2012
	5. Media featured abstract AUA Washington DC. 2011 meeting (AAP Founded Grant Project) – 2011
	6. Second prize at the EAU Vienna – 2011
	7. First Place Michigan Urologic Society's annual Resident research day – 2010
* **Firas F Abdollah**
	1. Best Poster 95th annual NCS AUA 2021 Prostate Malignant Session - 2021
	2. Best Podium 95th annual NCS AUA 2021 Prostate Malignant Session - 2021
	3. Davidson Fellowship for Entrepreneurs in Digital Health Program
	4. Best Poster award AUA 2020
	5. Wayne State Medical student research fellowship – Mentor, 2020
	6. Winner of the Dykstra Foundation Grant 2017
	7. Excellence in Research Southeast Michigan Center for Medical Education – 2017
	8. First Place in the Slide Competition Southeast Michigan Center for Medical Education
	9. Outstanding reviewer for Cancer: ranked in the top 2% of reviewers for the period spanning September 1, 2016 to August 31, 2017
	10. First Prize for the Best Abstract, 33rd Annual EAU Congress – 2018
	11. Article of the Month BJUI March 2018
	12. 1st place fellow clinical research 25th annual medical education research form in Henry Ford Health System – 2018
	13. Best poster award AUA 2018
	14. Outstanding Fellow Award Nomination by Henry Ford Alumni Association - 2018
	15. Best poster award 34th EAU Congress
	16. Best Reviewer Journal of Urology 2018

1. Bronze Reviewer BJUI 2019
2. 1st place – High Value care research 27th annual medical education research form in Henry Ford Health System
3. 2nd place – High Value care research 27th annual medical education research

form in Henry Ford Health System

1. Article of the month BJUI -2015
	1. Best poster award 29th EAU Congress – 2014
	2. Best poster award 28th EAU Congress – 2013
	3. Reviewer of the month European Urology – 2012
	4. Best poster award 27th EAU Congress – 2012
* **Nabeel Shakir**
	1. AUA South Central Section Resident Essay Competition, 3rdPlace, 2019
	2. AUA South Central Section Resident Essay Competition,1stPlace, 2018
	3. John D. McConnell Award for Excellence in Urology, 2014
	4. Outstanding Poster (Oncology Section) and Podium Presentation, AUA 2014
	5. NIH-Medical Research Scholars Program Fellow, 2013—2014
	6. Alpha Omega Alpha, 2013
	7. Southwestern Medical Foundation Scholarship, 2010—2015
	8. Phillips Petroleum Award for Outstanding Research, 2010
	9. Robert C. Byrd Honors Scholarship, 2007—2010
* **Naveen Kachroo**
	1. Davidson Fellowship for Entrepreneurs in Digital Health 2021-2022 Program
	2. Best Poster prize HFHS basic science symposium (surgeon-scientist to receive that recognition)
	3. Consultant of the Year Award, Henry Ford Wyandotte, 2022
* **Hans Stricker**
	1. Elected to Chair of the Board of Governors of the Henry Ford Medical Group
	2. Best Doctors in America 2010, 2011, 2012, 2013
	3. Top Docs, Hour Magazine 2009, 2010, 2011, 2012, 2013
	4. Pfizer Academic Excellence in Urology 1998
	5. Joseph C. Cerny Resident Teaching Award 1998
* **Johar Raza Syed**
	1. 5th Place Resident Essay Competition, South-Central AUA annual meeting –

2018

1. Best Basic Science and Clinical Reports Roswell Park Cancer Institute - 2015 o Best Abstract EAU Robotic Urology Section meeting – 2014
2. Best Research Resident Department of Surgery, Aga Khan University – 2011

* 1. Société Internationale d'Urologie Travel Fellowship – 2011
	2. Best Poster Presentation, 21st Annual AUA meeting – 2011
	3. Gold Medal for Best Oral Presentation at JPMC symposium – 2010
	4. Young Investigator’s Award for Best Poster Presentation, UROCON – 2009
* **Humphrey O Atiemo**
	1. TopDoc HOUR magazine, 2021
1. Selected ABU examination committee
	1. Elected chair of DEI subcommittee of GME
* **Amit Patel**
	1. Davidson Fellowship for Entrepreneurs in Digital Health Program
* **Kandis K Rivers**
	1. TopDoc HOUR magazine, 2021
	2. Elected to the Board of Governors of the Henry Ford Medical Group
* **Joseph Haddad**
	1. TopDoc HOUR magazine, 2021
* **Janae Preece**
	1. TopDoc HOUR magazine, 2021

o

* **Kristina D Suson**
	1. TopDoc HOUR magazine, 2021
* **Yegappan Lakshmanan**
	1. TopDoc HOUR magazine, 2021

**Attachment 4**

**Grants**

**Current Federal**

* Genomics in Michigan to AdJust Outcomes in prostate canceR (G-MAJOR): A randomized controlled multi- center study for men with newly diagnosed favorable risk prostate cancer 2019-2022
* Tribbles 2: A Novel Molecular Target for Therapy of Aggressive Kidney Cancer. DoD 2021-2022 (Jagadananda Ghosh PhD)
* Tribbles 2, a Novel Target for Therapy of Enzalutamide Resistant, Neuroendocrine Prostate Cancer. DoD 2022-2025 (Jagadananda Ghosh PhD)
* DOD Prostate Cancer Research Program, Translational Science Award (W81XWH-22-1-0400): Co-targeting telomere integrity and repair of telomere damage for CRPC therapy 2022-2025 (Sahn-Ho Kim PhD)

**Current Non-Federal**

* Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES) 2022
* W029636 phase III, open-label, multicenter, randomized study of atezolizumab (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection 2017-2023
* A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) 2022-2024
* Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) 2019-2024
* Medtronic Evaluation of Implantable Tibial Neuromodulation (TITAN 2) Pivotal Study 2022 – 2025 (Humphrey Atiemo)
* Ambu Research Grant for evaluation of efficiency of disposable cystoscopes in clinic (Craig Rogers)
* ACS Pfizer Grant to improve PSA Screening among underrepresented men in Detroit (Firas Abdollah Co-PI)
* Development of novel small molecule inhibitors of Tribbles 2 using artificial intelligence. HFH-MSU Pilot Grant 2022-2023 (Jagadananda Ghosh PhD)
* Characterize the Tribbles 2 interactome to reveal actionable novel targets for therapy of enzalutamide-resistant, lethal prostate cancer. HFH-MSU Pilot Grant 2022-2023 (Jagadananda Ghosh PhD)
* Henry Ford Cancer Institute (HFCI) – Internal Funding for project development- ‘Evaluation of prostate cancer tumor heterogeneity in repeat biopsy samples’ (Nallasivam Palanisamy)
* Henry Ford Cancer Institute (HFCI) – Internal Funding for project development- ‘Characterization of a novel recurrent gene fusion in prostate cancer’(Nallasivam Palanisamy)
* Pfizer 2021 Global Medical Grant (01/2022 – 06/2023); Integrating Orthodox and Traditional Prostate Cancer Care and Treatment in Ghana: Evelyn Jiagge, PI, Eleanor Walker, Nallasivam Palanisamy, Clara Hwang and Sylvester Antwi

**Attachment 5**

**Practice Changing Contributions - Urology**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Practice Changing Contribution (brag point)** |  | **MD/Researc** |  | **Citation/Source** | **Add’l** |  |
| Ford Hospital which resulted in a remarkable milestone of significant | **her** |  |  | **Link** | **Comments** |  |
| Dabaja |  | 196- |  |  |  |
| CAUTI Reduction: • Dr. Dabaja led multidisciplinary initiative at Henry | Dr. Ali |  |  | urnal.org/article/S0 |  |  |
|  |  | https://www.ajicjo |  |  |
| reduction in catheter acquired UTI’s (CAUTI). He helped develop a |  |  |  | 6553(21)00459- |  |  |  |
| Urinary Catheter Alleviation Navigator Protocol (UCANP) to reduce the |  |  |  | 4/fulltext |  |  |
| use of indwelling catheters and unnecessary urine cultures to enhance |  |  |  |  |  |  |  |
| patient safety. This work has been published. |  |  |  |  |  |  |  |  |
| multidisciplinary robotic genitourinary reconstructive surgery |  | Shakir |  |  | [construction.org)](https://www.multidisciplinaryreconstruction.org/) |  |  |
| Gender affirming surgery using Single Port Robot. Hosted first |  | Dr. Nabil |  |  | [(multidisciplinaryre](https://www.multidisciplinaryreconstruction.org/) |  |  |
|  |  |  | [Home | MERGERS](https://www.multidisciplinaryreconstruction.org/) |  |  |
| symposium (MERGERS) with international audience. First Single port |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| robotic vaginoplasty in the Midwest. Collaboration with Plastic Surgery. |  |  |  |  |  |  |  |
| the first in the country to go "all in" on using disposable scopes during | Rogers |  |  |  |  |  |  |
| Leadership in use of reusable cystoscopes: Our department was one of | Dr. Craig |  |  |  |  |  |  |
| the pandemic and received recognition on a national podcast about how |  |  |  |  |  |  |  |
| using disposable scopes helped save clinic procedures when the Fairlane |  |  |  |  |  |  |  |
| clinic was displaced after the floods and when staffing shortages affected |  |  |  |  |  |  |  |
| our ability to do procedures. |  |  |  |  |  |  |  |  |
| (HIFU) Procedure for focal therapy of localized prostate cancer. Our |  | Rogers |  |  | nry-ford-health- |  |  |
| First in Michigan to offer fully robotic High Intensity Focused Ultrasound | Dr. Craig |  |  | etroit.com/news/he |  |  |
|  |  | https://www.fox2d |  |  |
| prostate HIFU program was recently featured in a press release and on |  |  |  | can-target-and- |  |  |
| Fox 2 news. One of first programs in the country to offer both robotic |  |  | treat-prostate- |  |  |
| HIFU and single port robotic surgery for prostate cancer. |  |  |  | cancer-through- |  |  |
| Helped build Robotic kidney transplant program in collaboration with | Dr. Wooju |  | robotic-technology |  |  |
| Henry Ford Transplant Institute that is now a highly successful program | Jeong / Dr. |  |  |  |  |  |
| for them |  | Atsi Yoshida |  |  |  |  |  |
| applicantsDEIJ:Urologytoourstaffprogramstarted andscholarshiptoprovidetomentorshiphelpattractopportunitiesresidency | to | Littleton,Dr.Ray | Dr. |  |  |  | AtiemoHumphreywas |  |
| college and high school students who are underrepresented in medicine. | Humphrey |  |  |  | voted as Chair |  |
| Dr. Abdollah featured in presentation about disparities in prostate cancer | Atiemo |  |  |  |  | of |  |
| and is part of grant with Dr. Walker and Dr. Hwang to reduce disparities |  |  |  |  |  | the Diversity E |  |
| in prostate cancer diagnosis in the community. |  |  |  |  |  |  | quity and |  |
|  |  |  |  |  |  |  | Inclusion (DEI) |  |
|  |  |  |  |  |  |  | sub-committee |  |
| Allegiance.Firstrobotic partial cystectomy and first targeted biopsies at HF |  | RanasingheBuddima |  |  |  | of the GME |  |
|  |  | Dr. Wooju |  |  |  |  |  |
|  |  | Jeong |  |  |  |  |  |  |
| diversion in our department and region |  | Syed Raza |  | [prostate-](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |
| First robotic cystectomy with intracorporeal “W-pouch” urinary |  | Dr. Johar |  |  | [ford.com/services/](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |
|  |  |  | https://www.henry |  |  |
|  |  |  |  |  | cancer/patient - |  |  |
| First health system in Michigan to perform Single Port (SP) robotic |  | Dr. Craig |  |  | [stories/donnel](https://www.henryford.com/services/prostate-cancer/patient-stories/donnel) |  |  |  |
| prostatectomy surgeries, which includes both extraperitoneal and |  | Rogers / Dr. |  |  |  |  |  |
| intraperitoneal approaches, and facilitates same day discharges. |  | James |  |  |  |  |  |  |
|  |  | Peabody |  |  |  |  |  |  |
| in Michigan for patients with abdominal adhesions otherwise not eligible | Rogers/Dr. |  |  |  |  |  |
| First Transvesical single port simple and radical prostatectomy surgeries | Dr . Craig |  |  |  |  |  |
| for traditional surgical approaches |  | Wooju Jeong |  |  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| First in the country to enroll a patient in phase 2 clinical trial involving | Drs. Ali |  |  |
| MRI-guided targeted injections of nanoparticle paclitaxel directly into | Dabaja & |  |  |
| localized prostate cancer. This was followed by single port | Craig Rogers |  |  |
| extraperitoneal prostatectomy |  |  |  |
| Our targeted MRI fusion prostate biopsy results rank among the top in |  |  |  |
| the state over the past 3 years for detection of clinically significant |  |  |  |
| prostate cancer |  |  |  |
| 20th anniversary of the first robotic prostatectomy performed in the U.S., |  |  |  |
| leading to the first robotic prostate surgery program in the U.S. and the |  |  |  |
| foundation for robotic surgery in all other aspects of urology and other |  |  |  |
| specialties. 100th Urology Department anniversary celebrating legacy of |  |  |  |
| innovation in Urology in department |  |  |  |
| Innovations in prostate biopsy: Transperineal technique for prostate | Dr. Craig |  |  |
| biopsy in the office. One of first departments in the country to have | Rogers, Dr. |  |  |
| entire staff convert to transperineal approach for office biopsy, resulting | Amit Patel & |  |  |
| in a reduction in biopsy sepsis and bleeding complications as well as | Dr. Ali |  |  |
| antibiotic use. The Henry Ford biopsy technique has received | Dabaja |  |  |
| international attention and was recently published in the Urology 'Gold' |  |  |  |
| journal, featured in the AUA Core Curriculum and MUSIC websites, and |  |  |  |
| was presented at the AUA national meeting and the World Congress of |  |  |  |
| Endourology. Unique "Executive Biopsy" program with streamlined one - |  |  |  |
| stop diagnostic process for prostate cancer that can allow for a prostate |  |  |  |
| MRI targeted biopsy and pathology results in less than 48 hours. |  |  |  |
| Numerous publications, international meeting abstracts, and research | Dr. Firas |  |  |
| awards, led by VCORE research group, averaging about 50 publications | Abdollah |  |  |
| per year, with about 500 publications in the past 10 years |  |  |  |
| Leadership in Michigan Urologic Surgery Improvement Collaborative | Dr. Craig |  |  |
| (MUSIC): Led research on active surveillance and reducing ER | Rogers |  |  |
| readmissions after kidney surgery |  |  |  |
| Innovation Precision Prostatectomy technique to remove the cancer | Dr. Wooju |  |  |
| while preserving a thin rim of prostate capsule on the uninvolved side of | Jeong |  |  |
| the prostate opposite to the dominant lesion to help preserve sexual and |  |  |  |
| urinary function. Published largest experience in the world. First-in-the |  |  |  |
| world to perform procedure using a single-port robotic approach |  |  |  |
| through a small incision in the bladder. Dr. Abdollah performed first |  |  |  |
| precision prostatectomy at HF Macomb |  |  |  |
| endovascularCollaboration removalwithInterventionalofIVCtumorRadiology:thrombusFirstinpatientinworldwith metastaticperform |  |  |  |
| kidney cancer, facilitating a subsequent robotic cytoreductive |  |  |  |
| nephrectomy and enrollment in a clinical trial to make a vaccine from the |  |  |  |
| tumor. First in Michigan to offer prostate artery embolization for BPH |  |  |  |
| and super selective embolization of kidney tumors prior to nephrectomy. |  |  |  |
| Collaboration with Radiation Oncology: First in world to treat a patient |  |  |  |
| with prostate cancer using the combined MRI Linac technology for |  |  |  |
| precise radiation therapy. Same technology now offered for select |  |  |  |
| patients with kidney cancer. |  |  |  |
| Feaured on Channel 4 news discussing research linking COVID infections | Dr. |  |  |
| to an increased risk of ED. | Amarnath |  |  |
|  | Rambhatla |  |  |
| Dr. Peabody led recent JAMA surgery article about sexual function after | Dr. James |  |  |
| radical prostatectomy. | Peabody |  |  |
| Innovations in robotic kidney surgery: First in Michigan to perform | Dr. Craig |  |  |
| cooling of the kidney during robotic partial nephrectomy now used in | Rogers |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | robotic ultrasoundkidneytransplantprobe.forHelpedroboticdeveloppartialroboticnephrectomybulldog. clampsFirstliveand |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  | webcast of robotic partial nephrectomy in the US and first live |  |  |  |  |  |  |  |
|  | demonstration of robotic partial nephrectomy at the AUA National |  |  |  |  |  |  |  |
|  | meeting |  |  |  |  |  |  |  |
|  | EPIC that monitor stent implants and alert providers monthly when the | Dabaja |  | [Report Server](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  | Stent and Implant tracking. Currently we have algorithm build within | Dr. Ali |  | [n-V2 - Power BI](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  |  | [UrologyStentsAdmi](https://biselfservice.hfhs.org/pbireports/powerbi/EDWAnalytics/StrategicOperation/Surgical%20Services/Reporting%20Drafts/UrologyStentsAdmin-V2) |  |  |
|  | implants are in place over 90 days |  |  |  |  |  |  |  |
|  |  | (hfhs.org) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | prostate cancer. Initial results are highly sensitive and specific to detect | Abdollah |  |  |  |  |  |  |
|  | Working on very innovative technique to isolate exosome specific for | Firas |  |  |  |  |  |  |
|  | not only prostate cancer, but its exact grading too. These are based on |  |  |  |  |  |  |  |
|  | urine and blood samples alone, without the need to obtain a biopsy. This |  |  |  |  |  |  |  |
|  | has the potential of totally changing the practice and the way we take |  |  |  |  |  |  |  |
|  | care of prostate cancer |  |  |  |  |  |  |  |
|  | with hope of identifying differences in exosomes among different races, | Abdollah |  |  |  |  |  |  |
|  | We are studying racial disparity in prostate cancer exosome expression, | Firas |  |  |  |  |  |  |
|  | and use that in designing specific biomarkers, and treatments |  |  |  |  |  |  |  |
|  | First to use Koelis machining to place SpaceOAR hydrogel | Firas |  |  |  |  |  |  |
|  |  | Abdollah |  |  |  |  |  |  |
|  | biopsy using Koelis machine along with MRI-fusion - working on | Abdollah |  |  |  |  |  |  |
|  | We are one of the few centers in Michigan to offer 3D US guided prostate | Firas |  |  |  |  |  |  |
|  | developing an AI model to decide the best biopsy scheme based on data |  |  |  |  |  |  |  |
|  | from these biopsies |  |  |  |  |  |  |  |
|  | Henry Ford providers going retrospectively to 20 years ago and | Abdollah |  |  |  |  |  |  |
|  | We developed a PSA testing/screening database based on EMRs from all | Firas |  |  |  |  |  |  |
|  | connected it to Michigan death certificates to obtain follow- up. This is a |  |  |  |  |  |  |  |
|  | unique source, which allows us for the first time to examine how PSA is |  |  |  |  |  |  |  |
|  | used in real practice (outside RCT), and the impact of that on patients’ |  |  |  |  |  |  |  |
|  | outcomes |  |  |  |  |  |  |  |
|  | country to address UTUC outcomes (the ROBUUST collaboration), which | Abdollah |  |  |  |  |  |  |
|  | Created new collaboration with several institutions from across the | Firas |  |  |  |  |  |  |
|  | has procedure 6 publications in high-impact factor journals in the last |  |  |  |  |  |  |  |
|  | year |  |  |  |  |  |  |  |

Attachment 6

CHM Assurances in Response to Dean Amalfitano’s Concerns

Submitted to CAC October 17, 2022

On Friday, October 14, Dean Amalfitano sent the email copied below in response to the CHM submissions for Departments of Neurosurgery and Urology. To help clarify our response to the questions, we have inserted bold numbers before the questions. Our responses follow the email.

“Afternoon Aron, Nara, Carol, and members of the CHM CAC. I have also cc’ed Dr. David Kaufman, Asst.VP of Clinical Affairs in the Office of Health Sciences, as there are clinical implications related to the new department request(s) , as noted below.

We again appreciate the opportunity to participate in the “assurances” portion of your processes. We have had several questions and suggestions generally arise in regard to the proposed departments, which I’ve again pasted below for your team’s consideration.

**[1]**Questions as to adding these departments (some of which are clearly duplicative of existing depts/divisions-with vague plans as to how to reconcile these duplications in the future) will create confusion as to which departments are East Lansing based, vs Providence based, vs HF based, and where faculty will be residing primarily, in particular when initially responding to job postings etc. **[2]** This also touches on referral pattern confusion, for example if we have Neurosurgeons/Spine Surgeons in the COM Osteopathic Surgical and Orthopedic Specialties depts at MSU-HCI in East Lansing, yet there is another “Neurosurg” dept, practicing in South East Michigan, and another at Providence Hospital as well.

[Variation for the urology proposal also emailed on October 14, “This also touches on referral pattern confusion, for example if we have Urologists in the COM Osteopathic Surgical Specialties dept at MSU-HCI in East Lansing, yet there is another Urology dept, practicing in South East Michigan.”]

[Variation for the Dermatology proposal emailed by Dean Amalfitano on September 19, 2022, “Morning Aron, and members of the CHM CAC.

We appreciate the opportunity to participate in the “assurances” portion of your processes. We have had several questions and suggestions generally arise in regard to the proposed 4 new departments, which I’ve basically pasted below for your team’s consideration. Thank you. AA

This also touches on referral pattern confusion, for example if we have ENT’s at MSU-HCI in East Lansing, yet there is another ENT dept, practicing in South East Michigan.”]

1. Will any research done by the no-cost faculty becoming part of these depts., be attributed to MSU generally, MSU CHM or strictly to the jointly funded Health Sciences Center at Henry Ford?. **[4]** Will future investments in research faculty be shared across colleges, should they reside in a HF located dept?
2. In line with the above, a general theme is questioning why these departments, and the faculty assigned to them, could not be shared between the medical schools, just as several other departments already are. We note that in the creation of the most recent dept on the MSU East Lansing campus., the Dept. of Orthopedics, this premise was highly desired by both colleges, and indeed the current Dept of Orthopedics is shared between COM and CHM.

1. Is there a mechanism or plan for clinically active HF faculty to also be appointed through the

MSU HCI?

1. We are concerned with the lack of acknowledgement of COM education or role in some of these proposed new departments. For example, it is critical that the new Urology dept. chair recognize two completely different educational approaches in CHM and COM and joint appointments might be considered to recognize these dichotomies, especially as both COM and CHM students are being trained currently at Henry Ford System hospitals.

Thank you for your thoughtful consideration of these comments and questions.

AA”

-----------

The College of Human Medicine responds:

As to [1]

It is true that we have some existing divisions (e.g., Neurosurgery *division which is* not a *department*). Divisions are constructs of the dean’s office and are not recognized by the university. Our proposal here is to create statewide departments, as all CHM departments are. In general, if there are existing divisions, structurally these will be incorporated into the appropriate departments either as a sub-entity or as a merger (depending on faculty needs and wishes). It is true that some departments have more faculty based in East Lansing (e.g., Medicine) or Grand Rapids (e.g., Pediatrics and Emergency Medicine), but that does not define the department, and faculty from all over the state can be in the department. It is also true that the collaborations in each department can be complex, but all departments in the university that engage with the community deal with complexity at some level. The college does not specify where faculty have to live as long as they can fulfill their role. Also note, we are purposely not creating duplicative departments.

As to [2]

Inclusion in MSU HealthCare, Inc. practices (and referrals to MSU physicians) is a separate issue than membership in a department. In this sense, these new departments will be the same as existing departments that include non-HCI faculty, including non-prefix faculty, from Flint, Grand Rapids, Detroit, the Upper Peninsula, or other communities across Michigan. Clinical integration partnerships between MSU and hospital systems, including joint ventures in radiology, or non-clinical relationships, including a statewide residency consortium, create more areas for confusion than these departments will. As a particular example, the neurosurgeons based at Ascension Providence are faculty for both CHM and COM, yet both colleges have decided that any confusion clinically is tolerable given the benefits to students.

As to [3]

The creation of this department will not change the eventual attribution of research funding. As a matter separate from the creation of these departments, we believe MSU, the Health Science Center, applicable college and department will all have attribution, but that system has not been implemented.

As to [4]

Investments from the college to departments will continue as they have for all departments, whether they are joint or in a single college. The attribution and indirect costs follow the appointments and investments as they do now, regardless of the geographical location of the department. For example, for departments located in Grand Rapids and Flint and invested in by CHM- research attribution and indirect costs will flow through CHM. Similarly, for departments located in East Lansing and jointly invested by COM- research attribution and indirect costs flow through the respective college in which the faculty is appointed. CHM has no interest in overturning the current system.

As to [5]

Neither the College of Human Medicine nor the collaborating physicians at Henry Ford Health envision these as joint departments. Some joint departments have been successful, but they are more difficult to administer. The orthopedics department is an interesting example, because administration of that unit has been a challenge and not an experience to be replicated. As in all of our departments, we will welcome faculty from other departments and colleges who are interested in secondary appointments in the new departments.

As to [6]

As of October 16, 2022, there is no pathway for Henry Ford Medical Group faculty to be appointed in MSU HeathCare, Inc., and any decisions to create such a pathway are separate from the department decisions. This is analogous to the CHM Emergency Medicine department created a decade ago; faculty employed by ECS are not “appointed” or credentialed in MSU HCI.

As to [7]

We expect the new department will only increase options available to COM students. The college and the new department are open to cross-listing classes as happens now across the university, and we will ensure the courses of the new department will be available to medical students regardless of college. Finally, there is nothing in the creation of the department that disturbs the existing curricular courses used by COM students. In fact, these additional departments enhance research, educational and clinical opportunities for COM students.